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SYNTHETIC CANNABINOIDS VERSUS DELTA-9-TETRAHYDROCANNABINOL: 
ABUSE-RELATED CONSEQUENCES OF ENHANCED EFFICACY AT THE 
CANNABINOID 1 RECEPTOR 
By Travis Grim, B.S.  
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University.  
Virginia Commonwealth University, 2015  
Major Director: Aron H. Lichtman, Ph.D., Department of Pharmacology and Toxicology 
 
 In the past ten years, synthetic cannabinoids (SC) have emerged as drugs of abuse. The 
first generation of these were research chemicals used to elucidate the existence and function of 
the cannabinoid receptor 1 (CB1). Unlike 
9-tetrahydrocannabinol (THC), many SCs are 
associated with serious health complications and death. One way in which THC and SCs differ 
lies with their enhanced potency and efficacy at the CB1 receptor. Accordingly, much lower 
concentrations of SCs are needed to elicit their THC-like effects, and many of these ligands are 
able to stimulate far more activity per receptor than THC. No current methods exist to measure 
efficacy at the CB1 receptor in vivo, and the abuse-related properties of SC cannabinoids are not 
well explored. Here, we utilized CB1 wild type (WT), heterozygous (HET), and knockout (KO) 
mice, which possess 100%, 50%, and 0% of normal CB1 expression. By employing CB1 ligands 
which differ in efficacy we have developed a method to explore the relationship between 
efficacy and the ability to produce cannabimimetic (catalepsy, hypothermia, and antinociception) 
xii 
 
effects when CB1 expression was reduced by half. Additionally, the intracranial self-stimulation 
procedure (ICSS) was utilized to investigate the effects of enhanced efficacy at CB1 upon reward 
processes using representative SC CP55,940. As predicted, the potency shift between WT and 
HET mice inversely correlated with the efficacy of the test drug for both hypothermia and 
antinociception, but not catalepsy. This efficacy stratification was correlated with the agonist-
stimulated [35S]GTPS binding assay, demonstrating this model as an effective tool to ascertain 
in vivo efficacy differences at CB1. In ICSS, CP55,940 elicited only rate-decreasing effects 
acutely, although tolerance developed following repeated dosing. No evidence for spontaneous 
or rimonabant-precipitated withdrawal was observed. Together, these data indicate that highly 
efficacious cannabinoid ligands require few receptors to produce cannabimimetic effects, and 
that the model provides an effective means to quickly ascertain differences in efficacy. SCs 
continue to be a public health concern, and as they emerge their similarities to known 
cannabimimetic agents can be examined both in terms of efficacy and abuse-related effects. 
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Chapter 1: Introduction 
 
1.1 Development and synthesis of cannabinoids as research tools 
Written records and archeological evidence document that Homo sapiens have utilized 
the Cannabis sativa and Cannabis indica plants for recreational and medicinal purposes for at 
least 5000 years (Adrian, 2015). These uses of cannabinoids continue to the present day. 
Although inhalation of smoked cannabis or oral consumption produces well-described effects, 
including somnolescence (Belendiuk et al, 2015; Tart, 1970), euphoria as well as dysphoria, 
visual and auditory distortions of perception, elevated heart rate (Isbell et al, 1967; Weil et al, 
1968), increased blood pressure, and impaired cognition (Waskow et al, 1970), the mechanisms 
by which cannabis (or marijuana) exerted its psychoactive effects were largely unknown until its 
chief primary psychoactive constituent, 9-tetrahydrocannabinol (THC), was discovered. THC 
was first isolated  in an impure form and its structure postulated more than seven decades ago 
(Wollner et al, 1942). In 1964, THC was again isolated from Cannabis sativa in a more pure 
preparation (Gaoni and Mechoulam, 1964). Subsequent work by Mechoulam showed THC 
extracted from marijuana and marijuana itself engendered similar psychoactive effects in humans 
(Mechoulam and Gaoni, 1967), and further examination of the composition of Cannabis sativa 
identified THC as a major component of marijuana (Mechoulam, 1970). The phytocannabinoid 
cannabidiol was also discovered at this time (Mechoulam et al, 1970; Mechoulam and Shvo, 
1963), but unlike THC, it did not possess high affinity for CB1 or CB2 (Showalter et al, 1996), 
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lacked cannabimimetic activity (Bloom et al, 1978; Chesher et al, 1973; Pertwee, 1972), and 
failed to substitute for THC’s discriminative stimulus (Bueno et al, 1976; Järbe et al, 1977). 
Although these studies taken together implicated THC as the primary psychoactive ingredient of 
marijuana, they raised the following question: how was THC evoking its pharmacological 
effects? 
 Initial studies proposed various mechanisms to explain the pharmacological effects of 
THC such as plasma membrane perturbation or enzymatic interactions (Laurent and Roy, 1975; 
Roth and Williams, 1979). However, the concentrations of THC needed to achieve these effects 
were in the mid to upper micromolar range and far exceed the low or sub mg/kg doses sufficient 
to produce psychoactive effects in humans (Mechoulam and Gaoni, 1967). Promising 
mechanistic experiments conducted by Howlett and colleagues identified THC as a potent 
inhibitor of adenylyl cyclase. The findings that pharmacological blockade of a variety of 
receptors, including secretin, alpha adrenergic, serotonergic, and mu-opioid receptor antagonists 
(Howlett, 1984) did not prevent THC-induced inhibition of adenylyl cyclase suggest that a 
discrete cannabinoid receptor might exist and that it likely did not exert its pharmacological 
effects through the proposed disturbance of plasma membranes (Howlett and Fleming, 1984). 
Early radioligand displacement studies employing [3H]trimethylammonium-8-
tetrahydrocannabinol ([3H]TMA) and unlabeled THC in rat brain homogenates strongly 
suggested discrete binding sites in a stereoselective manner, though potent displacement by 
cannabinoids with weak affinity for THC binding sites called into question the binding 
specificity of [3H]TMA and precluded definitive identification of a discrete cannabinoid receptor 
(Nye et al, 1985). Fortunately, a series of potent cannabinoid ligands synthesized by Pfizer 
utilizing a bicyclic backbone structure provided highly useful tools for structure activity 
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relationship (SAR) and radioligand binding studies. A notable compound produced from these 
efforts was CP55,940, which was shown to behave similar to THC in inhibition of adenylyl 
cyclase (Howlett et al, 1988). This compound was subsequently radiolabeled with tritium and 
used to characterize the putative cannabinoid receptor(s) (Devane et al, 1988). [3H]CP55,940 
was utilized in autoradiography studies to characterize the distribution of cannabinoid receptor 
binding sites in the CNS (Herkenham et al, 1990). Proof of the existence of specific cannabinoid 
receptors culminated with the cloning of the CB1 (Matsuda et al, 1990) and CB2 (Munro et al, 
1993) receptors, conclusively providing the sites of action by which cannabinoids exert their 
effects. The discovery of cannabinoid receptors would not have been possible without the 
synthesis of novel cannabinoids. 
 Other cannabinoids were developed for basic research as well as for potential therapeutic 
development. The classical cannabinoids possess the tricyclic structure characteristic of THC and 
include compounds such as HU series (Mechoulam et al, 1990). The alkylindole class of 
cannabinoids, including the JWH series (Aung et al, 2000) and the widely adopted WIN55,212-2 
(Kuster et al, 1993), contained a great variety of backbone structures capable of binding and 
activating the CB1 receptor. Similar to THC, many of these synthetic cannabinoids (SC) bound 
CB1 and CB2 (e.g. CP55,950; (Thomas et al, 1998), but the advent of the highly CB1 selective 
antagonist SR141716A (or rimonabant) (Rinaldi-Carmona, 1994) revealed CB1 in humans was 
the mechanism by which marijuana evoked its psychoactive effects (Huestis et al, 2001). 
Rimonabant also antagonized the in vivo subjective effects of CP55,940, WIN55,212-2,  and 
THC in rats trained to discriminate THC from vehicle in the drug discrimination assay (Järbe and 
Henriksson, 1974; McMahon and Koek, 2007; Wiley et al, 1995) suggesting a similar 
mechanism of action between rodents and man. Finally, radiolabeled [3H]SR141716A was used 
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to validate further that the majority of cannabinoid receptors in brain autoradiographs was CB1 
(Rinaldi-Carmona et al, 1996), cementing the CB1 as the major cannabinoid receptor in the 
central nervous system. Cannabinoid ligands proved to be a promising molecules for numerous 
potential therapeutic indications, such as neuropathic pain, weight loss, and anxiolysis; thus, the 
push to synthesize and optimize new cannabinoids for these purposes continued. The 
cannabinoid field began to amass knowledge of hundreds of CB1 ligands, and the SAR became 
very well understood for numerous scaffolds. Unwittingly, scientific publications that described 
the chemical synthesis of these drugs and their pharmacology set the stage for CB1 agonists to be 
utilized for illicit purposes. 
1.2 Pharmacological actions of marijuana, THC, and synthetic cannabinoids   
Later efforts provided a more thorough investigation of the pharmacological effects of 
both marijuana and isolated THC in man and laboratory animals. Cardiovascular effects 
measured included elevated heart rate and increased blood pressure in human subjects (Isbell et 
al, 1967; Kochar and Hosko, 1973; Tashkin et al, 1973; Weil et al, 1968). The psychotropic 
effects in humans included subjective high (Weil et al, 1968), euphoria (Isbell et al, 1967), 
relaxation (Tart, 1970), memory impairments (Clark et al, 1970; Tinklenberg et al, 1970), 
disruption of cognitive tasks (Weil et al, 1968), and changes in temporal perception (Clark et al, 
1970; Tinklenberg et al, 1970). Both anxiogenic (Zuardi et al, 1982) and anxiolytic (Fabre and 
McLendon, 1981) effects were also observed. In animal subjects, the subjective effects of 
cannabinoids were assessed utilizing the drug discrimination procedure, finding that generally, 
most cannabinoids substituted for THC and vice versa (Hruba et al, 2012; Järbe et al, 2014; 
McMahon, 2006; Wiley et al, 1995, 2013, 2014). In vivo, cannabinoids in rodents generally elicit 
hypolocomotion, hypothermia, catalepsy, and antinociception (Compton et al, 1992; Fan et al, 
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1994; Little et al, 1988a; McLaughlin et al, 2013), a constellation of effects generally referred to 
as the cannabinoid tetrad. Memory impairments (Ferrari et al, 1999; Heyser et al, 1993; 
Nakamura et al, 1991), anti-allodynic properties (Conti et al, 2002; Herzberg et al, 1997), and 
anxiety-related properties (Genn et al, 2004; Haller et al, 2002) were also commonly observed. 
Abuse-related behaviors represented a notable discrepancy between humans and laboratory 
animals. 
1.3 Emergence of synthetic cannabinoids as drugs of abuse 
 With the growing scientific literature describing the synthesis of research compounds that 
bound CB1 and produced cannabis-like effects, it should not be altogether surprising that many 
of these ligands eventually appeared as drugs of abuse. Indeed, John W. Huffman, the progenitor 
of the JWH cannabinoid series, was quoted in a Los Angeles Times interview saying “I always 
had a hunch that someday somebody would say: ‘Hey, let’s try smoking them.’ And lo and 
behold, that’s what happened” (Zucchino, 2011). Beginning in 2004, small packages of inert 
plant material imbued with unknown cannabimimetic agents labeled “not for human 
consumption” began to emerge (UNODC, 2014). Despite this disclaimer, these preparations with 
names such as “K2” and “Spice” were imbibed usually via smoking and soon precipitated 
unexpected health-related consequences. Ten cases of seizures were reported in Sweden in 2007 
(EMCDDA, 2014), and soon after these incidents formal monitoring process of these abused 
preparations began. These events also spurred research to identify the chemical components that 
might be responsible for producing this alarming phenotype. The plant material itself was 
determined to be largely inert, serving primarily as a vehicle (EMCDDA, 2014). CP47,497 
(Melvin et al., 1993), cannabicyclohexanol (Melvin et al., 1993), and JWH-018 (Wiley et al, 
1998) were the first SCs positively identified in several different “Spice” products (Auwärter et 
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al, 2009). Their detection led to emergency scheduling of CP47,497, cannabicyclohexanol, 
JWH-018, JWH-073, and JWH-200 by the Drug Enforcement Administration (DEA) (The Drug 
Enforcement Administration, 2011), which in turn led the sellers to circumvent the law by using 
a new variety of SCs in their preparations. Subsequent emergency scheduling in 2013 of the SCs 
UR-144, XLR-11, APINACA, and AKB48 (The Drug Enforcement Administration, 2013), 
further actions in 2014 to schedule PB-22, 5F-PB-22, AB-FUBINACA, and ADB-PINACA (The 
Drug Enforcement Administration, 2014), and the more recent scheduling of AB-CHIMINACA, 
AB-PINACA, and THJ-2201 (The Drug Enforcement Administration, 2015) highlight the 
difficulty in keeping pace with the emergence of new SCs. Especially alarming is the emergence 
of compounds such as XLR-11, synthesized de novo with unknown pharmacology and 
toxicology (Center for Disease Control, 2013). This evidence suggests that newer SCs are likely 
produced by clandestine chemists with knowledge concerning structure activity relationships, 
given commonplace modifications, such as the addition of biosteric fluorine moieties that 
typically improve binding affinity at the CB1 receptor (Banister et al, 2015). Each new 
cannabinoid structure also requires development of new methods of detection (Scheidweiler and 
Huestis, 2014), further complicating assessment of the risk to human health. 
 Numerous case reports point to potential health risks associated with SC use. Heart and 
kidney failure, respiratory depression, and seizures are repeatedly mentioned in case reports, as 
well as psychiatric indications, such as acute onset psychosis, anxiety, and cognitive impairment 
(Table 1). Alarmingly, a subset of synthetic cannabinoids has been linked to several deaths 
(Trecki et al, 2015). These reports are in marked contrast to THC, which has not been linked to a 
direct cause of death, despite its prolonged and high incidence of use. A large scale survey 
determined the risk of an emergency department visit is approximately 30 times higher for SCs 
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than for THC (Winstock et al, 2015), corroborating the trends seen in the plentiful case reports. 
The continued emergence of new SCs contributes to public health concerns of these drugs, but 
the underlying reasons for their higher health risk compared to THC remains poorly understood. 
Given the diversity in structures of abused cannabinoids, one explanation for these adverse 
events could be a non-CB1 target which produces toxicity either through direct action of the 
parent compound or via metabolites. Alternatively, notable distinctions between THC and SCs 
are their abilities to bind and activate the CB1 receptor. SCs are often more potent and more 
efficacious than THC (for review see Howlett, 2005). Thus, increases in the magnitude of CB1 
stimulation combined with high doses of SCs may potentially contribute to their toxic effects. In 
contrast, doses of THC obtained from marijuana consumption and its relatively low efficacy at 
the CB1 may be insufficient to elicit these actions. Notable toxicological effects of high affinity, 
high efficacy SCs are consistent with of CB1 expression in the relevant organs, such as the heart 
lungs, kidneys, and vast abundance in the central nervous system (CNS) (Galiègue et al, 1995), 
though a causal link between increased efficacy and the resulting deleterious health effects 
remains to be established. In order to evaluate the degree to which potency and/or efficacy at the 
CB1 receptor contribute to the adverse effects of SCs, an efficient method of assessing these 
measures would be a helpful tool for both basic research and public health. The effects of SCs on 
CB1 in the CNS represent an important aspect to study given the large number of psychiatric 
effects associated with their use. 
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Synthetic Cannabinoid Health effects Reference 
"K2" myocardial ischemia Clark et al., 2015 
PB-22 death 
Gerostamoulos et al., 
2015 
5F-APINACA driving impairment Karinen et al., 2015 
APINACA driving impairment  
UR-144 driving impairment  
UR-144 degradant driving impairment   
AM-2201 
memory impairment, inappropriate 
giggling Obafemi et al., 2015 
AB-CHIMINACA 
driving impairment, slurred speech, 
confusion 
Peterson and Couper, 
2015 
AB-PINACA 
driving impairment, slurred speech, 
confusion   
"K2" withdrawal, seizures Sampson et al., 2015 
5F-PB-22 seizure Schep et al., 2015 
AM2233 Seizure  
BB-22 seizure  
JWH-122 (cyclohexylmethyl 
substituted) seizure  
PB-22 seizure   
ADB-PINACA delirium Schwartz et al., 2015 
XLR-11 death Shanks et al., 2015 
AB-PINACA respiratory depression Thornton et al., 2015 
MDMD-CHMICA sudden cardiac death Westin et al., 2015 
5F-PB-22 sudden death Behonick et al., 2014 
"K2" acute cerebral ischemia, stroke 
Bernson-Leung et al., 
2014 
XLR-11 acute kidney injury Buser et al., 2014 
AM-2201 schizophrenic symptoms Celofiga et al., 2014 
PB-22 seizure 
Gugelmann et al., 
2014 
XLR-11 
driving impairment, hypothermia, 
rigid muscle tone Lemos, 2014 
JWH-122 xerostomia, chest pain, tachycardia Lonati et al., 2014 
MAM-2201 xerostomia, chest pain, tachycardia   
"Black Diamond" mutilation, amputation Meijer et al., 2014 
AM-2201 
impaired driving, dizziness, 
somnolescence Musshoff et al., 2014 
JWH-018 
impaired driving, dizziness, 
somnolescence  
JWH-019 
impaired driving, dizziness, 
somnolescence  
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JWH-122 
impaired driving, dizziness, 
somnolescence  
JWH-210 
impaired driving, dizziness, 
somnolescence  
JWH-307 
impaired driving, dizziness, 
somnolescence  
MAM-2201 
impaired driving, dizziness, 
somnolescence  
UR-144 
impaired driving, dizziness, 
somnolescence   
"Spice/K2" toxic hepatitis Sheikh et al., 2014 
XLR-11 acute cerebral ischemia Takematsu et al., 2014 
AM-2201 driving impairment Tuv et al., 2014 
JWH-018 driving impairment  
JWH-081 driving impairment  
JWH-122 driving impairment  
JWH-250 driving impairment  
RSC-4 driving impairment   
AM-2201 diffuse pulmonary infiltrates Alhadi et al., 2013 
JWH-122 diffuse pulmonary infiltrates  
JWH-210 diffuse pulmonary infiltrates   
"Spice" oliguric acute kidney injury 
Bhanushali et al., 
2013 
JWH-018 acute cerebral ischemia, stroke Freeman et al., 2013 
JWH-018 
mild agitation, laugh attacks, panic 
attacks, vomiting, myoclonic 
jerking 
Hermanns-Clausen et 
al., 2013 
JWH-018 
mydriasis, aniscoria, retrograde 
amnesia, somnolescence  
JWH-018 
mydriasis, mild tachycardia, 
hypokalemia, leukocytosis  
JWH-018 seizures, difficulty breathing  
JWH-073 
mild agitation, laugh attacks, panic 
attacks, vomiting, myoclonic 
jerking  
JWH-081 
mild agitation, laugh attacks, panic 
attacks, vomiting, myoclonic 
jerking  
JWH-122 
mydriasis, aniscoria, retrograde 
amnesia, somnolescence  
JWH-122 
mydriasis, mild tachycardia, 
hypokalemia, leukocytosis  
JWH-122 seizures, difficulty breathing  
JWH-210 seizures, difficulty breathing  
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UR-144 
mydriasis, aniscoria, retrograde 
amnesia, somnolescence   
AM-2201 cannabinoid hyperemesis 
Hopkins and Gilchrist, 
2013 
AM-694 cannabinoid hyperemesis  
JWH-0122 cannabinoid hyperemesis  
JWH-018 cannabinoid hyperemesis  
JWH-073 cannabinoid hyperemesis   
AM-2201 seizures McQuade et al., 2013 
"Mr. Nice Guy" 
withdrawal not alleviated by THC, 
anxiety, cramps, loss of appetite Nacca et al., 2013 
THC 
withdrawal not alleviated by THC, 
anxiety, cramps, loss of appetite   
AM2201 
psychiatric complications, death, 
mutilation Patton et al., 2013 
JWH-073 
psychiatric complications, death, 
mutilation   
XLR-11 acute kidney injury Thornton et al., 2013 
AM-2201 driving impairment 
Yeakel and Logan, 
2013 
JWH-081 driving impairment  
JWH-122 driving impairment  
JWH-210 driving impairment  
JWH-250 driving impairment   
"K2" 
catatonic, non-responsive to verbal 
or painful stimuli Cohen et al., 2012 
"Spice" aggression, tachycardia   
"K2" emesis, tachycardia Faircloth et al., 2012 
"K2" respiratory depression 
Jinwala and Gupta, 
2012 
"Spice" psychosis Peglow et al., 2012 
"K2" suicidal ideation Thomas et al., 2012 
JWH-018 
respiratory depression, tachycardia, 
fever Tofighi and Lee, 2012 
JWH-018 seizure, tachyarrhythmia Lapoint et al., 2011 
"K2" myocardial infarction Mir et al., 2011 
JWH-018 anxiety Schneir et al., 2011 
JWH-073 anxiety   
JWH-018 tachycardia, unresponsiveness Simmons et al., 2011 
JWH-073 tachycardia, unresponsiveness   
"Spice Gold" 
anxiety, nocturnal nightmares, 
sweating, nausea, tremors, 
headache 
Zimmermann et al., 
2009 
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Table 1. A summary of case reports detailing the health effects linked to specific SCs detected in 
abused preparations. Many earlier SCs were diverted research chemicals, while later generations 
of “Spice” and “K2” preparations possessed SCs with novel structures and unknown 
pharmacology.  
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1.4 Structure activity relationships of synthetic cannabinoids. 
 Cannabinoid SAR studies used THC as a molecular scaffold to explore the effects of 
structural modifications in producing cannabimimetic activity. As depicted in Figure 1, four 
primary pharmacophores on the molecule were targeted for structural alterations: 1) alkyl chain 
length at C-3, 2) the hydroxyl at the C-1 position, 3) the methyl at the C-9 position, and 4) the 
“B” ring at the C-6 position. The earliest SAR studies explored the alkyl chain length and methyl 
substitutions at the first position on the alkyl chain in producing static ataxia in dogs (Adams et 
al, 1948a, 1948b), and found that 1ˊ,2ˊ-dimethyl-heptyl chains were the most potent. Martin and 
colleagues demonstrated that the alkyl chain length was an important determinant of in vivo 
potency (Martin et al, 1999). Structural modifications of the dimethylheptylpyran backbone 
elucidated the SAR of these highly potent cannabinoids (Razdan and Dalzel, 1976). Later work 
by Mechoulam and would explored the stereospecificity of the dimethyl additions at the first 
position of the alkyl chain, leading to the synthesis of HU-210, a highly potent synthetic 
cannabinoid approximately 85 times more potent than 1-tetrahydrocannabinol to produce 
subjective effects in rats (Mechoulam et al, 1988). Modifications to the hydroxyl at the C-1 
position revealed a mechanism to convey CB2 selectivity via methylation of the hydroxyl 
(Pertwee et al, 2000; Zitko et al, 1972) as measured in radioligand binding studies. The C-11 
methyl group was determined to be nonessential for binding, but modifications, such as ketone 
(nabilone) (Archer et al, 1977) or dimethyl hydroxyl (HU-210) (Mechoulam et al, 1988) groups 
enhanced CB1 receptor binding affinity. Representative classical, tricyclic cannabinoids (Figure 
2) demonstrated modifications at the aforementioned positions alongside THC.  The 
aforementioned structures utilized the tricyclic structure of cannabinoids, but work by chemists 
from Pfizer  utilized the bicyclic CP47,497 as the backbone structure to reveal the “B” ring as 
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non-essential (Figure 3), while the other three pharmacophores continued to exert their predicted 
effects on binding affinity to cannabinoid receptors (Melvin and Johnson, 1987; Melvin et al, 
1993a). 
 The aminoalkylindole WIN55,212-2 was initially developed as a structural derivative of 
pravadilone, a non-acidic, potent inhibitor of cyclooxygenase enzymes. Surprisingly, 
WIN55,212-2 and pravadilone inhibited electrically-evoked mouse vas deferens contractions, 
inhibited adenylyl cyclase, and possessed greater than expected antinociceptive properties (Bell 
et al, 1991). WIN55,212-2 was later discovered to bind to cannabinoid receptors with nanomolar 
affinity, which accounted for its unexpected in vivo and in vitro cannabimimetic activity, and it 
failed to appreciably inhibit prostaglandin synthesis (D’Ambra et al, 1992). Ensuing studies 
investigated the SAR of this new class of cannabinoid compounds. Much of the SAR work in 
this series of compounds was performed in collaboration with John W. Huffman, who helped 
established the amino portion of the aminoalkyl side chain could be eschewed for an alkyl chain, 
thus resembling more closely the classical and non-classical cannabinoids (Wiley et al, 1998). 
Important contributions were also made by Alex Makriyannis, who demonstrated common 
pharmacological moieties between classical cannabinoids and the seemingly structurally 
dissimilar aminoalkylindoles (Xie et al, 1995). The benzene ring was also discovered to be 
nonessential (Figure 4), and from these modifications the JWH series was born including the 
eventually abused JWH-018 and JWH-073 (Huffman, 1999; Huffman et al, 1994).  
 Other cannabinoid SAR studies searched for CB2-selective indoles and pyrroles for 
therapeutic purposes, though many of these compounds retained appreciable affinity for the CB1 
receptor (Frost et al, 2010). Once emergency scheduling events began (The Drug Enforcement 
Administration, 2011), a rapid increase in clandestine synthesis of structurally unique 
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cannabinoids began, resulting in myriad structures designed to maintain cannabimimetic effects 
while evading legal restrictions and established assays of detection, accomplished by utilizing 
small substitutions such as fluorination (Banister et al, 2015; Gatch and Forster, 2014). 
Adamantylindoles, such as APICA and APINACA, became increasingly found in preparations 
and were subsequently scheduled (Figure 5) (The Drug Enforcement Administration, 2013, 
2014).  Unlike the older generation of SCs, new SCs were synthesized to evade illegality and 
generally lack the preclinical testing, which resulted in abused compounds that possessed 
unknown pharmacodynamics, pharmacokinetics, and toxicology. To date, the relationship 
between enhanced efficacy and potency at the CB1 receptor and the health risks remains 
unexplored, though SCs generally possess much higher efficacy and affinity at the CB1 receptor 
than THC.  
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Figure 1. The pharmacophores of THC were established via SAR studies. The alkyl chain at C-3 
was determined to be an important determinant of both binding affinity and efficacy, with an 
optimal chain length of 6-7 carbons. An addition of a dimethyl group at the first carbon of the 
chain also improved binding affinity. Substitution of the C-1 or C-9 pharmacophores could 
drastically change binding affinity at the CB1 receptor, while methylation of the C-1 hydroxyl 
could enhance selectivity for the CB2 receptor. The B ring, specifically the oxygen at position 5 
and the carbon at position 6, was determined to be nonessential via SAR work utilizing Pfizer’s 
nonclassical, bicyclic cannabinoid series. 
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Figure 2. Classical cannabinoids, based upon the structure of THC, were instrumental in 
discovering the CB1 receptor. Researchers identified discrete cannabinoid binding in rat brains 
utilizing the THC analogue 5´-trimethylammonium-8-tetrahydrocannabinol. HU-210, 
synthesized by Mechoulam and colleagues, allowed investigation of the stereospecificity of 
cannabinoids, strongly suggesting the presence of a discrete cannabinoid receptor. Likewise, 
nabilone represents a series of structural modifications to improve binding affinity of THC, 
notably the dimethyl substitution at the first carbon of the alkyl chain at C-3 and the ketone at C-
9. 
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Figure 3. Nonclassical cannabinoids developed by Pfizer were instrumental in demonstrating the 
B ring of classical cannabinoids as nonessential for cannabinoid receptor binding and 
cannabimimetic activity. CP47,497 and its C-8 homologue cannabicyclohexanol were among the 
first synthetic cannabinoids detected in abused “Spice” and “K2” formulations. CP55,940 
emerged as an important research tool to explore cannabinoid pharmacology in vitro and in vivo, 
and contributed to the discovery of cannabinoid receptor distribution in the CNS via 
autoradiography studies. 
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Figure 4. The serendipitous discovery of the indole backbone based upon the structure of the 
non-steriodal anti-inflammatory drug pravadilone led to the synthesis of many cannanabinoids. 
WIN55,212-2 was among the first of the cannabimimetic indoles and became popular as a 
research tool in part due to its high efficacy at the CB1 receptor. Later SAR experiments by John 
W. Huffman determined the benzene ring of the indole to be nonessential for cannabimimetic 
activity as demonstrated by JWH-018 and JWH-073. Along with many other cannabinoids from 
the JWH series, JWH-018 and JWH-073 were eventually detected in abused preparations. 
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Figure 5. Following the scheduling of many of the first wave of abused synthetic cannabinoids, 
a huge variety of structures were detected via toxicological screens following emergency 
department visits. AM-2201 and XLR-11 represented fluorinated analogues of the scheduled 
JWH-018 and UR-144, respectively, and reveal how small structural modifications were made to 
sidestep scheduling of their parent compounds. APICA and APINACA, similar to the JWH 
series, contained the indole backbone, but the addition of the adamantyl moiety instead of the 
napthyl exhibit the large variety of cannabinoid structures present in the modern abused 
preparations. 
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1.5 Determination of efficacy utilizing receptor theory  
 Modern pharmacology was born of physiologists attempting to empirically determine the 
underpinnings of drug interactions with the tissues they acted upon. The concept of the receptor 
was a theoretical “receptive substance” for a given compound as described by Langley (Langley, 
1905). Clark later expanded this treatment by Langley to incorporate the law of mass action, 
defining explicitly the relationships between the amount of ligand present and the amount of 
available receptors. Briefly, the ligand-receptor complexes associate and dissociate at a rate 
proportional to the number of complexes (Stephenson, 1956). Thus, at equilibrium (or 
occupation of half of the available receptors) one may determine the affinity of the ligand. Clark 
applied this concept to relate the number of ligand-receptor complexes to the response of the 
tissue, generating the familiar hyperbolic dose-response relationship (Clark, 1926, 1927). 
However, Clark also assumed the fractional occupancy was proportional to the tissue response, 
which later experiments would demonstrate to be a false assumption. Subsequently, Stephenson 
showed that compounds varied in their intrinsic activity, or efficacy, at a given target 
(Stephenson, 1956). This conceptual frame work led to the definition of a partial agonist as “low 
efficacy compounds possess properties intermediate to agonists and antagonists.” Much of this 
work culminated in the two-state model (Black and Leff, 1983), which related the concepts of 
fractional occupancy, receptor number, and efficacy into a single equation. From this derivation 
also came the postulate that to differentiate between the efficacies of ligands, receptors number 
must be reduced to deplete spare receptors, such that rightward and downward shifts in dose-
response relationships might be revealed. 
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 In vitro methods to ascertain efficacy at the CB1 receptor have largely focused on 
agonist-stimulated guanosine [35S]5'-O-[gamma-thio]triphosphate ([35S]GTPS) binding. This 
assay enabled measuring efficacy at the first step  of the canonical G-protein-adenylyl cyclase-
protein kinase A signal transduction pathway and was effective in stratification of ligands by 
efficacy in both cell cultures (Glass and Northup, 1999) and tissue harvested from experimental 
animals (Griffin et al, 1998, 2001; Selley et al, 2001). However, there are a number of reagents 
and assay parameters which interact to determine the relative differences in efficacy, and 
variation across studies afforded relatively poor resolution to estimate relative efficacy when 
utilizing the body of literature. In vivo, both experimenter imposed constraints and the 
underlying neurobiology of the CB1 receptor present challenges to determine efficacy for various 
endpoints. 
1.6  CB1 signal transduction 
 CB1 receptors are seven transmembrane G-protein coupled receptors (GPCR) which 
classically signal through heteromeric G proteins consisting of , , and  subunits. Upon ligand 
binding, a conformational change in the receptor occurs, spurring the dissociation of the  
subunit from the  subunits as well as an exchange of guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP), likely mediated by a guanine exchange factor) at the  subunit. 
The dissociated  subunit then translocates to its target protein and exerts its action (Console-
Bram et al, 2012). The signal is then terminated by the hydrolysis of bound GTP to GDP and the 
and  subunits are once again complexed together to begin the cycle anew. More recently, 
GPCRs were found to simultaneously interact with multiple downstream signaling pathways in a 
ligand dependent manner, an emerging concept which has been termed “biased agonism” or 
“biased signaling” (Kenakin, 2015), although the concept has other names such as “functional 
22 
 
selectivity” or “stimulus trafficking”. The downstream targets obviously depend on the 
expression and abundance of interacting proteins be they scaffolds or metabolically active thus 
these pathways are likely to be tissue or even cell specific (Kenakin, 2015). Signaling bias has 
been described for the CB1 receptor for numerous ligands, although not all were described with a 
focus on elucidating the phenomenon. Therefore, current knowledge of signal transduction 
pathways should be considered with the likelihood that multiple pathways could be activated and 
the tissue and ligand inherently dictate the pattern of signaling which occurs. 
CB1 receptors are among the most abundant GPCRs in the human, non-human primate, 
and rodent CNS (Herkenham et al, 1990). They are typically coupled to Gi/o, thus they 
attenuate production of cyclic adenosine monophosphate (cAMP) via interactions with 
membrane bound adenylyl cyclase (Howlett, 1984; Melvin et al, 1993b). There are multiple 
subtypes of both Gi (1,2, and 3) and Go (1 and 2) and differential signaling via Gi or Go 
based upon the ligand occurs depending on the agonist used (Glass and Northup, 1999). 
WIN55,212-2 is distinct from other cannabinoids (THC, HU-210, CP55,940, 2-AG, 
methanandamide (mAEA), and cannabidiol) in its activation of the Gq-inositol phospate 
pathway to release intracellular calcium although WIN55,212-2 does so with relatively lower 
potency at Gq compared to Gi/o (Felder et al, 1995; Lauckner et al, 2005). When CB1 is co-
expressed with dopamine 2 (D2) receptors, its signaling can switch to Gs, thus increasing 
adenylyl cyclase activity to produce cAMP in a pertussis toxin insensitive manner (Glass and 
Felder, 1997; Jarrahian, 2003). This stimulatory effect may be due to heterodimerization with the 
D2 receptor (Kearn, 2005), as D2 receptor KO mice display diminished catalepsy following 
CP55,940 treatment (Andersson, 2005). The CB1 receptor also interacts with G-protein activated 
inward rectifying potassium (GIRK) channels (Felder et al, 1995; McAllister et al, 1999) via 
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translocation of the  dimer following dissociation with the G subunit (Ho et al, 1999). 
WIN55,212 also may have effects on outward currents, though they seem to occur in a non-CB1 
manner (Zhang et al, 2013). 
Repeated administration of THC results G-protein receptor kinase (GRK) 2 and 4 
expression and subsequent GRK-mediated phosphorylation of the intracellular surface of the 
CB1 receptor (Rubino et al, 2006). This phosphorylation event then recruits beta arrestin 1 
(BARR1) and beta arrestin 2 (BARR2) which can then result in internalization of receptors (Jin 
et al, 1999), or alternatively serve as a scaffold for proteins which phosphorylate extracellular 
signal-regulated kinase (ERK1/2) which seems to be inversely related to desensitization at the G-
protein level (Daigle et al, 2008a). Genetic deletion of BARR2 increases sensitivity to the effects 
of THC relative to wild type mice, although CP55,940, methanandamide, and JWH-073, and O-
1812 failed to produce the same differences (Breivogel et al, 2008). However, the lack of effects 
may be due to the high doses of each compound relative to reported ED50 values. Some 
experiments indicate downregulation drives the switch from G signaling to BARR2-ERK1/2 
(Flores-Otero et al, 2014), while other studies posit that these signaling events occur 
simultaneous in a ligand-dependent manner (Laprairie et al, 2014). Interestingly, these two 
hypotheses are not mutually exclusive. Ligands could possess an initial bias for one pathway or 
another, and following chronic administration of the same agonist one pathway may become 
energetically unfavorable resulting in an alternative coupling to another pathway or pathways. In 
the context of cumulative dosing, a shift to the BARR2 signaling is entirely possible during 
testing though measuring this potential shift remains to be done. 
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1.7  Assay parameters and their effect on measuring efficacy in agonist stimulated 
GTPS binding 
The vast majority of studies conducted to differentiate cannabinoids by their efficacy 
employ the agonist-stimulated [35S]GTPS binding technique. Thus, these experiments served as 
a guide to select ligands to test in the whole animal. Though reliable, this in vitro technique may 
utilize a variety of reagents which may affect the sensitivity of the assay to detect the efficacy of 
ligands. In principle, agonist-stimulated [35S]GTPS binding measures the maximum possible 
stimulation of GDP for radiolabeled GTPS in cells or membranes from biological samples, 
which triggers the dissociation of the G subunit from the  dimer. The G subunit signal is 
normally terminated by hydrolysis of GTP to GDP, yet the GTPS resists this catabolism such 
that accumulation of bound GTPS can be measured via a liquid scintillation counter. The 
relative concentrations of MgCl2, GTPS, GDP, Na
+, and membrane protein will each affect the 
resolution in measuring efficacy. Each of these reagents can be used within a wide range of 
concentrations and still produce the desired accumulation of GTPS bound to G-proteins. The 
available literature reflects this considerable tolerance. Emax values for the widely used, high 
efficacy agonist CP55,940 varies from 136±11% above basal (Burkey et al, 1997a) to 200±7% 
(Hillard et al, 1999). In contrast, THC produces ~25% above basal (Burkey et al, 1997b) in some 
cases and in others produce no discernable stimulation (Griffin et al, 1998). Addition of 
adenosine deaminase (Moore et al, 2000) reduces basal activity by destroying ATP present in the 
tissue. This in turn increases resolution to distinguish high efficacy ligands by eliminating 
purinergic GPCR activity. A summary of cannabinoid agonist-stimulated GTPS studies that 
includes reported Emax values of various ligands and assay conditions is included in Table 2. 
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Ligand 
EC50 
[nM] SEM 
Emax 
%net SEM 
MgCl2 
[mM] 
Na+ 
[mM] 
GDP 
[] 
GTPS 
[nM] 
GDP/ 
GTPS 
Tissue 
Conc. 
[g/ml] Species/Strain Tissue Type Reference 
CP55,940 270 30 129.2 1.82 3 100 100 0.1 1000 300 C57BL6 mice whole brain 
Basavarajappa 
and Hungund, 
1999 
CP55,940 230 20 121.1 0.71 3 100 100 0.1 1000 300 DBA mice whole brain  
HU-210 180 20 130 1.18 3 100 100 0.1 1000 300 C57BL6 mice whole brain  
HU-210 160 10 120.6 2.5 3 100 100 0.1 1000 300 DBA mice whole brain  
WIN55,212-2 330 10 155.4 4.08 3 100 100 0.1 1000 300 C57BL6 mice whole brain  
WIN55,212-2 350 30 142.9 3.2 3 100 100 0.1 1000 300 DBA mice whole brain   
WIN55,212-2 ND ND 132 7 3 100 30 0.05 600 10 to 15 Sprague-Dawley cerebellum 
Breivogel et 
al., 1999 
WIN55,212-2 ND ND 115 18 3 100 30 0.05 600 10 to 15 Sprague-Dawley hippocampus  
WIN55,212-2 ND ND 249 48 3 100 30 0.05 600 10 to 15 Sprague-Dawley 
striatum plus 
globus pallidus   
3 mM levonantrodol ND ND 620 36 3 100 30 0.05 600 10 to 15 Sprague-Dawley cerebellum 
Breivogel and 
Childers, 2000 
3 mM levonantrodol ND ND 210 12 3 100 30 0.05 600 10 to 15 Sprague-Dawley hippocampus  
3 mM levonantrodol ND ND 140 15 3 100 30 0.05 600 10 to 15 Sprague-Dawley hypothalamus   
AEA 3600 2000 41 3 3 100 30 0.1 300 5 CB1 KO cerebellum 
Breivogel et 
al., 2001 
AEA 1400 300 150 7 3 100 30 0.1 300 5 CB1 WT cerebellum  
WIN55,212-2 1800 700 64 7 3 100 30 0.1 300 5 CB1 KO cerebellum  
WIN55,212-2 170 80 180 11 3 100 30 0.1 300 5 CB1 WT cerebellum   
CP55,940 ND ND 149 13 3 100 30 0.1 300 10 to 30 Sprague-Dawley cerebellum 
Breivogel et 
al., 2003 
HU-210 ND ND 141 13 3 100 30 0.1 300 10 to 30 Sprague-Dawley cerebellum  
mAEA 80 23 154 7 3 100 30 0.1 300 10 to 30 Sprague-Dawley cerebellum  
THC 74 3 40 8 3 100 30 0.1 300 10 to 30 Sprague-Dawley cerebellum  
WIN55,212-2 18 5 212 8 3 100 30 0.1 300 10 to 30 Sprague-Dawley cerebellum   
AEA 846 84 96 5 2.5 150 50 0.1 500 
not 
reported Sprague-Dawley whole brain 
Burkey et al., 
1997a 
CP55,940 61.7 11.6 136 11 2.5 150 50 0.1 500 
not 
reported Sprague-Dawley whole brain  
HU-210 2.26 0.38 123 4 2.5 150 50 0.1 500 
not 
reported Sprague-Dawley whole brain  
THC 59  25  2.5 150 50 0.1 500 
not 
reported Sprague-Dawley whole brain  
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THC 70.9 31.7 37 2 2.5 150 50 0.1 500 
not 
reported Sprague-Dawley whole brain  
WIN55,212-2 357   ND   2.5 150 50 0.1 500 
not 
reported Sprague-Dawley whole brain   
2-AG 7585.78 
1570.2
6 68 4 3 100 30 0.1 300 10 shrew whole brain 
Darmani et al., 
2007 
cannabidiol ND ND ND ND 3 100 30 0.1 300 10 shrew whole brain  
CP55,940 5.25 1.33 105 1 3 100 30 0.1 300 10 shrew whole brain  
HU-210 0.19 0.19 120 5 3 100 30 0.1 300 10 shrew whole brain  
HU-211 ND ND ND ND 3 100 30 0.1 300 10 shrew whole brain  
mAEA 1230.27 650.81 120 25 3 100 30 0.1 300 10 shrew whole brain  
SR141716A ND ND ND ND 3 100 30 0.1 300 10 shrew whole brain  
THC 36.31 6.68 53 14 3 100 30 0.1 300 10 shrew whole brain  
WIN55,212-2 107.15 98.58 104 8 3 100 30 0.1 300 10 shrew whole brain   
5 mM WIN55,212-2 ND ND 166.2 25.7 3 100 5 0.05 100 1 to 3 Wistar cerebellum 
Di Marzo et al., 
2000 
5 mM WIN55,212-2 ND ND 163.3 11.6 3 100 5 0.05 100 1 to 3 Wistar striatum  
5 mM WIN55,212-2 ND ND 167 15.3 3 100 5 0.05 100 1 to 3 Wistar hippocampus  
5 mM WIN55,212-2 ND ND 147.9 25.9 3 100 5 0.05 100 1 to 3 Wistar cerebral cortex  
5 mM WIN55,212-2 ND ND 112.4 12.5 3 100 5 0.05 100 1 to 3 Wistar limbi forebrain  
5 mM WIN55,212-2 ND ND 94.8 14.7 3 100 5 0.05 100 1 to 3 Wistar brainstem   
AEA 538 54 71 6 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Gi 
Glass and 
Northup, 1999 
AEA 776 78 45 2 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Go  
HU-210 2.3 0.3 100 ND 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Gi  
HU-210 3.1 0.3 100 ND 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Go  
THC 196 13 64 10 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Gi  
THC 185 28 42 0.4 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Go  
WIN55,212-2 330 53 72 12 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Gi  
WIN55,212-2 362 93 65 3 1 100 4 0.4-0.8 50 20 to 40 NA Sf9 cells-Go   
AEA ND ND ND ND 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum 
Griffin et al., 
1998 
cannabinol ND ND ND ND 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
CP55,244 0.47 0.25 165 17 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
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CP55,940 ND ND 61 28 3 150 10 0.05 200 2 Sprague-Dawley cerebellum  
CP55,940 17.57 10.54 114 17 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
deoxy-HU-210 9.6 8.5 150 55 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
fluoro-mAEA 25.37 20.39 97 42 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
HU-210 0.55 0.3 140 23 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
JWH-030 82.4 68.4 56 19 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
JWH-073 104.8 87.86 29 20 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-1064 246.2 233.75 60 55 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
THC ND ND 51 7 3 150 10 0.05 200 2 Sprague-Dawley cerebellum  
THC ND ND ND ND 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
WIN55,212-2 ND ND 89 14 3 150 10 0.05 200 2 Sprague-Dawley cerebellum  
WIN55,212-2 151.1 50.5 156 12 3 150 100 0.05 2000 2 Sprague-Dawley cerebellum   
8-THC 0 ND 0 ND 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum 
Griffin et al., 
2001 
O-1125 165 12.8 17.4 6 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-1176 0 ND 0 ND 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-1184 0 ND 0 ND 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-1236 87.5 9.7 16.6 5 9 150 10 0.05 200 2 Sprague-Dawley cerebellum  
O-1237 51.3 5.5 10.6 8 9 150 10 0.05 200 2 Sprague-Dawley cerebellum  
O-1238 58.3 8.5 29.7 15 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-584 0 ND 0 ND 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-806 0 ND 0 ND 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum  
O-823 0 ND 0 ND 9 150 100 0.05 2000 2 Sprague-Dawley cerebellum   
11-OH-9-THC 94 6 132 4 5 150 10 0.65 15.38 
not 
reported Sprague-Dawley cerebellum 
Kearn et al., 
1999 
AEA 276 53 166 6 5 150 10 0.65 15.38 
not 
reported Sprague-Dawley cerebellum  
CP55,940 29.6 11 199 7 5 150 10 0.65 15.38 
not 
reported Sprague-Dawley cerebellum  
HU-210 4.3 1.7 179 13 5 150 10 0.65 15.38 
not 
reported Sprague-Dawley cerebellum  
THC 91 32 126 17 5 150 10 0.65 15.38 
not 
reported Sprague-Dawley cerebellum  
WIN55,212-2 102 28 217 8 5 150 10 0.65 15.38 
not 
reported Sprague-Dawley cerebellum   
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AEA 490 ND 134 3 3 0 30 0.5 60 10 to 15 CB1 KO cerebellum 
Monory et al., 
2002 
AEA 3040 ND 343 29 3 0 30 0.5 60 10 to 15 CB1 WT cerebellum  
HU-210 ND ND ND ND 3 0 30 0.5 60 10 to 15 CB1 KO cerebellum  
HU-210 17 ND 492 24 3 0 30 0.5 60 10 to 15 CB1 WT cerebellum  
THC ND ND ND ND 3 0 30 0.5 60 10 to 15 CB1 KO cerebellum  
THC 1490 ND 171 13 3 0 30 0.5 60 10 to 15 CB1 WT cerebellum  
WIN55,212-2 1780 ND 206 16 3 0 30 0.5 60 10 to 15 CB1 KO cerebellum  
WIN55,212-2 1720 ND 444 21 3 0 30 0.5 60 10 to 15 CB1 WT cerebellum   
11-hydroxy-THC 110 50 162 6 1 0 50 0.2 250 30 rat cerebellum 
Petitet et al., 
1997 
11-nor-8-THC-9-
carboxylic acid >10000 ND ND ND 1 0 50 0.2 250 30 rat cerebellum  
11-nor--THC-9-
carboxylic acid >10000 ND ND ND 1 0 50 0.2 250 30 rat cerebellum  
AEA 2300 1100 186 12 1 0 50 0.2 250 30 rat cerebellum  
cannabinol 170 30 130 2 1 0 50 0.2 250 30 rat cerebellum  
CP55,940 9 3 200 2 1 0 50 0.2 250 30 rat cerebellum  
mAEA 180 80 204 14 1 0 50 0.2 250 30 rat cerebellum  
THC 530 310 154 8 1 0 50 0.2 250 30 rat cerebellum  
WIN55,212-2 99 45 175 10 1 0 50 0.2 250 30 rat cerebellum  
WIN55,212-3 >10000 ND ND ND 1 0 50 0.2 250 30 rat cerebellum   
cannabidiol 0 ND 0 ND 1 0 100 0.2 500 30 Sprague-Dawley cerebellum 
Petitet et al., 
1998 
cannabinol 187 ND 24 ND 1 0 100 0.2 500 30 Sprague-Dawley cerebellum  
CP55,940 53 ND 84 ND 1 0 100 0.2 500 30 Sprague-Dawley cerebellum  
THC 216 ND 54 ND 1 0 100 0.2 500 30 Sprague-Dawley cerebellum   
WIN55,212-2 ND ND 
140.2
5 10.15 3 100 50 0.1 500 ? Sprague-Dawley 
medial prefrontal 
cortex 
Rodríguez-
Gaztelumendi 
et al., 2009 
WIN55,212-2 ND ND 
173.7
1 12.63 3 100 50 0.1 500 ? Sprague-Dawley caudate-putamen  
WIN55,212-2 ND ND 
171.0
4 26.71 3 100 50 0.1 500 ? Sprague-Dawley hippocampus  
WIN55,212-2 ND ND 
110.0
7 2.98 3 100 50 0.1 500 ? Sprague-Dawley amygdala  
WIN55,212-2 ND ND 
105.5
5 5.26 3 100 50 0.1 500 ? Sprague-Dawley 
dorsal raphe 
nucleus   
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mAEA 114 4.2 542 84 3 100 30 0.08 375 5 to 10 CB1 HET cerebellum 
Selley et al., 
2001 
mAEA 63 0.4 277 36 3 100 30 0.08 375 5 to 10 CB1 HET hippocampus  
mAEA 33 4.9 551 103 3 100 30 0.08 375 5 to 10 CB1 HET 
striatum plus 
globus pallidus  
mAEA ND ND ND ND 3 100 30 0.08 375 5 to 10 CB1 HET cingulate cortex  
mAEA 160 14 375 23 3 100 30 0.08 375 5 to 10 CB1 WT cerebellum  
mAEA 96 6.9 265 33 3 100 30 0.08 375 5 to 10 CB1 WT hippocampus  
mAEA 67 5.6 227 47 3 100 30 0.08 375 5 to 10 CB1 WT 
striatum plus 
globus pallidus  
mAEA 56 3.6 183 42 3 100 30 0.08 375 5 to 10 CB1 WT cincgulate cortex  
THC 34 7.7 215 69 3 100 30 0.08 375 5 to 10 CB1 HET cerebellum  
THC 24 3.2 63 24 3 100 30 0.08 375 5 to 10 CB1 HET hippocampus  
THC 12 2.1 220 94 3 100 30 0.08 375 5 to 10 CB1 HET 
striatum plus 
globus pallidus  
THC ND ND ND ND 3 100 30 0.08 375 5 to 10 CB1 HET cingulate cortex  
THC 51 5.7 153 41 3 100 30 0.08 375 5 to 10 CB1 WT cerebellum  
THC 44 1.7 55 31 3 100 30 0.08 375 5 to 10 CB1 WT hippocampus  
THC 23 2.7 92 44 3 100 30 0.08 375 5 to 10 CB1 WT 
striatum plus 
globus pallidus  
THC 28 4 93 17 3 100 30 0.08 375 5 to 10 CB1 WT cingulate cortex  
WIN55,212-2 204 18 167 26 3 100 30 0.08 375 5 to 10 CB1 HET cerebellum  
WIN55,212-2 134 5.5 176 12 3 100 30 0.08 375 5 to 10 CB1 HET hippocampus  
WIN55,212-2 60 5.7 204 27 3 100 30 0.08 375 5 to 10 CB1 HET 
striatum plus 
globus pallidus  
WIN55,212-2 106 7.9 287 43 3 100 30 0.08 375 5 to 10 CB1 HET cingulate cortex  
WIN55,212-2 248 29 104 18 3 100 30 0.08 375 5 to 10 CB1 WT cerebellum  
WIN55,212-2 181 14 137 19 3 100 30 0.08 375 5 to 10 CB1 WT hippocampus  
WIN55,212-2 112 13 126 17 3 100 30 0.08 375 5 to 10 CB1 WT 
striatum plus 
globus pallidus  
WIN55,212-2 139 3.3 178 220 3 100 30 0.08 375 5 to 10 CB1 WT cingulate cortex   
WIN55,212-2 0.04 0.01 119 1.5 3 100 30 0.1 300 3.5 to 8 
Long-Evans 
female 
adolescent prefrontal cortex 
Wiley et al., 
2008 
WIN55,212-2 0.06 0.03 102 1.8 3 100 30 0.1 300 3.5 to 8 
Long-Evans 
female 
adolescent striatum  
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WIN55,212-2 0.19 0.02 87 10.6 3 100 30 0.1 300 3.5 to 8 
Long-Evans 
female 
adolescent midbrain  
WIN55,212-2 0.08 0.02 205 10 3 100 30 0.1 300 3.5 to 6 
Long-Evans 
female adult prefrontal cortex  
WIN55,212-2 0.13 0.02 194 5.1 3 100 30 0.1 300 3.5 to 6 
Long-Evans 
female adult striatum  
WIN55,212-2 0.08 0.03 137 8.5 3 100 30 0.1 300 3.5 to 6 
Long-Evans 
female adult midbrain  
WIN55,212-2 0.16 0.01 112 5.4 3 100 30 0.1 300 3.5 to 9 
Long-Evans 
male adolescent prefrontal cortex  
WIN55,212-2 0.14 0.02 96 5.1 3 100 30 0.1 300 3.5 to 9 
Long-Evans 
male adolescent striatum  
WIN55,212-2 0.14 0.01 105 5.8 3 100 30 0.1 300 3.5 to 9 
Long-Evans 
male adolescent midbrain  
WIN55,212-2 0.88 0.38 135 2.9 3 100 30 0.1 300 3.5 to 7 
Long-Evans 
male adult prefrontal cortex  
WIN55,212-2 1.46 0.45 100 2.6 3 100 30 0.1 300 3.5 to 7 
Long-Evans 
male adult striatum  
WIN55,212-2 0.41 0.17 91 5.1 3 100 30 0.1 300 3.5 to 7 
Long-Evans 
male adult midbrain  
 
 
              
              
Table 1. Assay conditions of agonist stimulated [35S]GTPS binding experiments as determinants of Emax estimations. Concentrations 
of MgCl2, Na+, relative concentrations of GDP and GTPS, strain, and selected CNS region all influence the magnitude of measured 
efficacy. Relative differences in efficacy, especially at either extreme, are highly dependent on the interplay of each reagent.
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Intracellular Na+ allosterically inhibits G-protein mediated signaling stimulated by 
dopaminergic, opioidergic, and serotonergic, and many other GPCRs (Katritch et al, 2014). CB1 
receptors are similarly regulated by Na+ via the same evolutionarily conserved aspartate residue 
on the second transmembrane helix (Tao and Abood, 1998). While mutation of the sodium-
binding aspartate appears to affect binding affinity of certain ligands, such as 
desacetyllevonantrodol (Houston and Howlett, 1998), it nonetheless reduces downstream 
inhibition of adenylyl cyclase resulting in greater than expected cAMP formation for 
WIN55,212-2, CP55,940, AEA, and THC (Tao and Abood, 1998). These results suggest the 
existence of an inverse relationship between the concentration of Na+ and the Emax measured by 
agonist-stimulated [35S]GTPS binding. Some experiments report no Na+ in the assay (Petitet et 
al, 1998), though most are within the 100-150 mM range (Breivogel and Childers, 2000; Griffin 
et al, 1998), a physiologically relevant concentration. 
Magnesium ions (Mg2+) are important co-factors for the binding of both GDP and GTP to 
the G-protein and typical concentrations in agonist-stimulated [35S]GTPS binding typically 
range from 1 mM (Petitet et al, 1997) to 5 mM (Thomas et al, 2005), though one study reports 
using 9 mM in the GTPS assay buffer (Griffin et al, 1999). In the absence of Mg2+ the affinities 
of GDP and GTP are drastically reduced, and if the concentrations of both are sufficiently low, 
G-proteins become unstable and may degrade (Sprang, 1997). Magnesium also extends the 
duration of GTPS binding (Higashijima et al, 1987); thus manipulating this ion can enhance the 
sensitivity to measure accumulation via scintillation counting. 
The quantity of protein for agonist-stimulated [35S]GTPS binding may also affect the 
measured Emax value. A high protein concentration should increase the relative concentration of 
CB1. Accordingly, the Stephenson equation predicts a positive relationship between protein 
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concentration and the maximum effect. Thus, ligands appear indistinguishable regardless of 
efficacy in preparations containing a large receptor reserve. As the density of CB1 expression 
varies with CNS region, different brain regions are often used to change the relative 
concentration of the receptor. All other factors being equivalent, the choice of protein 
concentration need only be sufficiently high to detect stimulation and not so high that it 
precludes differentiation. Thus, comparisons made between studies utilizing the same drugs, but 
different tissues, will likely yield calculated different Emax values. However, a series of ligands 
varying in efficacy assessed in different tissues may be comparable in a qualitative manner. 
Typical protein concentrations range from as low as 2 g/ml (Griffin et al, 1998) to as high as 30 
g/ml (Petitet et al, 1998). The brain region most utilized in in vitro cannabinoid studies is the 
cerebellum (Table 2), likely due to the ease of dissection and its relatively high expression of 
CB1. It also possess rather low endogenous basal activity, which bolsters the resolution to detect 
small, but significant, increases in binding of low efficacy cannabinoids. If the anatomical 
distribution of the functional activity of CB1 in the presence of an agonist is desired, agonist-
stimulated [35S]GTPS autoradiography is of great value (Sim et al, 1996a). However, this 
technique does not readily lend itself to testing a large range of drugs under the same conditions, 
as is the case with agonist-stimulated [35S]GTPS binding. Autoradiography does provide 
exquisite neuroanatomical detail but only one test ligand may be utilized per sample. For 
agonist-stimulated [35S]GTPS binding, samples are often distributed over many assay wells or 
tubes, thus affording the flexibility to assess the effect of many dose-effect curves in the same 
tissue. Importantly, this design allows quantitative inferences to be made regarding the 
pharmacological properties of the drugs tested, specifically as they relate to GDP-GTP exchange. 
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The relative concentration of GDP to [35S]GTPS can be easily manipulated and 
represents a highly useful assay parameter to vary in order to increase the resolution of the 
binding assay. Progressively increasing concentrations of GDP drives down basal activity (Sim 
et al, 1995), but facilitates detecting differences in efficacy for ligands clustered near the top of 
the continuum. Conversely, very low concentrations of GDP favor differentiation between 
agonists of very low efficacy, such as THC and analogs (see Table 2, Griffin et al., 2001). As 
with the tissue concentration, the range of GDP employed across studies is quite wide, ranging 
from 4 M (Glass and Northup, 1999) to 100 M (Griffin et al, 1998). As predicted, low 
concentrations do not as readily distinguish between high efficacy ligands, while high 
concentrations more easily separate high efficacy ligands (Griffin et al, 1998). The [35S]GTPS 
concentration in these assays often falls in the sub-nanomolar range, rendering the ratio of 
GDP/[35S]GTPS anywhere from 15 (Kearn et al, 1999) to 2000 (Griffin et al, 2001). Both GDP 
and GTP have nanomolar affinities for most G-proteins, with GTP having approximately 1-10 
fold higher affinity depending on the G-protein type and/or subtype (Sprang, 1997). [35S]GTPS 
has an even greater affinity for the G-protein that may, in part, account for the large discrepancy 
in relative concentrations, which are necessary to detect differences among ligands. Additionally, 
binding of a ligand to the CB1 receptor reduces the apparent affinity of GDP for G-proteins and 
increases that of GTPS (Breivogel et al, 1998). 
To effectively assess whether CB1 ligands differ in efficacy, the assay parameters must be 
able to capture agonist stimulation of CB1 activity for both high and low efficacy compounds. 
The NaCl (100 mM) and MgCl2 (3mM) should be sufficiently high to reduce basal activity and 
extend the time course of GTPS binding, respectively. Incubation with adenosine deaminase 
will metabolize much of the present ATP, reducing purinergic GPCR activity and reducing the 
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non-CB1 activity further. Concentrations of GTPS (0.1 nM) and GDP (30 M) will reflect a 
moderate ratio of GDP to GTPS (300) to facilitate sensitivity to both high and low efficacy 
compounds. This moderate concentration would likely reduce sensitivity to ligands with 
extremely high or low efficacy. However, this experimental window can be altered by varying 
the GDP concentration, and concomitantly altering the ratio of GDP to GTPS. In this thesis, I 
captured respective high and low receptor conditions by using cerebellum and spinal cord 
samples. Additionally, receptor levels were further varied through the employment of CB1 WT, 
HET, and KO mice will be used. The overall protein concentrations were held constant 
irrespective of genotype and brain region to ensure observed differences are the result of relative 
changes in CB1 expression, as well as to enable quantitative comparisons between brain regions 
and genotypes. 
1.8  Selection of cannabinoid ligands and controls based upon evidence from previous 
[35S]GTPS binding experiments 
 The ligands THC, CP47,497, JWH-073, CP55,940, and WIN55,212-2 were selected for 
study in the cumulative dosing triad and agonist-stimulated [35S]GTPS binding due to their 
apparent relative differences in efficacy, as reviewed in Table 2. CP47,497 and JWH-073 were 
also selected because of their historical detections in abused preparations of Spice and K2 
products (Auwärter et al, 2009). To aid in these studies, the heat degradant of the highly 
efficacious A-834,375 (A-834,735D) was selected as another high efficacy cannabinoid ligand. 
Preliminary data indicate the degradant form has very high efficacy at the CB1 receptor in 
recombinant human CB1 (hCB1) expressing human embryonic kidney (HEK) cells, and it will 
serve as an archetypal representative of newer SC compounds (Thomas and Wiley, 2014). 
Preliminary data from our own lab also indicated CP47,497 was lower in efficacy than 
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CP55,940. Although many of these ligands have been tested under the same conditions, the 
assays were often not optimized to detect differences between both and low efficacy ligands, and 
only WIN55,212-2 and THC were tested in CB1 KO tissue. Unlike most other cannabinoid 
agonists, WIN55,212-2 stimulates [35S]GTPS binding in these tissues suggesting that this non-
CB1 activity yields an over-estimation of reported Emax values. Indeed, reported studies do not 
account for the non-CB1 stimulation (Monory et al, 2002). The potential off-target stimulation is 
especially important to consider in the case of the only agonist-stimulated [35S]GTPS binding 
study conducted utilizing CB1 HET mice to manipulate receptor density (Selley et al, 2001). The 
same study also utilized methanandamide, which may stimulate [35S]GTPS binding in a similar 
fashion as the structurally related endocannabinoid anandamide (Breivogel et al, 2001; Monory 
et al, 2002). Accordingly, the estimated Emax values reported in WT and HET membranes might 
be equally inflated, rendering the relative efficacies closer to one another than when non-CB1 
stimulation is subtracted. In the studies reported in this thesis (Chapter 2), the same 
concentrations of agonists will be used in both WT and HET samples, while KO tissue will be 
used to detect potential non-CB1 stimulation. Each of the ligands selected has similar affinities 
for the CB1 receptor and the CB2 receptor. However, it is important to note that CB2 receptor 
mRNA is expressed at very low levels within the CNS, and likely contributes little to the overall 
signal.  In contrast, CB1 mRNA and protein are vastly abundant (Galiègue et al, 1995) and 
represents among the highest expressed GPCRs in the brain. Therefore, CB2 contribution to the 
signal is negligible and off target-stimulation is likely to reflect a heretofore unknown target or 
targets.  
 For in vivo experiments, the selectivity of the assay for cannabimimetic agents was 
assessed using the mu opioid receptor agonist morphine and the atypical antipsychotic 
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chlorpromazine. Despite possessing non-CB1 mechanisms of action, these drugs produce a 
subset of the triad endpoints. Importantly, both morphine and chlorpromazine were expected to 
be equipotent to produce their effects irrespective of genotype, indicating the specificity for CB1 
activity. 
1.9 Potential methods to determine efficacy at the CB1 receptor in vivo 
 CB1 receptors are heterogeneously expressed throughout the mammalian brain, with high 
receptor concentrations in brain regions believed to mediate the pharmacological effects of 
cannabis and THC  (Herkenham et al, 1990, 1991).  Many cannabimimetic effects occur via this 
receptor (Ledent et al, 1999; Rinaldi-Carmona, 1994; Rinaldi-Carmona et al, 1995; Zimmer et 
al, 1999a), including catalepsy, hypothermia, antinociception, and hypolocomotion. 
Consequentially, the receptor reserve mediating the pharmacological actions of cannabinoids 
may be sufficient for even very low efficacy compounds produce effects a similar magnitude to 
high efficacy agonists across many endpoints. This inability to distinguish efficacy due to dense 
CB1 receptor expression presents unique challenges to ascertain in vivo efficacy at the CB1 
receptor, especially with the knowledge that CB1 receptor expression varies considerably across 
brain regions (Herkenham et al, 1990). The requisite reduction in CB1 receptors available for 
signaling may be achieved through pharmacological and/or genetic approaches. In the following 
discussion, three general experimental approaches are discussed in which CB1 expression is 
experimentally reduced to investigate efficacy. 
First, repeated administration of THC and synthetic cannabinoids leads to tolerance and 
cross tolerance to other cannabinoids (Fan et al, 1994; Pertwee et al, 1993). This tolerance 
occurs concomitantly with receptor downregulation and desensitization which occurs in a brain 
region specific manner, as determined by radioligand and agonist-stimulated [35S]GTPS 
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autoradiography (Lazenka et al, 2014; Tai et al, 2015a).  Potency shifts may be used to infer 
differences in efficacy following chronic treatment in the case of drug discrimination (Hruba et 
al, 2012), though the neural substrates, which underlie this behavior, are not well understood. 
Other studies which demonstrate varying degrees of tolerance depending on which agonist is 
repeatedly administered also may not readily differentiate between efficacy of the test drugs, and 
the duration and timing of the dosing of the toleragen are determining factors for the degree of 
tolerance (Fan et al, 1994). Another limitation of this approach may lie within the inherent 
differences in ligand bias, which almost assuredly exist among cannabinoid agonists (Laprairie et 
al, 2014). BARR2 plays a role in both acute CB1-mediated effects of THC (Breivogel et al, 
2013) and tolerance following repeated administration (Nguyen et al, 2012). BARR2 also 
promotes CB1-mediated signaling via ERK1/ERK2 (Franklin et al, 2013); thus, observed 
tolerance may be the result of decreased Gi/o signaling and a shunting towards BARR2. In cell 
cultures, ERK1/ERK2 signaling elevates during prolonged CP55,940 exposure suggesting this 
may be the case (Daigle et al, 2008a). Unsurprisingly, this apparent shunting of pathways likely 
occurs in a CNS region dependent manner (Rubino et al, 2006), further complicating 
interpretations of chronic dosing regimens as they relate to efficacy. Chronic THC treatment 
induced changes in BARR2 and ERK/Ras signaling in striatum and cerebellum, but not in 
hippocampus or prefrontal cortex, and the desensitization observed may occur via alternate 
mechanisms (Rubino et al, 2006). 
 A second pharmacological approach to infer efficacy involves the use of an irreversible 
antagonist to progressively and dose-dependently reduce the number of receptors available. 
Irreversible antagonists are associated with insurmountable rightward and downward shifts in 
dose response curves. The reduction in receptor population in turn facilitates the estimation of , 
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or 
𝑅𝑇
𝐾𝐸
, via isolation of 𝐾𝐸, or the concentration of the agonist receptor complex to produce a 50% 
effect, as seen in the operational model (Black and Leff, 1983; Kenakin, 2014). As 𝑅𝑇 
approaches zero, the EC50 will collapse upon the KA. This approach has been demonstrated 
utilizing the irreversible mu opioid antagonist clocinnamox to estimate the of various mu 
opioid ligands (Pawar et al, 2007). However, this approach is not feasible to investigate efficacy 
of compounds at CB1, as no irreversible antagonist is available yet for this receptor. On the other 
hand, the anandamide analog AM3577, which binds covalently to the orthosteric site and inhibits 
adenylyl cyclase (Janero et al, 2015), may provide a tool for this sort of approach. However, 
AM3577 would unlikely be able to distinguish between agonists of lower or similar efficacy.  
Genetic approaches represent third way to reduce CB1 expression. Short interfering 
ribonucleic acid (siRNA) represents another potential method to reduce the overall expression of 
CB1, though the degree of knockdown may be challenging to be implemented in systematic and 
controlled manner throughout the entire CNS. Alternatively, the use of CB1 wild type (WT), 
heterozygous (HET), and knockout (KO) transgenic mice reflects a simple tool to reduce 
receptor levels in a controlled fashion (Ledent et al, 1999; Zimmer et al, 1999b). WT mice 
express the normal abundance of CB1, HET mice express approximately half of normal levels 
(Selley et al, 2001), and KO do not express functional CB1 (Zimmer et al, 1999b). Thus, these 
transgenic mice represent a way to assess the loss of potency and/or efficacy of different 
compounds at CB1, while simultaneously maintaining sensitivity to potential off target effects. 
This approach has several advantages versus the alternative methods described above. First, the 
reductions in receptor population are presumably constitutive and stable. Second, the reduction 
in CB1 expression is proportional to the tissue. While CB1 receptor density varies considerably 
with brain region (Herkenham et al, 1990), the expression in HET mice is approximately half of 
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WT levels in cerebellum, hippocampus, striatum, and cingulate cortex (Selley et al, 2001), and 
this pattern of half expression in HET mice presumably continues throughout the brain. A 
limitation of this approach is that it does not provide the graded reduction in receptor an 
irreversible antagonist would afford. Accordingly, the estimation of KE is not possible with a 
great degree of confidence. Instead, a simple formulation of the receptor theory equation may 
predict the pharmacological effects of agonists varying in CB1 efficacy. 
1.10 Theoretical predictions based upon the Stephenson receptor theory model 
𝐸 = [𝑅𝑇] ∗ [𝜀] ∗
[𝐴]
[𝐴] + 𝐾𝐷
 
 
E = maximum effect 
𝑅𝑇 = receptor population 
ε = efficacy of the drug 
[𝐴]
[𝐴]+ 𝐾𝐷
 = fractional occupancy 
 
The Stephenson equation (Stephenson, 1956) is an extension of the Furchgott receptor 
occupancy equation, but it includes the term “” which acknowledges the inherent differences in 
ligands in terms of the degree of activation they are able to produce. This equation also 
determines the maximum amount of activation an individual ligand can stimulate which accounts 
for the existence of partial agonists. The fractional occupancy term 
[𝐴]
[𝐴]+𝐾𝐷
 produces the 
characteristic hyperbolic (in a linear-linear scale) and sigmoidal (in a log-linear scale) shapes 
seen in dose-effect studies. Importantly, when [A] = 𝐾𝐷 then the fractional occupancy is half 
which in turn reflects the equilibrium between bound and unbound ligand. The affinity and 
efficacy terms determine potency insofar as drugs which are more efficacious or possess higher 
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affinity also tend to be more potent, with the most potent drugs tending to have high efficacy and 
high affinity. The other determinant of the effect of a drug is the number of receptor available to 
signal through. The number of receptors may vary from tissue from tissue, and in the case of 
cannabinoids definitely does. Another implication of this variance in receptor expression is 
differential tissue sensitivity given the same ligand. In the case of CB1 transgenic mice, the 
consequences of 100%, 50%, and 0% receptor expression may be modeled and explored (Figure 
6). 
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Figure 6. Utilizing the Stephenson receptor theory equation, predictions regarding changes in 
efficacy and potency regarding reductions in receptor populations were depicted. In WT tissue, 
which expresses normal levels of CB1, maximal activation was achieved. In HET tissue, exactly 
half of WT activation occurred and in KO tissue no activation was observed. This activation 
corresponds with 100%, 50%, and 0% expression of CB1. At a given dose of the agonist, the 
fractional occupancy in WT and HET tissues were identical. 
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 Using a single agonist in each genotype, the maximum effect is assumed to be 
proportional to the reduction in total receptor number. Accordingly, a given CB1 agonist is 
predicted to possess the following efficacies in the three genotypes, assuming no receptor 
reserve: 1) WT mice that possess 100% of the receptors will show a maximum effect; 2) HET 
mice, which possess 50% of the receptors, a concordant 50% reduction in efficacy will be 
observed; 3) KO mice, which have no receptors available for signaling, will not show any 
measurable effect regardless concentration. However, the proportion of the available receptors 
occupied does not change for a given concentration, as indicated by the vertical dotted line in 
Figure 6. At the EC50 in WT mice half of 100% of the receptors are occupied whereas half of 
50% of the receptors are occupied in HET mice. There is no occupancy in the KO mice as there 
are no receptors. It should be noted that these conditions do not allow for reliable estimation of 
KE as derived from the Operation Model as only two EC50 concentrations are observed, obviating 
the necessary nonlinear regression necessary to calculate KE. 
 The pharmacological effects of cannabinoids are mediated by distinct pools of CB1 
receptors. Moreover, the concentration of CB1 receptors are known to vary throughout the CNS. 
Intuitively, pharmacological effects mediated by circuits containing very high CB1 expression 
were hypothesized to show very small shifts between WT and HET mice (Figure 7). Under 
conditions of moderate receptor levels, more resolution is gained to distinguish between low and 
high efficacy ligands in which rightward and downward shifts may be readily observed with low 
efficacy ligands (Figure 8). Very low receptor expression conditions may further differentiate 
between ligands of varying efficacy when compared amongst the genotypes, but the resolution to 
do so may be lost as the dose-effect relationships begin to congregate towards the abscissa 
(Figure 9). For instance, ligands that both possess low, but different levels of efficacy could be 
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tested under both moderate and low receptor conditions. The moderate expression may 
differentiate between the efficacies of the two test ligands whereas the low receptor conditions 
would display a floor effect, preempting differentiation under those conditions. Consequently, it 
remains important to assess efficacy under a variety of conditions to properly ascertain actual 
differences in efficacy. 
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Figure 7. High receptor expression conditions revealed only small changes in potency between 
WT and HET dose-effect curves utilizing ligands with high or medium efficacy. Larger shifts 
were observed with low efficacy ligands, but maximal effects were achieved in WT but not HET 
mice. 
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Figure 8. Moderate levels of CB1 expression show better resolution to distinguish between 
ligands that vary in efficacy utilizing differential potency between WT dose effect curves. 
Additionally, downward shifts are readily observed across ligands which vary in efficacy due to 
a 50% reduction in receptor population. 
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Figure 9. Low receptor conditions differentiate high efficacy ligands more readily than low 
efficacy ligands. When low efficacy ligands are utilized under low receptor expression 
conditions, dose-effect curves collapse on the abscissa. In practice, experimental error may 
eclipse a potential differences between genotypes. 
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Practical and experimentally imposed limits of detection also influence the ability to 
stratify ligands based upon efficacy. The experimental floor may be a function of the sensitivity 
of the assay and/or tissue, or an experimenter imposed minimum value. In situations in which the 
floor is very high, the EC50 estimate will be shifted to the right relative to the theoretical (Figure 
10). The experimental ceiling is usually arbitrarily determined and may not be based upon the 
true maximum effect that might be achieved by various agonists. For example, in assays that can 
evoke tissue damage (e.g. warm water tail withdrawal and radiant heat tail-flick tests), a cutoff 
time is used for animal welfare concerns. Practical considerations such as the length of the test 
can also contribute, as in some cases additional observation does not yield a substantial degree of 
additional information. In cases where the ceiling is very low relative to the maximum 
observable effect, the potency of agonists which do achieve a maximum effect will shift to the 
left relative to the true measurable maximum (Figure 11). Although ceiling and floor effects 
represent challenges in deriving potency estimations, as long as the same assay conditions are 
applied for each agonist then the relative rank order efficacy among the agonists does not 
change. Provided the observable effects capture a sufficient portion of each dose-effect 
relationship, then whatever potency estimations are calculated will reflect the interrelationships 
between the agonists. In the context of using CB1 transgenic mice that express different 
concentrations of receptors, ceiling effects likely impose the largest restrictions on measuring 
actual differences in maximum effect. Although the maximum effect in HET mice will be half of 
what is observed in WT mice, the experimental window may afford maximum effects in both 
genotypes with the only apparent difference being potency. Therefore, the potency shift between 
the WT and HET mice may reflect efficacy differences, though Emax values may not differ. The 
shift in potency, however, would not reflect non-CB1 mediated contributions. 
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Figure 10. The experimental floor (as indicated by the solid black line) is often defined by the 
sensitivity of the assay. When the floor is high (i.e. sensitivity is low) then the calculated EC50 
may be shifted to the right. As the floor becomes lower (i.e. sensitivity is increased) the EC50 
shifts left. 
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Figure 11. The ceiling (solid black line) of the assay may be the result of experimenter imposed 
conditions. If the ceiling is high then it could reflect the actual gain of the system, although 
practically it is often reduced due to outside constraints. When the ceiling is low then EC50 
estimations are shifted left. 
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1.11  The cannabinoid tetrad: a summary of previous findings 
 As detailed above, numerous synthetic cannabinoids were synthesized utilizing a variety 
of backbone moieties. Binding properties of ligands to both cannabinoid receptors have been 
investigated using radioligand binding assays, while downstream signaling events such as G-
protein signaling, cAMP accumulation, or ERK1/2 phosphorylation have also been characterized 
using variety of in vitro and in vitro techniques. The physiological relevance of these 
biochemical measurements requires translational studies. Initial cannabinoid research utilized the 
common dog (Canis familiaris) because of their considerable sensitivity to the psychoactive 
effects of cannabinoids. THC and other cannabinoid agonists produced ataxia (Dewey et al, 
1972), bradycardia (Cavero et al, 1973), and analgesia (Kaymakçalan et al, 1974) in dogs. The 
use of canines began to fall out of favor, as reliable bioassays using mice and rats were 
increasingly employed. The first iteration of the cannabinoid tetrad was used to investigate 
structure activity relationships of THC analogs (Skinner et al, 1979). Later, Billy Martin and 
colleagues began heavy use of this method, recognizing that cannabimimetic agents produced a 
common spectrum of behavioral and physiological effects. specifically reduction of spontaneous 
activity (Martin, 1985), catalepsy, hypothermia (Beardsley et al, 1987), and antinociception 
(Martin, 1985) were utilized for these efforts. Catalepsy is defined as a fixed, rigid posture and is 
often measured utilizing the bar test or ring test. In the bar test, the forepaws of the subject are 
placed on a bar and the latency to remove themselves from the bar as set number of times 
(usually four) is measured. In the ring test, the animal is draped across a metal ring and latency to 
remove itself is measured. For both the ring test and the bar test, animals which do not have rigid 
posture (e.g. immobile but not cataleptic) will not remain on the apparatus. Usually the 
experimenter imposes a cut off time to limit the duration of the test. Antinociception can be 
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measured a number of ways, though the tail flick assay using radiant heat or immersion in hot 
water are the most common methods. In both cases, latency to remove the tail from the 
nociceptive stimulus is recorded. Stimulus intensity can be manipulated by adjusting the 
temperature, and the maximum may max also be altered though animal welfare concerns usually 
determine the ceiling. 
This constellation of effects was eventually coined the cannabinoid “tetrad” and 
employed to explore in vivo structure activity relationships (Little et al, 1988b). Little and Martin 
also employed the stereoselective effects of cannabinoids (Little et al, 1989), corroborating the in 
vitro work, which satisfied the requirements for the existence of a distinct cannabinoid receptor 
(Devane et al, 1988). Subsequent work featuring the CB1 antagonists rimonabant (Compton and 
Martin, 1996; Rinaldi-Carmona, 1994; Rinaldi-Carmona et al, 1995) or AM251 (McMahon and 
Koek, 2007), CB1 KO mice (Ledent et al, 1999; Zimmer et al, 1999a) further verified the tetrad 
as a reliable screen for in vivo cannabimimetic activity. If a given ligand exhibited these four 
effects, it was likely to be a cannabinoid, especially when complemented by biochemical assays 
to determine both receptor binding and activation (Compton et al, 1993). A later study adapted 
the cannabinoid tetrad assay into a cumulative dosing procedure (Falenski et al, 2010) to afford a 
more expeditious manner of generating dose-effect relationships. Because repeated exposure to a 
test apparatus leads to acclimation and reduction in exploratory motor behavior, the 
hypolocomotion measure was eschewed. 
  
1.12  CB1 transgenic mice as a model: advantages and limitations 
 Initially cloned in 1990, the CB1 receptor gene Cnr1 encodes a 473 amino acid sequence 
contained in a single large exon (Matsuda et al, 1990), and is a seven transmembrane G-protein 
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coupled receptor, which signals via Gi/o to inhibit downstream adenylyl cyclase (Devane et al, 
1988). The creation of CB1 knockout mice represented a complementary tool to CB1 antagonists 
in discerning whether this receptor mediated the pharmacological effects of cannabinoids and to 
investigate function of endogenous cannabinoids. Three varieties of mice with constitutive 
deletion of CB1 mice exist: outbred CD1 strain (Ledent et al, 1999), the inbred C57BL6/J 
(Zimmer et al, 1999a), and another on the C57BL6/J (Robbe et al, 2002). Both the Ledent and 
Manzoni approaches replaced a large portion of the gene as well as the upstream promoter region 
with a neo cassette. The Zimmer line did not replace the promoter, but rather replaced all but the 
first 32 and flanking 24 amino acids. Regardless, none of the lines exhibit CB1 radioligand 
binding and the vast majority of putative cannabinoid ligands do not stimulate G-proteins in 
these KO mice. The Zimmer line is used by the vast majority of laboratories employing CB1 
transgenic mice, although a fourth, doxycycline-inducible CB1 line exists (Marsicano et al, 
2002), affording temporal control of CB1 expression. 
 CB1 KO mice display stark physiological and behavioral phenotypes compared to their 
WT and HET siblings. In vivo, they display reduced bodyweight, higher mortality rates, reduced 
locomotor activity, and a higher incidence of seizures (Zimmer et al, 1999a). Physiologically, 
they display progressive loss of hippocampal neurons with age, though adolescent CB1 KO mice 
will sometimes outperform their WT littermates in the rotorod task (Bilkei-Gorzo et al, 2005), 
and increased expression of dopamine D2 receptors conveys a resistance to ethanol-induced 
conditioned place preference (Houchi et al, 2005) suggesting the deletion of CB1 may not be 
entirely deleterious. This finding could be specific to ethanol, although it may reflect a more 
general hyposensitivity to reward as CB1 KO imbibe lower totals of a sweetened saccharine 
solution (Sanchis-Segura et al, 2004) and do not acquire cocaine self-administration as readily as 
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their WT counterparts (Soria et al, 2005). Curiously, basal activity of delta, kappa, and mu 
opioid receptors seems to be elevated in CB1 KO mice relative to WT mice (Urigüen et al, 
2005), expression and function of GABAA and GABAB receptors is altered (Urigüen et al, 
2011), and hypofunction of serotonergic receptors (Mato et al, 2007), though the behavioral 
ramifications of these phenotypes are not yet explored. 
CB1 KO mice are generally difficult to breed. CB1 KO dams often display poor blastocyst 
implantation due to deficiencies in AEA-CB1 signaling (Wang et al, 2003). CB1 also plays a role 
in healthy development of sperm, as sperm from CB1 deficient mice show impaired motility 
(Maccarrone, 2005). Combined, these consequences of CB1 deletion render KO-KO breeding 
pairs generally unsuccessful, but the use of HET mice presents its own set of complications. 
During breeding, HET to HET sires and dams often do not yield a Mendelian (1:2:1 
WT:HET:KO) distribution of offspring, with the knockouts often underrepresented among their 
littermates. Some evidence exists for pre-implantation dynamic regulation of CB1 mRNA and 
endocannabinoid signaling (Paria et al, 1995), as well as impaired oviductal transport in CB1 KO 
embryos (Wang et al, 2004) which may contribute to the observed, unexpected offspring 
distribution. This inevitably necessitates the use of both male and female mice in some cases 
when maintenance of large numbers of breeding HET pairs is impractical.  
 The use of both male and female mice introduces potential variability given known 
interactions of the endocannabinoid system and sex-linked characteristics and hormones. Female 
rats display dynamic changes in CB1 expression during the estrous cycle, ovarectemized (OVX) 
rats express less CB1 in the hypothalamus, and progesterone may rescue this deficit (Rodríguez 
de Fonseca et al, 1994). A similar study corroborated the reduced CB1 density in the 
hypothalamus of OVX and male Sprague-Dawley rats, and also reported increases in amygdalar 
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expression of CB1 in OVX and male rats (Castelli et al, 2014; Riebe et al, 2010). Fluctuations in 
a variety of endocannabinoids and related lipids also occur in tandem with estrous (Bradshaw, 
2006) potentially affecting the exogenous administration of cannabinoids. Stressors may also 
induce changes in CB1 expression in a sex-dependent manner, though a daily non-contingent 
shock paradigm may be a severe example (Xing et al, 2011). The potency of some cannabinoids 
including THC show sex-dependent differences in producing antinociception, hypolocomotion 
(Tseng and Craft, 2001), anti-allodynic effects, and reduction of edema (Craft et al, 2013) in 
Sprague-Dawley rats. On the other hand, the synthetic agonist CP55,940 failed to elicit 
significant differences in potency to increase the tail withdrawal response in adolescent Sprague-
Dawley male and female rats (Romero et al, 2002), and THC produced few sex-related 
differences when injected via the intracerebroventricular  route of administration (Wakley and 
Craft, 2011). In Long-Evans rats, THC elicited catalepsy, antinociception, hypothermia, and 
hypolocomotion irrespective of sex (Wiley et al, 2007).  Agonist-stimulated [35S]GTPS of male 
and female rats treated chronically with THC revealed greater desensitization in female rats 
relative to males following application of CP55,940 (Burston et al, 2010). 
In mice, the pattern of results is similarly mixed. Following acute treatment with THC, 
female mice from the outbred Swiss-Webster strain displayed both locomotor enhancement at 
low doses (3-10 mg/kg), and suppression at the highest dose tested (30 mg/kg) whereas males 
displayed exclusively suppression (Wiley, 2003b). No locomotor enhancement was detected in 
mice bred for wheel running behavior following WIN55,212-2 (0.5-3.0 mg/kg) administration, 
though females seemed resistant to the locomotor suppressing effects of the highest dose tested 
relative to males (Keeney et al, 2012) 
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 The pharmacokinetics may also differ between male and female rodents, depending upon 
the drug. Both THC and its bioactive metabolite 11-hydroxy-9-tetrahydrocannabinol (11-OH-
THC) are detected in higher concentrations in the female rat brain than in male brains following 
an acute administration, although differences in magnitude to produce antinociception and 
catalepsy for either sex were not directly compared (Tseng and Craft, 2001; Wiley and Burston, 
2014). In addition to pharmacokinetic differences, sex may influence the downstream signaling 
events which CB1 receptors modulate. In female, but not male, guinea pig hypothalamic neurons, 
WIN55,212-2 increased the necessary voltage to activate A-type potassium channels (Tang et al, 
2005), and female Listar Hooded rats display larger depolarization-induced suppression of 
inhibition (DSI) compared to their male counterparts (Melis et al, 2013).  
 The numerous studies highlighting the potential for sex differences when testing 
cannabimimetic agents collectively indicate that researchers should remain sensitive to these 
outcomes. Transgenic mice are often in short supply necessitating mixed sex groups of mice 
during experiments. While utilizing both sexes may not result in measurable differences between 
them, this approach also has the advantage of being potentially sensitive to these outcomes 
should they arise. Moreover, humans display sex-related cannabinoid effects including frequency 
of use, anxiety, mental health status, and pharmacokinetic differences (Fattore and Fratta, 2010), 
thus highlighting the importance of sensitivity to these effects via inclusion of both sexes in 
preclinical assays of cannabimimetic effects. 
 
1.13  Experimental design to determine efficacy 
 To determine in vivo efficacy at the CB1 receptor, CB1 WT, HET, and KO mice were 
cumulatively dosed (similar to Falenski et al., 2010) with cannabinoid agonists until a pre-
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determined maximum has been reached in for catalepsy (60 seconds of immobility), 
antinociception (10 seconds in a 52C water bath), and hypothermia (C from baseline). The 
use of cumulative dosing does, however, preclude the use of hypolocomotion as measured by 
spontaneous activity. Observed reductions in spontaneous activity due to habituation are difficult 
to distinguish from CB1-mediated hypolocomotion during repeated testing (Drew and Miller, 
1973). Dose ratios calculated between WT and HET dose-effect curves via linear regression will 
serve as a proxy measure for efficacy differences which are not observable under these 
conditions due to extenuating factors influencing the ceiling of the assay. KO mice will serve as 
controls for potential off target effects of drugs. In cases where the solubility limits of a given 
compound preclude observing maximum effects, potency ratios will not be calculated although 
this pattern of effects provides strong evidence that the tested ligand possesses low efficacy. An 
alternative approach may be to consider the maximum effect stimulated by the ligands in HET 
mice, although solubility of the compounds at extremely high doses rendered interpretation of 
the data in this manner difficult. Finally, selection of ligands should include ligands of both very 
high and very low efficacy as determined by previously published results. 
In addition to relinquishing the hypolocomotion measure, cumulative dosing versus 
dosing distinct groups presents a number of methodological differences and practical 
considerations. Practically, cumulative dosing affords the use of a much smaller number of mice, 
can be completed at a much faster pace, and it allows the use of repeated measures statistics. 
Separate dosing requires many more mice and as such is much more time consuming. One must 
also use between subject experimental designs which may necessitate the use of a higher number 
of experimental animals per group to detect statistically significant differences. Additionally, 
with repeated testing of the same mice one can look at the relative differences between doses in 
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addition to change from baseline for each individual mouse therefore permitting normalization at 
each data observation for each mouse rather than a before and after approach often used with 
separate dosing procedures. Cumulative dosing was employed here as it allowed a high 
throughput, within subject approach to determine dose-effect relationships with reduced number 
of mice compared to separate groups of animals used to determine dose-effect relationships. 
Cumulative dosing is associated with potential pitfalls, notably pharmacokinetic and 
pharmacodynamics considerations, which are more adequately controlled in separate dosing 
procedures. Rodents dosed cumulatively are exposed for a much longer duration of time to drug 
and are often dosed at a specific interval (every 40 minutes typically) irrespective of the optimal 
onset and duration of the test drug. If the pretreatment time is too short or too long then maximal 
effects of a given dose may be missed or observed later in the presence of additional drug. This 
may result in an erroneous estimation of the ED50. Separate dosing necessarily avoids this 
complication, as each animal is given the same pretreatment time for a given dose of drug. 
Additionally, time course studies may readily be incorporated into separate dosing experiments 
so that the peak effects at each dose are observed, informing the timing of dosing in subsequent 
experiments. In the case of cannabinoids, the duration of effects in the tetrad are typically quite 
long, even in mice, so in many cases a 30 minute pretreatment is likely sufficient (see Chapter 2, 
Figures 17-23). However, the characteristic long duration of action also introduces potential 
pharmacodynamic confounds to estimation of the ED50 and therefore potency. Tachyphylaxis, or 
rapid changes in the response to a drug, is a form of short term adaptation. The mechanisms 
underlying tachyphylaxis are not well understood in relation to cannabinoids, but on longer 
timescales receptor level adaptations occur. Repeated administration of numerous cannabinoids 
produce tolerance and cross tolerance to the acute effects of these drugs in the tetrad (Fan et al, 
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1994), and concurrent internalization, downregulation, and desensitization (Nguyen et al, 2012) 
likely occur. If an animal is exposed to progressively higher doses of an agonist capable of 
producing these adaptations, the likelihood that these same changes occur within session may 
correspond with the current cumulative dose. Thus, as increasing concentrations are administered 
the number of receptors available will be reduced and the remaining receptors may be less 
sensitive to the application of the same agonist. If tachyphylaxis occurs under cumulative dosing 
conditions the ED50 would be underestimated when compared to separate dosing. These 
stipulations do not consider differences among test ligands in regards to efficacy which can cause 
differential degrees of receptor adaptation. 
The Stephenson model of receptor theory predicts that lower efficacy drugs must occupy 
a higher fraction of the available receptors to elicit the same response. In mice continuously 
infused with ED50 doses of  opioid agonists which differ in efficacy, lower efficacy ligands 
produced the greatest degree of tolerance while much smaller magnitudes of tolerance were 
observed for those ligands with high efficacy (Madia et al, 2009). As low efficacy ligands must 
occupy more receptors than high efficacy ligands to elicit the same response, receptor occupancy 
may drive tolerance. When naloxone was administered at the peak effect of morphine 
administered intravenously (Hovav and Weinstock, 1987), diminished or no tolerance occurred, 
implicating receptor occupancy as a potential determinant of tolerance. Many cannabinoid 
agonists induce downregulation and desensitization in vitro, such as THC (Sim et al, 1996a), 
CP55,940 (Rinaldi-Carmona et al, 1998),  and WIN55,212-2 (Jin et al, 1999). THC has been 
reported to cause considerable desensitization measured at the G-protein level while not 
appreciably reducing receptor number in some brain regions such as cerebellum, hippocampus, 
and striatal regions (Breivogel et al, 1999), perhaps indicating higher efficacy ligands reduce 
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receptor sensitivity to subsequent stimulation while occupying few receptors resulting in 
minimal downregulation. Another study using WIN55,212-2 and THC in which ED50 doses were 
doubled every three days revealed that this may not be correct, as each drug caused similar 
reductions in CB1 receptors across brain regions while THC produced much higher levels of 
desensitization. Additionally, chronic administration of the low efficacy endocannabinoid AEA 
(Breivogel et al, 2001; Griffin et al, 1998) in rats does not result in downregulation while 
substantial desensitization occurs (Rubino et al, 2000). This study does not however, consider 
the rapid metabolism of AEA by fatty acid amide hydrolase (FAAH) (Giang and Cravatt, 1997), 
which would effectively render AEA concentration in the brain negligible. Additionally, AEA is 
known to produce agonist-stimulated [35S]GTPS binding in mice devoid of CB1 (Di Marzo et 
al, 2000); thus, a non-CB1 mechanism likely accounts for the observed desensitization. Though 
evidence for receptor occupancy driving cannabinoid tolerance remains inconclusive, it 
nonetheless should be considered in terms of cumulative dosing when utilizing mice which 
already possess a reduced number of receptors as is the case with CB1 HET mice. A high 
efficacy ligand would require fewer receptors to elicit the same response as a lower efficacy 
ligand, therefore a higher fractional occupancy is necessary. The degree of tachyphylaxis may be 
higher for drugs which require higher numbers of receptors, therefore the ED50 estimation under 
cumulative dosing conditions might shift further to the right for lower efficacy drugs as 
compared to the same drug tested with separate dosing. When trying to make comparisons 
between drugs to assess efficacy with cumulative dosing, the apparent ED50 for higher efficacy 
drugs is likely closer to that of separate dosing groups while lower efficacy drugs may be shifted 
considerably to the right. This effect means that resolution to differentiate CB1 ligands which 
possess high efficacy would be diminished while lower efficacy drugs may more readily be 
60 
 
differentiated.  Utilizing experimental endpoints which depend upon CNS regions possessing 
lower concentrations of CB1 would potentially exacerbate this effect, while very high 
concentrations of CB1 could functionally negate this effect. 
The CB1 ligands tested were chosen based upon previously published results in both 
triad/tetrad experiments as well as agonist-stimulated [35S]GTPS binding. Most cannabimimetic 
agents elicit full suppression of spontaneous locomotor activity, up to several minutes of 
catalepsy in the ring immobility (Wiley et al, 1998) and bar tests (Falenski et al, 2010), 
significant reductions in body temperature, and increases in latency to withdrawal responses 
from a noxious stimuli. However, considerable methodological differences exist across the 
literature for each endpoint and in most cases the ceiling of the assay is determined arbitrarily. 
Agonist-stimulated [35S]GTPS binding provides an enhanced ability to distinguish efficacy 
between ligands via measuring the functional activity at the CB1 receptor as one may readily 
measure difference in maximal activation, (Emax). The differentiation in efficacy depends on a 
number of factors which are discussed more specifically above, but it should be noted that GDP-
GTP exchange at the G-protein does not fully encompass the spectrum of effects elicited by 
cannabinoids via the CB1 receptor. Many other pathways are possible including BARR2-
mediated ERK1/2 signaling, which may interfere with the a priori selection of cannabinoids 
based upon their efficacy to produce effects at one level for one pathway. As such, it will be 
necessary to compare findings in the triad to functional CB1 activity via agonist-stimulated 
[35S]GTPS binding. 
1.14  Cannabinoids in preclinical abuse liability testing assays 
 Homo sapiens have imbibed marijuana in various forms for millennia, both for 
therapeutic and recreational uses. The intoxicating effects are well documented and elicited 
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primarily by THC through the activation of CB1 receptors (Huestis et al, 2001), and marijuana 
remains the most popular drug of abuse worldwide. CB1 receptors are expressed on GABAergic 
and glutamatergic neurons (Tsou et al, 1998) and are abundant in reward-relevant regions of the 
mammalian brain such as the ventral tegmental area (VTA) and the nucleus accumbens (NAcc) 
(Herkenham et al, 1990). Relatively low doses of THC evoke dopamine release in the NAcc 
(Chen et al, 1991; Ng Cheong Ton et al, 1988), which is thought to be a common mechanism for 
many drugs of abuse (Di Chiara and Imperato, 1988). Despite its abundant use by man, THC 
remains an enigma in preclinical abuse liability testing, as it fails to elicit reliable abuse-related 
effects in the many assays of abuse liability, including conditioned place preference (CPP), self-
administration (SA), and intracranial self-stimulation (ICSS).  
 CPP is a Pavlovian conditioning procedure in which animals (typically mice or rats) are 
exposed to two chambers with a variety of differing cues including the pattern on the walls, the 
floor texture, and potentially other cues. A neutral connecting chamber is sometimes present as 
well. A drug is then randomly paired for each subject to one of the chambers while an 
appropriate vehicle is paired to the other. The subject is later returned to the apparatus with 
access to all chambers and the time it spends in each is counted. Common drugs of abuse such as 
psychomotor stimulants (Spyraki et al, 1982), opiates (Mucha et al, 1982), ethanol (Shimizu et 
al, 2015), and nicotine (Kota et al, 2008) produce condition place preference wherein the subject 
spends more time in the drug paired side than it did prior to conditioning (or more time in the 
drug-paired versus vehicle-paired chamber), whereas aversive drugs, such as kappa opioid 
receptor agonists (Suzuki et al, 1992) or lithium chloride (Mucha et al, 1982), elicit conditioned 
place aversion such that the subject spends less time in the drug paired side. THC has been 
reported to elicit conditioned place preference (Braida et al, 2004; Lepore et al, 1995; Manwell 
62 
 
et al; Valjent et al, 2002) as well as place aversion (Cheer et al, 2000; Manwell et al; Parker and 
Gillies, 1995; Sañudo-Peña et al, 1997). Similarly, SCs, such as CP55,940 (McGregor et al, 
1996), WIN55,212-2 (Chaperon et al, 1998), and HU-210 (Cheer et al, 2000), tend to elicit 
conditioned place aversion though a conditioned place preference has been reported for very low 
doses of CP55,940 (Braida et al, 2001a). Pre-exposure to the test ligand in the absence of the 
chamber may unmask a conditioned place preference for THC (Valjent and Maldonado, 2000) 
and the synthetic cannabinoid AM281 (Botanas et al, 2015), although the underlying 
neurobiological mechanisms are not well understood. 
 SA has long stood as the standard for testing the abuse liability of drugs. Laboratory 
animal models of SA are generally highly predictive of abuse potential in humans. While abused 
drug classes, such as opiates and psychomotor stimulants, are readily self-administered (van Ree 
et al, 1978), cannabinoid SA has been difficult to demonstrate in laboratory animals. Rhesus 
monkeys failed to acquire THC self-administration under fixed-interval schedule (Mansbach et 
al, 1994), while squirrel monkeys self-administered very low doses of THC (Justinova et al, 
2003; Tanda et al, 2000). Intracerebroventricular self-administration of THC was also achieved 
in Wistar rats (Braida et al, 2004). SA of SCs is also difficult to demonstrate in laboratory 
animals, though WIN55,212-2 SA seems comparatively robust relative to that of other 
cannabinoids. WIN55,212-2 is self-administered by DBA mice at very low doses (Martellotta et 
al, 1998) and by Long-Evans rats at low doses as well under an FR1 schedule (Fattore et al, 
2001). CD1 mice also self-administer WIN55,212-2 if given a priming dose (Mendizábal et al, 
2005). Sprague-Dawley rats trained to self-administer WIN55,212-2show an elevation of 
extracellular dopamine in the NAcc shell, but not in the core  (Lecca et al, 2006). This effect was 
also found in Listar Hooded and Long-Evans rats (Fadda et al, 2006). In a subsequent study by 
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the same research group, Lister Hooded and Long-Evans rats, but not Sprague-Dawley rats, self-
administered WIN55,212-2 (Deiana et al, 2007). In another study, Long-Evans rats learned to 
self-administer WIN55,212-2, but failed to acquire THC self-administration, calling into 
question the validity of WIN55,212-2 as a screen for cannabinoid abuse liability (Lefever et al, 
2014). Other cannabinoid agonists are also self-administered to some degree, though reports are 
scarce. Wistar rats self-administered CP55,940 via the intracerebroventricular route of 
administration (Braida et al, 2001b) and the endogenous cannabinoid 2-AG was self-
administered by squirrel monkeys (Justinová et al, 2011). Finally, JWH-018 was self-
administered by both Sprague-Dawley and C57BL/6J mice and increases extracellular dopamine 
in rats (De Luca et al, 2015). To date, it is unknown why some SCs, and WIN55,212-2 in 
particular, are readily self-administered by some strains while THC is generally not regardless of 
strain. This effect may be related to the partial agonist properties of THC, or the apparently very 
narrow dose range at which THC might be self-administered. Higher doses of THC produce 
aversive-like states in other assays such as CPP thus SA of THC may also elicit a similarly 
aversive state. 
ICSS is another preclinical assay of abuse liability which has good predictive validity for 
drugs of abuse (Negus and Miller, 2014). ICSS functions via implantation of an electrode into 
the medial forebrain bundle (MFB) (Olds & Milner, 1954), a tract of ascending and descending 
neuronal projections, some of which synapse onto dopaminergic neurons in the VTA, which then 
project into the NAcc resulting in release of dopamine in the NAcc (Phillips et al, 1989; Stellar 
and Stellar, 1985). The results of tandem ICSS and fast scan cyclic voltammetry (Kruk et al, 
1998) and microdialysis studies (Miliaressis et al, 1991) suggest that dopamine release alone 
may not be sufficient to drive the behavior, though strong neurochemical evidence implicates 
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dopamine release as a major component of ICSS (Fiorino et al, 1993). Electrical stimulation of 
the MFB elicits vigorous operant responses for brain stimulation. The electrical stimulation 
offers tight temporal control and the frequency and amplitude of the electrical stimulation can be 
easily manipulated within session to generate a wide range of response rates in a relatively short 
period of time. Facilitation of ICSS is considered predictive of abuse liability, while suppression 
may indicate abuse-limiting effects (Negus and Miller, 2014). Monoamine releasers (Bauer et al, 
2013), mu opioid agonists (Altarifi et al, 2013), GABAA agonists (Tracy et al, 2014), and 
nicotinic agonists (Freitas et al, 2015) facilitate ICSS. In contrast, kappa opioid agonists (Negus 
et al, 2010) and serotonin releasers (Bauer et al, 2015) tend to suppress ICSS. THC has been 
reported to modestly facilitate ICSS in Lewis rats at a dose of 1.5 mg/kg (Gardner et al, 1988) 
and Sprague-Dawley rats at doses of 1.0 mg/kg and 0.1 mg/kg (Katsidoni et al, 2013; Lepore et 
al, 1996), though other experiments indicate it produces little effect at low doses and suppression 
of ICSS at high doses in Sprague-Dawley rats (Kwilasz and Negus, 2012; Vlachou et al, 2007) 
and C57BL/6J mice (Wiebelhaus et al, 2015). In contrast to its effects in self-administration 
studies, WIN55,212-2 produces marked suppression of ICSS in Sprague-Dawley rats (Mavrikaki 
et al, 2010; Vlachou et al, 2004). CP55,940 suppresses ICSS in Sprague-Dawley rats (Arnold et 
al, 2001; Kwilasz and Negus, 2012; Vlachou et al, 2004) and in C57BL/6J mice (Grim et al, 
2015). HU-210 (Vlachou et al, 2004) suppresses ICSS in Sprague-Dawley rats. Inhibition of 
FAAH, the primary catabolic enzyme of anandamide, does not affect ICSS at low doses but 
produces a small suppression of ICSS via a non-CB1, non-CB2 mechanism (Kwilasz and Negus, 
2012; Wiebelhaus et al, 2015). Similarly, inhibition of monoacylglycerol lipase (MAGL), which 
elevates endogenous 2-AG, suppresses ICSS in a CB1-dependent manner (Wiebelhaus et al, 
2015). 
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 Although cannabinoids do not display the usual pattern of results that most other drugs of 
abuse display, the fact remains that humans abuse them. This discrepancy may reflect a failure to 
identify assay conditions in which abuse-related properties are unveiled. For instance, blood 
concentrations of THC in humans smoking marijuana are quite low (~10 ng/ml peak) (Cone et 
al, 2015) compared to blood concentrations achieved via interperitoneal injection necessary to 
produce robust catalepsy, hypothermia, and antinociception in mice (~500-1000 ng/ml) (Falenski 
et al, 2010), reflecting a large gap between the doses that are self-administered in humans versus 
the experimentally-induced doses in preclinical assays. Route and method of administration may 
also play a role. Animal models generally rely upon non-contingent, intravenous or 
interperitoneal injection as opposed the human method of ingestion which is generally smoked 
and done so purposefully. Ongoing efforts to identify the abuse liability of cannabinoids 
nonetheless remain important, and alternative approaches are clearly needed. Testing for 
tolerance and dependence represents a possible mechanism by which other aspects of drug abuse 
beyond the acute abuse-related effects could be assessed. 
 
1.15  Dependence and synthetic cannabinoids in humans and laboratory animals  
 Abrupt cessation of marijuana consumption following prolonged use can lead to 
withdrawal in humans. Cannabinoid withdrawal features at least three of the following seven 
clinical signs: 1) irritability, anger, or aggression; 2) nervousness or anxiety; 3) sleep difficulty 
(e.g. insomnia, disturbing dreams); 4) decreased appetite or weight loss; 5) restlessness; 6) 
depressed mood; and 7) physical symptoms such as abdominal pain, shakiness, tremors, 
sweating, fever, chills, or headache (American Psychiatric Association, 2013). Heavy cannabis 
users report experiencing robust withdrawal symptoms following discontinuation of cannabis use 
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(Allsop et al, 2012). Laboratory animal models of cannabinoid dependence have been developed 
in which a cannabinoid is administered over a period of days, and then subjects are challenged 
with a CB1 receptor antagonist to precipitate withdrawal. The most common precipitated somatic 
withdrawal signs include paw tremors and head shakes, and are readily observed following 
rimonabant challenge in THC-dependent rats (Aceto et al, 1995, 1996) and mice (Cook et al, 
1998). Rimonabant is known to act as an inverse agonist (Smith et al, 2015), suggesting that the 
ensuing withdrawal signs in cannabinoid-treated animals is the result of this property, instead of 
simple displacement of the agonist.  However, recent work by Jarbe’s group demonstrated that 
the neutral CB1 receptor antagonist AM4113, precipitated withdrawal responses in THC-
dependent animals, demonstrating that CB1 receptor blockade is sufficient to precipitate 
withdrawal  (Tai et al, 2015b). In contrast to precipitated withdrawal models, spontaneous 
withdrawal from cannabinoids is more difficult to detect, though spontaneous somatic signs of 
withdrawal were detected following continuous infusion of WIN55,212-2 (Aceto et al, 2001). 
Non-somatic signs of withdrawal have been more difficult to demonstrate, even when 
withdrawal is precipitated. Mice treated with THC sub-chronically and administered rimonabant 
displayed deficits in spatial memory as measured by the Morris water maze (Wise et al, 2011). 
Rimonabant precipitated withdrawal also unveils an anxiety-like phenotype in mice (Huang et al, 
2010). Abrupt cessation of CP55,940 (0.5 mg/kg, b.i.d., 7 days) produced an anxiety-like 
phenotype and locomotor depression in rats (Aracil-Fernández et al, 2013), while cessation of 
HU-210  elicited only hypolocomotion (Moreno et al, 2005). To date, only two studies 
investigated the consequences of repeated cannabinoid administration on reward processes 
utilizing the ICSS procedure (Chapter 3) (Grim et al, 2015; Mavrikaki et al, 2010). In the case of 
WIN55,212-2, rats did not become tolerant to the rate decreasing effects of WIN55,212-2, 
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despite 22 days of administration, and no mention of withdrawal from these effects was reported. 
Similarly, mice treated repeatedly with CP55,940 did not display signs of spontaneous or 
precipitated withdrawal following seven days of dosing, though tolerance was reported (Chapter 
3) (Grim et al., 2015).  
1.16  Objectives and hypotheses 
Given the dissimilar patterns of abuse-related and toxicological effects between THC and 
SCs, there is a need to assess potential mechanisms that might mediate the obvious discrepancy. 
SCs also generally possess unknown pharmacology and toxicology, and they are generally used 
first in man, highlighting the need for in vivo methods of assessing their pharmacological 
properties. One aspect of abused SCs which distinguishes them from THC is their enhanced 
potency and efficacy at the CB1 receptor. A first step to determine whether or not this enhanced 
CB1 activity plays a role in the health complications engendered by SCs is determination of their 
relative efficacies in vivo, and what effect that may have upon abuse-related behaviors. The 
research presented in this thesis investigated the consequences of acute and repeated 
administration of synthetic cannabinoids in established mouse models of abuse and 
cannabimimetic activity. 
As SCs possess a spectrum of effects ranging from toxicity to abuse-related effects, they 
should be assessed in assays that capture effects on various physiological effects and effects on 
reward processes. Here, I utilized a “bottom-up” approach, first characterizing the efficacy of six 
cannabinoids for their CB1 functional activity in an in vitro assay and centrally-mediated 
physiological consequences of CB1 activation in the whole animal. Next, one ligand (CP55,940) 
was selected as a representative SC and assessed for abuse-related effects on reward processes. 
More specifically, I applied basic pharmacological principles to determine in vitro and in vivo 
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efficacy and receptor mediation of synthetic cannabinoids (see Chapter 2) and then assessed the 
abuse- and dependence-related properties of the synthetic cannabinoid CP55,940 in the ICSS 
(see Chapter 3). Together, these aims will explore the contribution of efficacy to elucidate 
possible differences between THC and abused SCs. 
 
Hypothesis: SCs will have enhanced efficacy at the CB1 receptor as compared to THC to elicit 
in vivo cannabimimetic effects, and this will translate into enhanced abuse-related effects. 
 
1.17  Chapter 2: hypothesis 
Determination of in vivo efficacy and receptor mediation of cannabimimetic effects were 
conducted using CB1 WT, HET, and KO mice in a cumulative dosing procedure in which mice 
were assessed for catalepsy, hypothermia, and antinociception (the cannabinoid triad) after each 
dose The cannabinoid triad was utilized to establish a rapid screening method to ascertain in vivo 
efficacy as well as test whether a 50% reduction in CB1 receptors will produce a concordant loss 
of potency in the CB1 HET mice. Additionally, CB1 KO mice enabled the detection of whether 
any of the test compounds elicited non-CB1 triad effects. ED50 values were calculated by linear 
regression after conversion to % effect, when appropriate, to examine shifts in potency between 
CB1 WT and HET mice. The ceiling of each measure is as follows: 60 seconds for catalepsy, -
8C from baseline for hypothermia, and 10 seconds for tail withdrawal. Data transformations are 
detailed below. Dose ratios will be calculated by dividing the WT ED50 by the HET ED50. 
 
Catalepsy  =
𝑡𝑒𝑠𝑡
60
 x 100 
Hypothermia  = 
𝑡𝑒𝑠𝑡−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
−8
 x 100 
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Antinociception =  
𝑡𝑒𝑠𝑡−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
10−𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 x 100 
 
Hypothesis: For the in vivo determination of efficacy, the efficacy of the test ligand is expected 
to vary inversely with the potency shift observed between WT and HET mice, while KO display 
no pharmacological effects of each agonist. Furthermore, this potency shift will correlate with ex 
vivo agonist stimulated [35S]GTPgS binding utilizing the same test drugs in WT, HET, and KO 
CNS tissue. The non-CB1 drugs morphine and chlorpromazine are expected to be equipotent 
across WT, HET, and KO mice. 
1.18.  Chapter 3: hypothesis 
For abuse liability and dependence testing in ICSS, CP55,940 was selected as an 
archetypal representative of highly potent and efficacious synthetic cannabinoids commonly 
found in abused preparations. To assess whether synthetic cannabinoids facilitate ICSS an acute 
dose response of CP55,940 will be determined. To determine whether rate decreasing or rate 
increasing effects are CB1-mediated, a high dose of CP55,940 will be preceded by a dose of 
rimonabant sufficient to return responding to baseline levels. Tolerance to these effects will be 
assessed over seven days of dosing with a high dose of CP55,940 after which changes in baseline 
responding will be analyzed for changes related to spontaneous withdrawal. The same seven day 
dosing procedure will be used again, this time with a high dose of rimonabant on the final day to 
assess precipitated withdrawal. Together, these studies will examine the effect of both acute and 
repeated administration of a highly potent and efficacy cannabinoid on brain reward processes. 
 
Hypothesis: For abuse-liability and dependence testing utilizing the representative SC CP55,940 
in ICSS, mice will display changes in rates of responding for ICSS following spontaneous and 
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precipitated withdrawal. Acutely, CP55,940 will suppress rates of responding in a CB1 
dependent manner, and rimonabant will elicit no rate-suppressing effects. 
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ABSTRACT 
Diversion of synthetic cannabinoids (SCs) from research purposes to abused preparations 
threatens public health. Ensuing emergency scheduling resulted in clandestine synthesis of novel 
SCs with heretofore unseen structures detected in abused preparations. Here, we incorporated 
commonly employed in vivo and in vitro assays, CB1 transgenic (CB1 wild type (WT), 
heterozygous (HET), and knockout (KO)) mice to vary receptor density, and basic 
pharmacological principles to provide insight into the potency, selectivity and efficacy of CB1 
receptor-mediated effects produced by these rapidly emerging drugs of abuse. Accordingly, we 
examined the dose-response relationships of THC and five SCs in producing well-established in 
vivo (catalepsy, hypothermia, and antinociception) and in vitro (agonist-stimulated GTPS 
binding) pharmacological effects of cannabinoids. Whereas cannabinoid-induced catalepsy was 
resistant to a 50% reduction in CB1 density, hypothermia and antinociception showed ligand-
dependent increases in agonist ED50 values and decreases in Emax values. In contrast, non-
cannabinoid compounds (morphine and chlorpromazine) produced pharmacological effects in 
subsets of these assays, regardless of genotype. In vitro CB1 activity  assessed by agonist-
stimulated GTPS binding significantly correlated with altered drug potency (WT ED50 ÷ HET 
ED50) to produce hypothermia (r=0.84) and antinociception (r=0.95), but not catalepsy. These 
findings suggest that neural substrates subserving cannabinoid-induced antinociception and 
hypothermia contain a smaller CB1 reserve than for cannabinoid-induced catalepsy. More 
generally, this study offers a conceptual framework and high-throughput screening method to 
evaluate potency, selectivity and efficacy of not only emerging abused cannabimimetic ligands, 
but also naturally-occurring cannabinoids and other cannabinoids being developed as research 
tools or potential therapeutics.  
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1. Introduction  
 Synthetic cannabinoids (SCs), comprised of myriad structures and largely unknown 
pharmacology (Kronstrand et al, 2013; Louis et al, 2014; Sobolevsky et al, 2015), have emerged 
as drugs of abuse representing significant public health threats (Law et al, 2015; Trecki et al, 
2015). In stark contrast to THC, the primary psychoactive constituent of cannabis, SCs have 
been linked to life-threatening medical complications (Clark et al, 2015; Freeman et al, 2013; 
Mir et al, 2011; Takematsu et al, 2014; Thornton et al, 2013), psychological complications 
(Celofiga et al, 2014; Meijer et al, 2014; Peglow et al, 2012; Schwartz et al, 2015; Thomas et al, 
2012), and death (Behonick et al, 2014; Gerostamoulos et al, 2015; Shanks et al, 2015; Westin et 
al, 2015). These clinical observations suggest that SCs pose a more general threat than 
cannabis/THC to public safety. Withdrawal-like symptoms from SCs have also been reported 
(Nacca et al, 2013; Sampson et al, 2015), indicating a possibility for dependence.  
The mechanisms that underlie heightened risk for medical complications by SCs in 
comparison to cannabis/THC are not known and may vary according to the particular SC under 
consideration.  Similar to THC, SCs bind and activate  CB1, a GPCR, which plays an important 
role in mediating behavioral effects produced by marijuana and CB1 agonists (Huestis et al, 
2001; Rinaldi-Carmona, 1994).  Effects of SCs at non-CB1  could be one factor that contributes 
to toxicity associated with these drugs (Sherpa et al, 2015).  Moreover, based largely on results 
from in vitro assays of agonist-stimulated [35S]GTPS binding (Burkey et al, 1997a, 1997b; 
Selley et al, 1996), THC is defined as a low-efficacy CB1 agonist, whereas many SCs are defined 
as high efficacy CB1 agonists.  Accordingly, high efficacy of SCs at CB1 may also contribute to 
heightened risk for clinical complications. However, existing in vivo assays used to assess 
cannabinoid effects have poor resolution for distinguishing CB1 agonist efficacy. For example, 
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although in vitro assays of agonist-stimulated [35S]GTPS binding indicate that THC and the SC 
WIN55,212-2 possess low and high efficacy at CB1 receptors, respectively (Griffin et al, 1998), 
these drugs produce similar maximal effects in assays of catalepsy, hypothermia and 
antinociception that are commonly used to assess behavioral pharmacology of cannabinoids in 
mice (Fan et al, 1994).  Drug discrimination procedures, in which efficacy requirements are 
manipulated by using different training doses of a high-efficacy cannabinoid training drug (Järbe 
et al, 2014) or by induction of tolerance to THC (Hruba et al, 2012), represent effective 
strategies to improve sensitivity of behavioral assays to detect agonist efficacy. However, 
throughput with these procedures is relatively slow, and they have not been widely used.  
Consequently, new strategies for rapid in vivo evaluation of CB1 selectivity and efficacy could 
facilitate efforts to evaluate pharmacology of novel SCs and predict potential for abuse or 
clinical harm.  
Here, we hypothesize that comparison of in vivo drug effects in CB1 wild type (WT) and 
knockout (KO) mice will provide information on CB1 selectivity of SCs, and comparison of drug 
effects in WT and CB1 heterozygous (HET) mice will provide information on CB1 efficacy. To 
test this hypothesis, we utilized CB1 KO, HET, and WT mice to determine in vivo and in vitro 
effects of THC, CP55,940, WIN55,212-2, and SCs associated with abuse (CP47,497, JWH-073 
(Atwood et al, 2011), and A-834,735D). We incorporated a similar in vivo approach to that used 
previously for investigation of mu opioid receptor (MOR) agonist efficacy, in which MOR HET 
mice showed diminished morphine antinociception compared with WT mice (Sora et al, 2001). 
The present study employed a cumulative dosing procedure to increase throughput in 
determining the dose-response relationships of each ligand to elicit well described 
cannabimimetic effects (i.e., catalepsy, hypothermia, and antinociception). In addition, the non-
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cannabinoids morphine and chlorpromazine, which are active in some of these assays (Wiley, 
2003a), were included as negative controls predicted to produce effects independent of CB1 
genotype. Finally, [3H]SR141716A binding was conducted to confirm that CB1 density was 
reduced by half in HET mice, and drug effects on agonist-stimulated [S]GTPS binding were 
evaluated to provide an in vitro correlate for in vivo measures of CB1 selectivity and efficacy.  
Membranes from both cerebellum and spinal cord from WT, HET and KO mice were used in 
assays of [S]GTPS binding to provide tissue sources with varying CB1 densities.   
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2. Methods 
2.1 Subjects 
Male and female CB1 WT, HET, and KO mice (Zimmer et al, 1999a) derived from CB1 
HET breeding pairs backcrossed at least 15 generations with C57BL/6J mice served as subjects. 
Mice had ad libitum access to food and water and were maintained on a 12 h light/dark cycle. 
Approximately 80 mice between 8 and 36 weeks of age were used for all experiments, which 
were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals 
and were approved by the Virginia Commonwealth University Institutional Animal Care and Use 
Committee (IACUC). 
2.2 Drugs 
Studies were conducted with THC and with five SCs purported to have higher efficacy 
than THC at CB1 receptors.  The five SCs were (in order from purported highest to lowest 
efficacy) A-834-735D, WIN55,212-2, and CP55,940, JWH-073, CP47,497 (Atwood et al, 2011; 
Auwärter et al, 2009; Griffin et al, 1998).  The mu opioid receptor agonist morphine and 
dopamine receptor antagonist chlorpromazine were also studied as negative controls expected to 
produce behavioral effects insensitive to the CB1 receptor density. A-834,735D, WIN55,212-2, 
CP47,497, JWH-073 and chlorpromazine were obtained from Cayman Chemical (Road, Ann 
Arbor, MI), and morphine, THC and CP55,940 were generously supplied by the National 
Institutes on Drug Abuse Drug Supply Program (Research Triangle Institute, Raleigh, NC) for 
behavioral experiments. Each drug was dissolved in 100% ethanol, an equal volume of 
Emulphor EL-620 was added, and then 18 parts of 0.9% saline was added for a final ratio of 
1:1:18. For binding assays, THC-CRM was acquired from Cayman, and [3H]SR141716A was 
purchased from Perkin-Elmer (Waltham, MA). 
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2.3 Behavioral Assays 
To assess in vivo cannabimimetic activity, catalepsy, hypothermia and antinociception 
(see Supplementary Methods for details) were measured at baseline, and cumulative dose 
response curves were established for each test compound as previously described (Falenski et al, 
2010). The three tests required approximately 10 min to complete for six mice; thus groups of six 
mice were injected every 40 min with increasing doses of the test agonist and tested 30 min after 
each injection. Dose-effect curves for each agonist on each behavioral endpoint were analyzed 
by two-way ANOVA, with dose and genotype as the two factors. A significant ANOVA was 
followed by Holm-Sidak post hoc analysis, assessing dose-dependent changes within genotype 
as well as differences in drug effect between genotypes at each dose.  In addition, ED50 values 
and 95% confidence limits for drug effects on behavioral measures were determined via linear 
regression (Colquhoun, 1971), and ED50 values were considered to differ if 95% confidence 
limits did not overlap.  The ED50 was defined as the dose to produce immobility for 30 sec in the 
catalepsy test, a 4°C loss in body temperature in the hypothermia test, or 50% of the maximum 
possible effect in the antinociception test.  To assess changes in agonist effects produced by the 
lower CB1 receptor density in HET vs. WT mice, dose ratios (DR) were calculated using the 
equation (WT ED50/HET ED50) for each agonist on each behavioral measure.   We hypothesized 
that this dose ratio would serve as an in vivo measure of agonist efficacy.  
 
2.4 Cellular Assays 
2.4.1 Membrane Preparation 
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Male and female CB1 WT, HET, and KO mice were euthanized via rapid decapitation. 
Cerebellum were harvested and bisected and spinal cords were taken from lumbar to cervical 
regions. Details for membrane can be found under Supplementary Methods.  
2.4.2 [3H]SR141716A radioligand binding 
Using established methods (Selley et al, 2001), cerebellum and spinal cord samples were 
diluted with assay buffer to 10 g/ml and 15 g/ml, respectively. Membrane homogenates were 
then incubated with [3H]SR141716A (0.03-10 nM) in the absence and presence of a saturating 
concentration of unlabeled SR141716A (5 M) to assess specific and non-specific binding. The 
assay was incubated until equilibrium was attained (90 min) at 30 °C, and then the reaction was 
terminated by rapid filtration under vacuum through Whatman GF/B glass fiber filters pre-
soaked in Tris buffer containing 0.5% bovine serum albumin (BSA) followed by three washes. 
Bound radioactivity was measured via liquid scintillation spectrophotometry at 45% efficiency 
after a 9 h delay to allow the liquid scintillation fluid to dissolve the filter paper. For 
[3H]SR141716A radioligand binding assays, saturation binding (Bmax) and affinity were 
determined by non-linear regression saturation analysis in GraphPad Prism 6.0. Data are 
expressed as mean values ± standard error of the mean. 
2.4.3 Agonist-stimulated [35S]GTPS binding 
Following membrane preparation, varying doses of cannabinoid agonist were added to 12 
mm x 75 mm silicate tubes along with 30 M guanosine diphosphate (GDP), 0.1 nM 
[35S]GTPS, and 0.1% bovine serum albumin in duplicate and incubated at 30° C for 2 h 
(Lazenka et al, 2015). Non-specific binding was determined in the presence of 20 M unlabeled 
GTPS. The reaction was terminated by vacuum filtration through grade GF/B glass fiber filters 
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followed by two washes with cold Tris buffer (50 mM, pH 7.4). After overnight extraction in 
scintillation fluid (Research Products International, Mount Prospect, IL), bound radioactivity was 
assessed via liquid scintillation spectrophotometry at 95% efficiency. In agonist-stimulated 
[35S]GTPS binding experiments, non-specific binding was subtracted from each drug curve, and 
data were expressed as % net stimulation (net stimulation / basal x 100). As a small magnitude of 
stimulation was detected in CB1 KO tissue in certain instances (e.g., WIN55,212-2) (Breivogel et 
al, 2001; Monory et al, 2002), the stimulation from KO tissue was subtracted from CB1 WT and 
HET curves to provide a clearer representation of CB1-mediated agonist-stimulated binding. 
Maximal stimulation (Emax) and EC50 values were determined via nonlinear regression using 
GraphPad Prism 6.0 software. Significant differences between WT and HET Emax values were 
determined by Student’s T-test for each drug. Differences in Emax across WT samples were 
analyzed using one-way ANOVA followed by a Tukey post hoc test. 
2.5 Data Analyses 
To assess whether decreases in drug potency to produce behavioral effects in CB1 HET 
mice correlated with reductions in Emax values generated in agonist-stimulated [
35S]GTPS 
binding assays, Pearson correlations were calculated between dose ratios (WT ED50 / HET ED50) 
from behavioral experiments and WT Emax from in vitro studies. These correlations were 
performed using in vivo data from each behavioral assay (catalepsy, hypothermia, and 
antinociception) vs. in vitro data from each tissue source (cerebellum and spinal cord). 
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Results 
3.1 in vivo effects of cannabinoids in CB1 WT, HET, and KO mice 
Figure 12 depicts tail withdrawal responses of A-834,735D (Figure 12A), WIN55,212-2 
(Figure 12B), CP55,940 (Figure 12C), JWH-073 (Figure 12D), CP47,497 (Figure 12E), and 
THC (Figure 12F) in WT, HET, and KO mice. As shown in Table 3, the antinociceptive potency 
of WIN 55,212-2 was similar between HET and WT mice, while the dose ratio of each of the 
other cannabinoids revealed decreased potency in HET mice compared with WT mice. Within 
the dose range tested, the maximum %MPE values for JWH-073, CP47,497, and THC were 
lower in HET mice than in WT mice.  As the magnitude of respective effects of CP47,497 and 
THC did not surpass 50% and 25% MPE, neither the antinociceptive ED50 values in HET mice 
nor the dose-ratios (WT/HET mice) could be calculated.   
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Figure 12. Dramatic differences in potencies and efficacies of THC and SCs between CB1 WT 
and HET mice in producing antinociception. The high efficacy agonists A-834,735D (A, PR 
(95% CL) = 1.83 (1.11-3.11)) and WIN55,212-2 (B, PR (95% CL) = 2.54 (1.38-4.97))  produced 
comparable shifts in potency. CP55,940 (C, PR (95% CL) = 7.32 (3.47-18.48)) differed 
significantly from A-834,735D, but not from WIN55,212-2. JWH-073 (D), CP47,497 (E), and 
THC (F) failed to produce maximal effects in CB1 HET mice, which precluded the accurate 
calculation of potency ratios. The mean ± SEM baseline tail withdrawal latency for all groups 
was 2.05 ± 0.05 s.  VEH indicates an injection of 1:1:18 vehicle prior to cumulative dosing with 
the indicated drug. Filled shapes indicate p<0.05 CB1 WT and HET versus CB1 KO controls, 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 WT versus CB1 HET mice, n=7-10 mice per 
genotype per drug. 
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Figure 13 shows hypothermic effects of A-834,735D (Figure 13A), WIN55,212-2 (Figure 
13B), CP55,940 (Figure 13C), JWH-073 (Figure 13D), CP47,497 (Figure 13E), and THC 
(Figure 13F).  Each cannabinoid, with the exception of THC, produced dose-dependent 
hypothermia in WT and HET mice, but not in KO mice.  THC produced significant hypothermia 
in all three genotypes, but effects in HET and KO mice were similar to each other and less in 
magnitude than those in WT mice.  Table 3 shows ED50 values and dose ratios for all 
compounds.  All drugs were more potent in WT mice than in HET mice. Neither the ED50 value 
nor the dose ratios (WT/HET mice) could be could be calculated for THC in HET mice because 
the magnitude of hypothermia did not achieve the level required (-4°C) required for calculation.     
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Figure 13. Differential potencies of THC and SCs between CB1 WT and HET mice in producing 
hypothermia. A-834,735D (A, PR (95% CL) = 1.82 (1.44-2.34)), WIN55,212-2 (B, PR (95% 
CL) = 1.80 (1.34-2.45)), CP55,940 (C, PR (95% CL) = 2.05 (1.54-2.76)), and JWH-073 (D, PR 
(95% CL) = 2.74 (2.00-3.81)) produced similar, significant shifts in potency, while CP47,497 (E, 
PR (95% CL) = 3.55 (2.69-4.67)) produced an increased rightward shift relative to A-834,735D 
and WIN55,212-2. THC-induced hypothermia (F) showed an apparent loss of efficacy in CB1 
HET mice, with CB1 HET and KO mice showing identical drops in body temperature (2.9 ± 0.5 
C and 2.8 ± 0.4 C, respectively) at THC (560 mg/kg). The pre-injection mean ± SEM rectal 
temperatures for all groups was 36.72 ± 0.05 C. Data are expressed as a change from baseline. 
VEH indicates an injection of 1:1:18 vehicle prior to cumulative dosing with the indicated drug. 
Filled shapes indicate p<0.05 CB1 WT and HET versus CB1 KO controls, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 WT versus CB1 HET mice, n=7-10 mice per genotype per drug. 
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Figure 15 shows cataleptic effects of each drug in WT, HET and KO mice. Each drug 
produced dose-dependent catalepsy in WT and HET mice, but did not produce significant effects 
in KO mice. Table 3 shows that ED50 values did not differ between WT and HET mice for any 
drug, and dose ratios (WT ED50/HET ED50) ranged from 0.56 to 1.15. 
Figure 16 depicts the in vivo pharmacological effects of morphine and chlorpromazine in 
each genotype.  Morphine produced dose-dependent hypothermia and antinociception that was 
equivalent in WT, HET, and KO mice. Chlorpromazine produced dose-related catalepsy and 
hypothermia irrespective of genotype. Figure 16 also shows that repeated vehicle injections 
generally was without effect in each genotype, with the exception of KO mice, which displayed a 
small increase in catalepsy after the fifth vehicle injection. Figures 17-23 show the time courses 
of single doses of each agonist and vehicle on each endpoint in WT and HET mice.  All drugs 
had onsets of action by 30 min and durations of action ranging from 3-6 h. Table 5 contains 
results from ANOVAs for each drug and cannabinoid triad endpoint. 
3.2 Radioligand binding and agonist-stimulated [35S]GTPS binding in CB1 WT, HET, and KO 
mice 
[3H]SR141716A binding experiments (Table 6) confirmed high and low CB1 expression 
in cerebellum and spinal cord, respectively, with CB1 HET possessing approximately half of the 
number of receptors compared with WT mice in each case. Cerebellum and spinal cord 
membranes from CB1 WT, HET, and KO mice were assessed for differences in maximal 
stimulation of GTPS binding. Consistent with previous results (Breivogel et al, 2001; Monory 
et al, 2002), WIN55,212-2 elicited significant stimulation in CB1 KO samples in cerebellum 
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(Figure 24, Table 7); therefore, CB1 KO stimulation was subtracted to eliminate non-CB1 
mediated stimulation from WT and HET binding dose-effect curves (Figure 25). Nonlinear 
regression analyses of the curves prior to subtraction are shown in Table 7. None of the other 
ligands stimulated G protein activity in cerebellar homogenates from CB1 KO mice. In 
cerebellum membranes (Table 4), A-834,735D (T (6) = 2.544, p<0.05), WIN55,212-2 (T (6) = 
5.482, p<0.01), CP55,940 (T (6) = 3.474, p<0.05), JWH-073 (T (6) = 20.97, p<0.0001), 
CP47,497 (T (6) = 6.837, p<0.001) and THC (T (6) = 4.442, p<0.01) had significantly lower 
Emax values in CB1 HET membranes than in WT membranes. THC yielded a significantly 
reduced Emax relative to the other ligands (F (5,18) = 23.14, p<0.0001). In spinal cord (A-
834,735D (T (6) = 5.826, p<0.01), WIN55,212-2 (T (6) = 4.283, p<0.01), CP55,940 (T (6) = 
2.601, p<0.05), and CP47,497 (T (6) = 5.332, p<0.01) Emax values were significantly lower in 
membranes from CB1 HET than in WT membranes (see Table 2). Statistical differences were not 
detected between CB1 HET and WT spinal membranes for JWH-073 (p=0.052) or THC (p = 
0.11), the latter of which failed to produce stimulation above basal levels in CB1 HET mice. 
Across agonists in WT samples, THC (F (5, 18) = 15.26, p<0.0001) produced significantly less 
stimulation than each other ligand, while none of the other drugs differed from one another. 
3.3 Correlation of in vivo and in vitro measures of agonist efficacy 
Figure 14 shows correlations between in vivo dose ratios (WT ED50/HET ED50) from 
each behavioral assay and in vitro WT Emax from [
35S]GTPS binding assays in cerebellum and 
spinal cord membranes.  Pearson correlation coefficients are shown in Table 4. HET and WT 
binding showed strong correlations between cerebellum and spinal cord. Catalepsy, hypothermia, 
and antinociception did not correlate with cerebellum binding. However, both hypothermia and 
antinociception highly correlated with [35S]GTPS binding in spinal cord. 
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Figure 14. Correlations between in vivo potency differences between WT and HET mice and in 
vitro Emax values from agonist-stimulated [
35S]GTPS binding experiments were assessed to 
elucidate whether triad measures reflected differences in functional CB1 activity. In both 
cerebellum (A) and spinal cord (B), WT Emax correlated with HET Emax demonstrating the 
reduction in receptor population results in a concordant reduction in the Emax magnitude. 
Cerebellum WT Emax values were not correlated with catalepsy, hypothermia, or 
antinociception (C) while spinal cord WT Emax values were highly correlated with in vivo 
losses of potency between WT and HET mice for both hypothermia (r=0.91; p<0.05) and 
antinociception (r=0.97; p<0.01) (D). 
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4 Discussion 
 The cumulative dose-response cannabimimetic screen utilizing CB1 transgenic mice that 
express varying levels of CB1 receptors provides a high throughput in vivo method to discern 
relative differences in agonist selectivity and efficacy. The results presented here extend 
knowledge regarding the application of receptor theory to modern pharmacological challenges 
regarding cannabinoids, as it applies to the CB1 receptor. Specifically, we elucidated the impact 
of reducing total CB1 population on the relationship between in vivo potency/efficacy and in 
vitro functional activity.  
Of the three in vivo pharmacological effects measured, antinociception was the most 
sensitive to reduction in receptor density. Specifically, CB1 HET mice showed the greatest 
reductions in antinociceptive potency and efficacy to the cannabinoids tested compared with WT 
mice. A-834,735D, WIN55,212-2, and CP55,940 produced full antinociceptive effects in WT 
and HET mice, but CB1 HET mice displayed 2 fold decreases in potency to A-834,735D, 
WIN55,212-2, and ~7 fold decrease in potency to CP55,940. THC was the least potent 
cannabinoid in producing antinociception in WT mice, and failed to achieve greater than 25% 
MPE in CB1 HET mice, rendering the ED50 value incalculable. Similarly, the dose-response 
analyses of JWH-073 and CP47,497 within the dose ranges tested revealed reduced magnitudes 
of antinociceptive effects in HET mice compared with WT mice. KO mice did not display 
relevant antinociception following administration of any of the cannabinoids. In contrast, the 
non-cannabinoid morphine produced full antinociceptive effects irrespective of genotype, while 
chlorpromazine did not produce antinociception. CB1 density is relatively low in CNS areas 
purported to mediate antinociception (e.g., periaqueductal gray, dorsal horn of the spinal cord) 
compared to other brain regions, such as the cerebellum (Herkenham et al, 1990, 1991; Matsuda 
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et al, 1990). Thus, these findings indicate relatively low CB1 receptor reserve for 
antinociception. Accordingly, THC, CP47,497, and JWH-073 behaved as low efficacy CB1 
agonists, while CP55,940 had higher efficacy, and A-834,735D and WIN55,212-2 were the 
highest efficacy compounds in producing antinociception. 
Similar to antinociception, the dose response curve for each agonist in producing 
hypothermia was rightward shifted in CB1 HET mice compared with WT mice. Interestingly, 
THC-induced hypothermia showed a profound reduction of Emax in CB1 HET mice, with body 
temperature only partially reduced at 300 and 560 mg/kg THC. The observation that body 
temperature drops did not differ between HET and KO mice suggests off-target effects at these 
excessively high concentrations of THC. However, none of the other cannabinoids, at the doses 
assessed, produced hypothermia in CB1 KO mice. Morphine and chlorpromazine elicited dose-
dependent hypothermia irrespective of genotype (Figure 16). These findings taken together with 
the reduced level of CB1 expression in the POA (Herkenham et al, 1990) suggest relatively low 
CB1 receptor reserve for cannabinoid-induced hypothermia.  
In contrast to the antinociceptive and hypothermic measures, WT and HET mice 
displayed similar dose-response relationships to the cataleptic effects of the six cannabinoid 
tested (Figure 15), suggesting a relatively high CB1 receptor reserve. Chlorpromazine produced 
catalepsy in all three genotypes, while morphine did not elicit catalepsy (Figure 16). The 
minimal rightward shift in the dose-response relationship of cannabinoids in CB1 HET mice is 
consistent with idea that the high levels of CB1 expression in brain areas mediating this behavior 
yield sufficient receptor reserve. Indeed, dorsal striatum (~3-4 pmol/mg) and cerebellum (4-6 
pmol/mg) CB1 expression represent among the highest levels in brain  (Selley et al, 2001). Work 
from Dhawan et al. 2006 suggests cannabinoid-induced catalepsy requires low CB1 occupancy. 
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Accordingly, a 50% reduction in receptor expression (Table 6) is likely insufficient to decrease 
ligand potency and efficacy in producing catalepsy. Similarly, THC, a low efficacy CB1 agonist 
as determined in agonist-stimulated [35S]GTPS binding experiments, elicited catalepsy that 
differed little between CB1 HET and WT mice. Interestingly, small, but significant differences 
between WT and HET mice were found for A-834,735D, WIN55,212-2, CP55,940, and THC, 
but not for JWH-073 and CP47,497. This pattern of effects does not follow the expected efficacy 
continuum, but rather may be mediated by other aspects of the ligand, such as alternative and/or 
additional signaling mechanisms, in addition to the canonical Gi/o and downstream cAMP 
inhibition pathway.  
In the present study, we determined dose-response relationships of each drug using a 
cumulative dosing within subject procedure, which allowed a fairly high throughout with a 
reduced total number of mice required (i.e., the entire dose-range was tested in each mouse 
during a single session). Consequently, the possibility of tachyphylaxis occurring during the 
cumulative dosing procedure may have contributed to potency reductions in HET mice, 
especially for measures that may be mediated by low CB1 receptor reserve. However, the time-
course studies (Figures 17-23) suggest a relatively long duration of action for each cannabinoid 
tested in both WT and HET. Thus, even if the dosing regimen leads to adaptive changes at CB1 
within the timeframe of the assay, the conditions were relatively similar across drugs and 
genotypes. Although the assessment of pharmacokinetic factors was beyond the scope of the 
present study, we previously reported similar blood and brain THC levels resulting from single 
bolus injection and cumulative dosing regimen at 10, 30, and 56 mg/kg (Falenski et al, 2010). 
Nonetheless, as CB1 agonists vary profoundly in structure, with endogenous cannabinoids 
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undergoing rapid hydrolysis within seconds or minutes (Blankman and Cravatt, 2013), future 
studies may need to take pharmacokinetic factors into consideration. 
Agonist-stimulated [35S]GTPS binding experiments generally corroborated the a priori 
selection of CB1 agonists, which vary from high to low efficacy (A-834,735D ≥ WIN55,212-2 > 
CP55,940 > JWH-073 ≥ CP47,497 > THC), when relative Emax differences of WT and HET mice 
were taken into account. This continuum was consistent under high (i.e., cerebellum 
homogenates) and low CB1 (i.e., spinal cord homogenates) expression conditions. The absence 
of a correlation between catalepsy and GDP-GTP exchange is consistent with the idea of high 
CB1 receptor reserve. Significant correlations were detected between in vitro WT Emax values 
from [35S]GTPS binding experiments in spinal cord and the in vivo hypothermia and 
antinociception measures, suggest that low receptor conditions reveal stratification of ligands by 
efficacy.  
One issue these assays do not address is potential signaling events outside of the 
canonical G-protein-cAMP pathway. Of the ligands tested here, potential bias has been described 
for CP55,940, WIN55,212-2, and THC in striatal cell cultures (Khajehali et al, 2015; Laprairie et 
al, 2014), though more work remains to be done in this emerging area. CB1 ligands with extreme 
bias for one pathway or another would be highly useful to test whether alternative signaling 
pathways play determining roles in the in vivo potency and efficacy of cannabinoids. For 
instance, the endogenous cannabinoid/endogenous TRPV1 agonist N-arachidonoyl dopamine 
(Redmond et al, 2015) preferentially modulates Ca2+ via Gq, though this compound may not be 
a good candidate for in vivo testing due to its likely rapid hydrolysis. Future studies may focus on 
investigating where novel, abused SCs fall along the efficacy continuum. Utilizing ligands with 
extreme bias may be particularly revealing in this assay. Although not commercially available, 
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irreversible CB1 antagonists would also provide great utility to investigate CB1 receptor density 
across relevant endpoints. This approach has already been implemented successfully for the mu 
opioid receptor (Madia et al, 2009; Pawar et al, 2007; Walker et al, 1998). 
In conclusion, the present study establishes a high throughput, within subjects approach 
to assess in vivo efficacy of SCs as well as naturally occurring cannabinoids by assessing their 
pharmacological effects in established assays using CB1 WT, HET, and KO mice. In particular, 
the strong relationship between loss of efficacy of cannabinoids in GTPS binding in spinal cord 
tissue and potency reductions of the six cannabimimetic ligands in producing antinociception and 
hypothermia in CB1 HET mice suggests that these endpoints reflect good predictors of in vivo 
efficacy. The lack of correlation between GTPS binding and catalepsy is likely due to the high 
number of spare CB1 receptors in brain regions mediating this pharmacological effect, which is 
consistent with the small reduction in potency observed in HET mice. The present study 
describes a solid preclinical approach, based on pharmacological principles, to provide valuable 
insight into the pharmacology of emerging abused SCs. More generally, the use of CB1 
transgenic mice through examination of dose-response relationships of cannabinoids on 
antinociception and hypothermia as well as on agonist-stimulated GTPS binding in spinal cord 
tissue possesses utility in determining in vivo and in vitro efficacy of emerging abused SCs, 
cannabinoids being investigated for basic research or being developed as potential medications, 
and naturally occurring cannabinoids.   
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Antinociception WT ED50 (95% CL) HET ED50 (95% CL) 
Dose Ratio 
(WT/HET) 
     
A-834,735D 0.85 (0.61-1.19) 1.84 (1.66-2.04)* 0.46 
WIN55,212-2 9.64 (6.44-14.41) 17.77 (10.61-29.77) 0.54 
CP55,940 1.00 (0.66-1.51) 4.04 (2.69-6.09)* 0.24 
JWH-073 7.74 (6.08-9.84) 96.58 (47.41-196.76)* 0.08 
CP47,497 6.20 (4.22-9.10) 100 mg/kg: 44.3±11.2 %MPE* <0.06 
THC 81.69 (51.32-130.03) 560 mg/kg: 19.2±2.7 %MPE* <0.15 
     
Hypothermia WT ED50 (95% CL) HET ED50 (95% CL) Dose Ratio (WT/HET) 
     
A-834,735D 0.85 (0.67-1.00) 1.64 (1.59-1.69)* 0.52 
WIN55,212-2 6.97 (5.24-9.29) 15.68 (9.95-24.71)* 0.45 
CP55,940 1.06 (0.74-1.51) 2.27 (1.85-2.79)* 0.47 
JWH-073 8.75 (6.99-10.94) 31.16 (21.08-46.06)* 0.28 
CP47,497 9.84 (7.81-12.39) 47.53 (32.29-69.97)* 0.21 
THC 155.67 (120.63-200.88) 560 mg/kg: -2.75±0.57ºC* <0.28 
     
Catalepsy WT ED50 (95% CL) HET ED50 (95% CL) Dose Ratio (WT/HET) 
     
A-834,735D 0.82 (0.62-1.08) 0.94 (0.73-1.21) 0.87 
WIN55,212-2 4.06 (3.09-5.34) 5.75 (4.43-7.47) 0.71 
CP55,940 0.93 (0.18-1.83) 0.81 (0.50-1.29) 1.15 
JWH-073 7.72 (5.97-9.99) 8.03 (6.01-10.73) 0.96 
CP47,497 3.68 (1.81-7.51) 6.57 (4.15-10.38) 0.56 
THC 28.36 (17.99-44.72) 49.27 (36.35-66.78) 0.58 
 
Table 3. The antinociceptive and hypothermic effects of each ligand were more potent in WT 
mice than in HET mice, with the exception of WIN55,212-2-induced antinociception, which did 
not significantly differ between genotypes. For catalepsy, none of the ligands differed in potency 
between WT and HET mice. ED50 values (expressed in mg/kg) for each dependent measure were 
calculated in WT and HET mice. Dose ratios were calculated by dividing the WT ED50 by the 
HET ED50. In the cases in which ED50 estimations were not possible to calculate (i.e., CP47,497 
for antinociception, and THC for antinociception and hypothermia in HET mice), the maximum 
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effect at the highest dose tested is presented. * indicates non-overlapping confidence intervals 
between WT and HET ED50 values.  
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Cerebellum         
  WT   HET  
Agonist   Emax EC50   Emax EC50   
HET Emax/ 
WT Emax 
          
A-834,735D  211.1 ± 11.4 22.3 ± 5.6  164.9 ± 14.1* 29.4 ± 11.9  0.78 
WIN55,212-2  202.5 ± 7.6 39.4 ± 7.6  152.6 ± 4.9** 50.4 ± 8.0       0.75 
CP55,940  198.7 ± 5.2 4.1 ± 0.6  166.3 ± 7.6* 6.1 ± 1.4  0.84 
JWH-073  185.5 ± 1.7 25.6 ± 1.2  95.5 ± 3.9**** 38.3 ± 7.1  0.51 
CP47,497  212 ± 8.6 102.1 ± 18.2  133.3 ± 7.6*** 94.5 ± 22.8  0.63 
THC  119.9 ± 4.6^ 24.3 ± 4.7  73.8 ± 8.7** 52.4 ± 29.0  0.62 
         
Spinal Cord         
  WT   HET  
Agonist   Emax EC50   Emax EC50   
HET Emax/ 
WT Emax 
          
A-834,735D  57.8 ± 2.4 15.0 ± 3.0  35.0 ± 3.0** 24.1 ± 9.6  0.61 
WIN55,212-2  56.3 ± 3.8 65.4 ± 22.0  36.9 ± 2.4** 84.8 ± 21.6  0.66 
CP55,940  49.6 ± 5.9 8.61 ± 5.1  30.4 ± 4.3* 9.5 ± 6.9  0.61 
JWH-073  41.3 ± 3.5 77.8 ± 29.9  20.6 ± 7.7 46.6 ± 91.0  0.49 
CP47,497  41.2 ± 3.9 93.2 ± 38.1  17.1 ± 2.2** 45.9 ± 24.2  0.42 
THC  11.4 ± 2.3^ 6.1 ± 11.2  ND ND  ND 
 
Correlations 
    
 
Cerebellum   
r 
  p 
Catalepsy  0.10  0.53 
Hypothermia  0.02  0.80 
Antinociception  0.08  0.65 
      
Spinal Cord   r   p 
Catalepsy  0.22  0.34 
Hypothermia  0.84  <0.05 
Antinociception  0.95  <0.01 
 
 
Table 4. Each agonist was assessed for its ability to stimulate [35S]GTPS binding in cerebellum 
and spinal cord membranes of CB1 WT, HET, and KO mice. In cerebellum, all agonist elicited 
comparatively lower stimulation in HET membranes than in WT membranes. Comparison of 
WT Emax values across drugs revealed that THC elicited the least stimulation of all ligands 
tested. Spinal cord membranes revealed a similar pattern of results, with only JWH-073 failing to 
elicit significant differences in Emax between WT and HET samples. No stimulation above basal 
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was detected for THC in HET spinal cord; therefore, Emax and EC50 values could not be 
determined (ND). Similar to cerebellum, only THC displayed significantly lower Emax values 
across WT samples in spinal cord. This loss of efficacy is expressed additionally as the HET 
Emax/WT Emax to show relative differences between the higher receptor conditions of cerebellum 
and low receptor conditions of spinal cord. ^indicates significant differences versus all other 
ligands within WT Emax values, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 for WT versus 
HET samples within tissue. No significant differences in EC50 were detected across brain region 
or genotype for each drug. 
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Figure 15. All drugs tested maintained comparable potency in the catalepsy measure of the triad 
in HET mice compared to their WT counterparts. There were significant dose by genotype 
interactions for A-834,735D (0.03-10 mg/kg, Figure 1A, F (14, 147) = 41.99, p<0.0001), 
WIN55,212-2 (0.3-50 mg/kg, Figure 1B, F (14, 133) = 31.69, p<0.0001), CP55,940 (0.03-56 
mg/kg, Figure 1C, F (16,168) = 29.84, p<0.0001), JWH-073 (0.3-100 mg/kg, Figure 1D, F (16, 
160) = 22.91, p<0.0001), CP47,497 (0.1-100 mg/kg, Figure 1E, F (18, 189) = 10.75, p<0.0001), 
and THC (1-560 mg/kg, Figure 1F, F (16, 176) = 13.70, p<0.0001). Table 1 shows no significant 
differences between WT and HET mice across drugs. BL indicates baseline and VEH indicates 
an injection of 1:1:18 vehicle prior to cumulative dosing with the indicated drug. Filled shapes 
indicate p<0.05 versus respective vehicle for each genotype, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 WT versus KO, ^p<0.05, ^^p<0.01, ^^^p<0.001, ^^^^p<0.0001 HET versus KO, 
n=7-10 mice per genotype per drug. 
 
  
97 
 
 
 
Figure 16. The mu opioid receptor agonists morphine elicits catalepsy in CB1 KO, but not WT 
or HET mice, at a cumulative dose of  56 mg/kg (A, F (10, 95) =  4.545, p<0.0001). Morphine 
also, produced dose-dependent hypothermia (B, main effect of morphine p<0.0001, no 
significant interaction p=0.7285) and antinociception (C, main effect of morphine p<0.0001, no 
significant interaction p=0.2545) irrespective of genotype. Cumulative dosing with the 
antipsychotic chlorpromazine resulted in dose-dependent increases in catalepsy (D, main effect 
of chlorpromazine, p<0.0001, no significant interaction p=0.9239) measured as well as dose-
dependent decreases in body temperature (E, main effect of chlorpromazine p<0.0001, no 
significant interaction p=0.5727) with no significant increases in antinociception (F, main effect 
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of chlorpromazine, p<0.0001, no significant interaction p=0.4886). To control for repeated 
injections, six single volume injections of vehicle followed by two double volume injections 
were administered. Significant increases in catalepsy were measured in CB1 KO mice (G, F (16, 
168) = 6.396, p<0.0001) though it is unclear whether this is due to repeated injections or 
habituation to the bar test itself. No significant changes were detected in hypothermia (H, 
p=0.4708) nor antinociception (I, p=0.4935). ****p<0.0001 versus WT and HET, n = 7-9. Filled 
shapes indicate p<0.05 versus respective vehicle for each genotype, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 WT versus KO, ^p<0.05, ^^p<0.01, ^^^p<0.001, ^^^^p<0.0001 
HET versus KO, n=7-10 mice per genotype per drug. 
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Antinociception   F ratio   p value 
       
A-834,735D  F (12, 126) = 15.33  <0.0001 
WIN55,212-2  F (12, 114) = 15.79  <0.0001 
CP55,940  F (14, 147) = 21.52  <0.0001 
JWH-073  F (14, 140) = 20.98  <0.0001 
CP47,497  F (16, 168) = 10.98  <0.0001 
THC  F (14, 154) = 18.74  <0.0001 
      
Hypothermia   F value   p value 
       
A-834,735D  F (12,126) = 67.78  <0.0001 
WIN55,212-2  F (12,114) = 37.42  <0.0001 
CP55,940  F (14, 147) = 77.85  <0.0001 
JWH-073  F (14,140) = 41.82  <0.0001 
CP47,497  F (16, 168) = 72.02  <0.0001 
THC  F (14,154) = 13.84  <0.0001 
      
Catalepsy   F value   p value 
       
A-834,735D  F (14, 147) = 41.99  <0.0001 
WIN55,212-2  F (14, 133) = 31.69  <0.0001 
CP55,940  F (16,168) = 29.84  <0.0001 
JWH-073  F (16, 160) = 22.91  <0.0001 
CP47,497  F (18, 189) = 10.75  <0.0001 
THC  F (16, 176) = 13.70  <0.0001 
 
Table 5. The results from the ANOVAs of each cannabinoid for each dependent measure of the 
cumulative dosing triad are depicted here. The results of post hoc Holms-Sidak analysis are 
depicted in the Figure 12, Figure 13, and Figure 15. 
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Figure 17. A-834,375D (3.0 mg/kg) produced cataleptic (A, F (5, 110) = 0.8960, p = 0.4866, no 
significant interaction; main effect of time, p<0.0001), hypothermic (B, F (4, 88) = 4.765, p < 
0.01), and antinociceptive (C, F (4, 88) = 1.521, p = 0.2028, no significant interaction; main 
effect of time, p < 0.0001) effects in a time dependent manner, revealing a long duration of 
action peaking at one hour post-injection in all three measures. CB1 WT mice only differed from 
HET mice at six hours post-injection in hypothermia. **p<0.01, n = 12. 
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Figure 18. A dose (30.0 mg/kg) of CB1 agonist WIN 55,212-2 produced cannabimimetic effects 
in a time-dependent manner. Separation between genotypes (indicated by asterisks) is readily 
apparent after three hours in catalepsy (A, F (5, 100) = 13.74, p < 0.0001) and after one hour in 
hypothermia (B, F (4, 80) = 12.46, p < 0.0001) and antinociception (C, F (4, 80) = 9.929, p < 
0.0001). HET mice approached baseline measurements in catalepsy and antinociception six 
hours post-injection while WT mice remained near or above peak measurements three hours 
post-injection in all three measures before declining at six hours post-injection. Between 
genotypes, significant differences were found at half an hour post-injection in antinociception, 
one hour in hypothermia and antinociception), three hours in all three measures, and six hours in 
all three measures. **p<0.01, ***p<0.001, ****p < 0.0001, n = 8-10.  
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Figure 19. Cannabinoid triad time course of CP 55,940 (3.0 mg/kg) showed peak 
cannabimimetic activity in both CB1 WT and HET mice at one hour post-injection in catalepsy 
(A, F (5, 110) = 5.875, p < 0.0001) and hypothermia (B, F (4, 88) = 8.668, p < 0.0001) and three 
hours post-injection in antinociception (C, F (4, 88) = 2.945, p < 0.05), indicating time 
dependent effects. Hypothermia and antinociception displayed significant differences between 
genotypes at three hours post injection. Catalepsy and hypothermia showed significant 
differences between genotypes at six hours post-injection. **p < 0.01, ***p < 0.001, ****p < 
0.0001, n = 12. 
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Figure 20. JWH-073 (30.0 mg/kg) elicited cataleptic (A, F (5, 90) = 3.025, p < 0.05), 
hypothermic (B, F (4, 72) = 5.830, p<0.001), and antinociceptive (C, F (4, 72) = 5.239, p < 
0.001) effects in a time dependent manner. Significant differences between CB1 WT and HET 
mice are discernible at half an hour post-injection in hypothermia, one hour post-injection in 
antinociception, and three hours post-injection in catalepsy. Differences are continuous to six 
hours post-injection in catalepsy and hypothermia, and three hours in antinociception. HET mice 
extinguished cannabimimetic behavior in all three measures earlier than WT mice. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001, n = 10. 
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Figure 21. CP 47,497 displayed a long, consistent duration of action in CB1 WT and HET mice 
in cannabinoid triad as evidenced by an absence of significant differences in measurements from 
the half hour time point (indicated by filled symbols) until six hours post-injection in catalepsy 
(A, F (5, 110) = 2.354, p = 0.0452), and three hours post-injection in hypothermia (B, F (4, 88) = 
9.108, p < 0.0001) and antinociception (C, F (4, 88) = 7.576, p < 0.0001). Separation between 
genotypes was observed in hypothermia and antinociception beginning half an hour post-
injection until six hours post-injection. **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 12. 
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Figure 22. THC (100.0 mg/kg) achieved peak cannabimimetic activity time dependently in CB1 
WT mice in cannabinoid triad time course at six hours post-injection in catalepsy (A, F (5, 110) 
= 2.354, p < 0.05) and hypothermia (B, F (4, 88) = 9.108, p < 0.0001) and three hours post-
injection in antinociception (C, F (4, 88) = 7.576, p < 0.0001) and in CB1 HET mice at one hour 
post-injection in catalepsy and antinociception and three hours post-injection in hypothermia. 
WT mice differed from HET mice at three and six hours for hypothermia, at six hours in 
catalepsy, and at six hours for antinociception. *p < 0.05, ***p < 0.001, ****p < 0.0001, n = 11-
13. 
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Figure 23. Vehicle (0.01 mL/g) produced no cannabimimetic effects in catalepsy (A), 
hypothermia (B, F (4, 88) = 0.437, p = 0.7812; no significant effect), or antinociception (C, F (4, 
88) = 0.5342, p = 0.7109; no significant effect). n = 12. 
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 Cerebellum  Spinal Cord 
  Bmax (pmol/mg)   KD [nM]   Bmax (pmol/mg)   KD [nM] 
        
CB1 
WT 4.32 ± 0.30  1.15 ± 0.14  0.97 ± 0.09  0.58 ± 0.12 
        
CB1 
HET 1.89 ± 0.36***  0.95 ± 0.21  0.58 ± 0.10#  0.90 ± 0.34 
 
Table 6. [3H]SR141716A binding confirmed approximately 50% CB1 expression in the brain 
areas tested in the agonist stimulated [35S]GTPS binding assay. The KD of the radioligand did 
not change between genotypes or across CNS regions (p=0.3957). Binding curves were fitted 
with nonlinear regression in GraphPad Prism 6.0. ***p<0.001 WT versus HET Bmax in 
cerebellum, #p<0.05 WT versus HET Bmax in spinal cord, n = 8 for each genotype per tissue. 
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Figure 24. All agonists tested stimulated [35S]GTPS binding to a similar degree in wild type 
cerebellum, except for THC which displayed significantly lower Emax values in wild-type tissue 
(Table 4) and WIN55,212-2 which displayed much higher stimulation. A-834,735D (A), 
WIN55,212-2 (B), and CP55,940 (C) displayed similar differences in Emax among heterozygous 
tissue (~80% of wild type), while JWH-073(D), CP47,497 (E), and THC (F) each displayed 
close to a 50% in efficacy. Dose-related changes in agonist-stimulated binding were detected in 
knockout samples for both WIN55,212-2 (F (7, 24) = 6.378, p<0.001) and THC (F (6, 21) = 
6.492), thus knockout stimulation was subtracted for the purposes of analysis from both wild 
type and heterozygous samples for each drug. EC50 and Emax values for the data here are shown 
in Table 7. ND indicates not determined, n = 4 per genotype. 
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  WT  HET  KO 
Agonist   Emax EC50   Emax EC50   Emax EC50 
           
A-834,735D  203.0 ± 15.9 18.6 ± 6.7  152.7 ± 16.3 20.2 ± 9.9  ND ND 
           
WIN55,212-2  262.6 ± 18.6 86.4 ± 31.6  209.3 ± 13.5 114.5 ± 36.1  ND ND 
           
CP55,940  179.6 ± 8.1 5.0 ± 1.2  146 ± 6.8 7.8 ± 1.8  ND ND 
           
JWH-073  199.1 ± 5.9 22.5 ± 3.3  109.9 ± 6.2 29.7 ± 7.9  ND ND 
           
CP47,497  222.2 ± 11.3 78.0 ± 18.6  142.1 ± 4.3 63.3 ± 8.8  ND ND 
           
THC  106.6 ± 6.2 14.4 ± 4.6  61.21 ± 4.9 26.8 ± 10.1  ND ND 
 
Table 7. Emax and EC50 values calculated from agonist-stimulated GTPS binding experiments in 
cerebellum which are uncorrected for KO stimulation. WIN55,212-2 achieved a maximum of 
40% above basal in KO tissue whereas the other five ligands tested elicited no discernable 
stimulation above basal in KO tissue.  
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Figure 25. Subtraction of knockout stimulation revealed equal efficacy in WT tissue of all 
agonists except for THC. EC50 values in wild type and heterozygous tissue for WIN55,212-2 
were much lower following subtraction, implying it may be more potent to activate CB1 
receptors than previous reported in cases where off target stimulation was not taken into account. 
EC50 and Emax values for the data here are shown in the table below. ND indicates not 
determined.  
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Figure 26. Unlike cerebellum, no significant stimulation was detected in knockout in spinal cord 
thus no subtraction was necessary.  EC50 and Emax values for the data here are shown in the table 
below. ND indicates not determined, n = 4 per genotype. 
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ABSTRACT 
 
Background: Synthetic cannabinoids have emerged as a significant public health concern. To 
increase the knowledge of how these molecules interact on brain reward processes, we investigated 
the effects of CP55,940, a high efficacy synthetic CB1 receptor agonist, in a frequency-rate 
intracranial self-stimulation (ICSS) procedure.  
Methods: The impact of acute and repeated administration (seven days) of CP55,940 on operant 
responding for electrical brain stimulation of the medial forebrain bundle was investigated in 
C57BL/6J mice.  
Results: CP55,940 attenuated ICSS in a dose-related fashion (ED50 (95% C.L.) = 0.15 (0.12-0.18) 
mg/kg). This effect was blocked by the CB1 receptor antagonist rimonabant. Tolerance developed 
quickly, though not completely, to the rate-decreasing effects of CP55,940 (0.3 mg/kg). Abrupt 
discontinuation of drug did not alter baseline responding for up to seven days. Moreover, 
rimonabant (10 mg/kg) challenge did not alter ICSS responding in mice treated repeatedly with 
CP55,940.  
Conclusions: The finding that CP55,940 reduced ICSS in mice with no evidence of facilitation at 
any dose is consistent with synthetic cannabinoid effects on ICSS in rats. CP55,940-induced ICSS 
depression was mediated through a CB1 receptor mechanism. Additionally, tolerance and 
dependence following repeated CP55,940 administration were dissociable. Thus, CP55,940 does 
not produce reward-like effects in ICSS under these conditions.  
 
Keywords: synthetic cannabinoid, intracranial self-stimulation, mice, withdrawal, tolerance, 
dependence, CP55,940. 
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1. Introduction 
Cannabis sativa has been used both medicinally and recreationally for thousands of years 
(Mechoulam et al. 1991). The psychotropic effects of this plant are due mainly to its primary 
psychoactive constituent 9-tetrahydrocannabinol (THC) (Mechoulam and Gaoni 1965; Martin-
Santos et al. 2012). THC falls within the class of drugs known as cannabinoids, which draw their 
moniker from the cannabis plant. Cannabinoids are primarily defined by their ability to bind and 
activate cannabinoid receptor 1 (CB1) (Herkenham et al. 1990; Matsuda et al. 1990) and 
cannabinoid receptor 2 (CB2) (Munro et al. 1993). Although CB1 is well known to play a 
predominant role in mediating the behavioral effects of THC and other cannabinoids and to 
modulate the rewarding effects of other classes of drugs (Rinaldi-Carmona et al. 1994; Ledent et 
al. 1999; Zimmer et al. 1999; Forget et al. 2005), emerging evidence indicates that CB2 plays 
opposing roles in the reinforcing effects of cocaine and nicotine (Xi et al. 2011; Ignatowska-
Jankowska et al. 2013; Navarrete et al. 2013).  
In addition to THC, hundreds of synthetic cannabinoids vary in structure and bind and 
activate cannabinoid receptors (for review, see (Pertwee 2006)). These synthetic compounds were 
crucial for establishing the binding and distribution of cannabinoid receptors in brain (Devane et 
al. 1988; Herkenham et al. 1990). However, in recent years, synthetic cannabinoids such as CP-
47,497 (Hudson et al. 2010), AM-2201 (Denooz et al. 2013), JWH-018, and JWH-073 (Brents and 
Prather 2014), emerged as new drugs of abuse. Synthetic cannabinoids are generally abused by 
smoking plant material imbued with these compounds in much the same manner as marijuana, and 
are readily available as preparations commonly referred to as “Spice” or “K2” among other brand 
names (Fantegrossi et al. 2014). Synthetic cannabinoids are often markedly more potent and/or 
efficacious than THC (Griffin et al. 1998). Moreover, toxicological information is limited, and 
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little is known about how these compounds affect brain reward circuitry in vivo. As synthetic 
cannabinoids have emerged as drugs of abuse (Maxwell 2014), further research is needed to 
characterize their pharmacology and toxicology. The impact of chronic exposure to nonclassical 
cannabinoids also remains to be determined. 
Similar to other drugs of abuse, cannabinoids can evoke dopamine release in the nucleus 
accumbens (NAcc), a characteristic often indicative of drugs of abuse (Chen et al. 1993; Cheer et 
al. 2004). The NAcc is one node in a neural circuit known as the mesolimbic dopamine pathway, 
which consists of dopaminergic neurons that originate in the ventral tegmental area (VTA) and 
project to NAcc and more rostral targets such as prefrontal cortex (PFC). Intracranial self-
stimulation (ICSS) of the medial forebrain bundle is one procedure that has been used to measure 
reinforced behavior mediated by the mesolimbic dopamine pathway (Carlezon and Chartoff 2007) 
and to assess abuse potential of drugs (Negus and Miller 2014). Although acute administration of 
synthetic cannabinoids generally suppresses ICSS (Arnold et al. 2001; Vlachou et al. 2003; 
Vlachou et al. 2005), the impact of repeated cannabinoid administration on ICSS has not been 
extensively studied but may be important. For example, repeated administration of mu opioid 
agonists evokes tolerance to their rate-decreasing effects and unmasks abuse-related ICSS 
facilitation (Altarifi and Negus 2011; Altarifi et al. 2012). Additionally, ICSS has been used to 
detect withdrawal-related anhedonia for some drugs of abuse such as cocaine, nicotine and 
morphine (Altarifi and Negus 2011; Stoker et al. 2012; Stoker et al. 2014).  
In the present study we tested the hypotheses that (a) repeated administration of a synthetic 
cannabinoid will facilitate ICSS in a similar fashion as other abused drugs, and (b) spontaneous or 
antagonist-precipitated withdrawal in mice repeatedly administered cannabinoids will produce an 
anhedonia-like depression of ICSS similar to that produced by withdrawal from other abused 
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drugs. Because of the wide variety of synthetic cannabinoids and the ever changing composition 
of abused preparations, we chose to use a single, representative compound, CP55,940, to model 
acute and repeated effects of synthetic cannabinoids. Although CP55,940 has not emerged as a 
drug of abuse and has not been scheduled by the Drug Enforcement Agency, it has been 
extensively characterized in preclinical studies, and it is structurally similar to the abused and 
scheduled nonclassical cannabinoids CP47,497 and cannabicyclohexanol (Logan et al. 2012). 
Moreover, these compounds bind with similar affinity to CB1 and CB2 (Huffman et al. 2010; 
Atwood et al. 2011). Acute administration of CP55,940 depressed ICSS in rats (Arnold et al. 2001; 
Kwilasz and Negus 2012), but its consequences on ICSS following repeated administration are 
unknown.  
In initial experiments, we examined the dose-response relationship and time course of the 
effects of acute CP55,940 administration on ICSS. Rimonabant was used to infer CB1 
involvement. We then tested whether the acute effects of CP55,940 on ICSS would undergo 
tolerance following repeated administration. Because cannabinoids are well established to alter 
motor function, such as catalepsy, we also assessed the relationship between catalepsy and ICSS 
measures during repeated administration of CP55,940 (Little et al. 1988). Catalepsy was selected 
as a concurrent endpoint because the behavior may confound the ability of the mice to engage in 
operant responding, and CB1-mediated depression of ICSS may reflect non-specific disruption of 
behavior rather than an ICSS specific effect. Finally, we examined whether mice treated repeatedly 
with CP55,940 displayed signs of either spontaneous or precipitated withdrawal in the ICSS 
procedure.  
1. Materials and Methods 
2.1 Subjects 
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A total of 43 male C57Bl/6J mice were used (Jackson Laboratories, Bar Harbor, Maine). 
Mice were between 10 and 14 weeks of age at the start of each experiment and were individually 
housed and maintained on a 12 h light cycle, with lights on from 0600 to 1800 h, with free access 
to food and water. All experiments were conducted in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals, and were approved by the Virginia Commonwealth University 
Institutional Animal Care and Use Committee (IACUC). 
2.2 Drugs 
CP55,940, rimonabant and cocaine HCl were obtained from the National Institute of Drug 
Abuse Drug Supply Program (Rockville, MD). CP55,940 and rimonabant were dissolved in a 
vehicle (VEH) consisting of 5% ethanol, 5% Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and 
90% 0.9% saline. Cocaine was dissolved in 0.9% saline. 
2.3 Intracranial Self-Stimulation (ICSS) 
2.3.1 Apparatus.  
ICSS testing was conducted in eight mouse operant conditioning chambers (18 X 18 X 18 
cm; Med Associates Inc., St. Albans, VT). Each chamber was equipped with a retractable lever 
located on one wall, LED stimulus lights over the lever, a chamber house-light, a tone-generator 
and an ICSS stimulator.  The stimulator was connected to the electrode via bipolar cables routed 
through a swivel commuator and into the experimental chamber. Chambers were enclosed within 
sound- and light-attenuating chambers equipped with exhaust fans. Custom software was used to 
control manipulations in the operant chambers and to record data during training and testing 
sessions.  
2.3.2 Stereotaxic Surgery 
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Surgical procedures for implanting electrodes in mice for ICSS studies were similar to 
those previously reported (Carlezon and Chartoff 2007; Wiebelhaus et al. 2014). Mice were 
anesthetized with isoflurane for implantation of bipolar twisted stainless steel electrodes (0.280 
mm diameter and insulated except at the flat tips; Plastics One, Roanoke, VA) into the right medial 
forebrain bundle (2.0 mm posterior to bregma, 0.8 mm lateral from midline, and 4.8 mm below 
dura). The electrode was fixed to the skull with anchoring screws and dental cement. Mice were 
given acetaminophen (1-2 mg/ml) in their drinking water for one day before and five days after 
surgery. Training began one week after surgery. 
2.3.4 Training 
During initial training, lever-press responding under a fixed-ratio 1 (FR1) schedule 
produced both (a) delivery of a 0.5 s train of square-wave cathodal pulses (0.1 ms pulse duration) 
light, and tone cues. Responding during stimulation had no scheduled consequences. Amplitudes 
of stimulation were individually adjusted for each mouse to maximize response rates, and final 
amplitudes ranged from 45–300 μA. Training continued during daily 30–120 min sessions until 
response rates exceeded 30 responses per min for at least three days.  
Once operant responding was established, mice were promoted to frequency-rate training 
as previously reported for mice (Wiebelhaus et al. 2014) and rats (Negus et al. 2010). Frequency-
rate sessions were divided into multiple components, and each component consisted of 10 
sequential frequency trials for presentation of a descending series of 10 stimulation frequencies 
(2.2-1.75 log Hz in 0.05 log increments). Each frequency trial began with a 10 sec time out period, 
during which behavior had no scheduled consequences. During the last 5 s of the time out period, 
the lever was extended, and non-contingent stimulations were delivered once per second at a given 
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frequency together with associated cues The time out period was followed by a 60 s response 
period when responding under the FR1 schedule produced brain stimulation at the specified 
frequency together with associated cues. After the 60 s response period, the lever was retracted, 
the stimulation frequency was decreased by 0.05 log units, and the next frequency trial began. 
Sessions consisted of three to five consecutive components per day, and current amplitudes were 
adjusted if necessary for each subject to maintain responding for at least three, and fewer than 
eight, stimulation frequencies at levels ≥ 50% maximal control rates (see Data Analysis).  
Once these criteria were met, preliminary testing was initiated. Test sessions consisted of 
three baseline components followed first by a 30 min treatment interval and then by two test 
components. Data from the first baseline component for each test session were excluded from 
analysis. Data from the next two baseline components were averaged to generate baseline data for 
that test session, and data from the test components were averaged to generate test data. Mice were 
eligible for drug testing when the total number of stimulations per component during baseline 
varied by less than 20% on three consecutive days, and baseline and test numbers of stimulations 
per component differed by ≤ 20% in the absence of an injection or after treatment with vehicle 
injections. Brains were harvested from select mice, which met criteria throughout testing, and 
histological analysis was performed to verify of electrode placement into the lateral hypothalamus 
(Figure 31). Microscopy was performed at the VCU Department of Anatomy and Neurobiology 
Microscopy Facility, supported, in part, with funding from the NIH-NINDS Center core grant 
(5P30NS047463). 
1.3.5 Dose-Effect Relationship of CP55,940 
Once the training criteria were met, drug testing was initiated using dose-effect, time-
course and repeated-dosing procedures. For antagonism studies, a single dose of CP55,940 (0.03-
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1.0 mg/kg, s.c. 30 minutes prior to test components) was administered alone or 15 min after 
rimonabant (3-30 mg/kg). The effects of cocaine (10.0 mg/kg, i.p. 10 min prior to testing) were 
also tested as a positive control (Figure 32). Test sessions were separated by at least 72 hr.  
2.3.6 Time Course of CP55,940.  
The procedures described above were modified to assess the onset and duration of effects 
produced by CP55,940. Test sessions consisted of three baseline components followed first by a 5 
min treatment interval and then by pairs of test components beginning 5 min, 30 min, 2 hr, 4 hr 
and 8 hr after injection. Mice were removed from the test chamber between the last four pairs of 
test components. If necessary, drug effects were also evaluated after 24 and 48 hr. The time course 
of vehicle injection was tested first. If the number of stimulations per component varied ≤ 20% for 
all test components from 5 min to 8 hr, then an identical procedure was used to evaluate effects of 
0.3 and 1.0 mg/kg CP55,940. Two different groups of mice were used for each dose in the time 
course studies. Thus, each group had a corresponding vehicle time course for comparison. 
2.3.7 Repeated Administration of CP55,940 
To test the effects of a fixed dose of CP55,940 administered repeatedly, two groups of mice 
were assessed in three phases, each of which lasted for seven days. On each day of Phases 1 and 
2, test sessions consisted of three baseline components followed first by treatment interval and 
then by two test components. Injections were administered during the treatment interval, 30 min 
before initiation of the test components. In addition, mice were tested for catalepsy (see below) 
immediately before the injection and again approximately 20 min after completion of the test 
components (75 min after the injection).  
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The first phase of testing consisted of seven consecutive days of vehicle testing using the 
procedure described above. This phase established a baseline for comparison to phases 2 and 3 
and permitted assessment of stability of responding during daily vehicle injections. If the number 
of stimulations per component during baseline components varied ≤ 20%, across days, and if the 
number of baseline and test stimulations per component varied ≤ 20% on each day, then mice were 
advanced to subsequent phases. In phase two, the mice were divided into separate groups. One 
group continued receiving daily injections of vehicle, whereas the second group received daily 
injections of 0.3 mg/kg CP55,940. In phase 3, treatment with CPP55,940 terminated, and only 
baseline components were conducted to probe for evidence of spontaneous withdrawal and to 
investigate whether or not mice would return to pre-drug baselines. 
Precipitated withdrawal experiments were conducted in a third group of mice in three 
phases as described above with the following procedural differences. Four h after the final injection 
of phase 1, mice were injected with 10 mg/kg rimonabant to examine its effects on ICSS before 
CP55,940 exposure. After two or three days of subsequent vehicle tests to allow for washout of 
rimonabant, mice were given daily injections of 0.3 mg/kg CP55,940 (Phase 2). On day 7 of phase 
2 mice were given a second test with rimonabant (10 mg/kg, 10 min i.p., 4h after CP55,940) to 
precipitate withdrawal. 
2.3.8 Data Analysis.  
All data were analyzed using GraphPad Prism 6.0 software. The primary dependent 
variables were the number of stimulations per min for each frequency and the number of 
stimulations per component across all frequencies as described previously (Negus and Miller 2014; 
Wiebelhaus et al. 2014). These data were then evaluated using two separate approaches. First, data 
for each frequency trial during baseline and test components were expressed as percent Maximum 
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Control Rate (%MCR), with maximum control rate defined as the maximum average rate observed 
at any frequency during baseline components for that mouse on that day. %MCR data were 
averaged across mice to generate the frequency-rate curves that were assessed using repeated-
measures two-way ANOVAs (treatment x frequency) between baseline and treatment curves for 
each drug/dose tested. A significant ANOVA was followed by the Holm-Sidak test, and the 
criterion for significance was p<0.05. 
In the second approach, the average total number of stimulations per test component was 
divided by the average number of stimulations per baseline component for each mouse on each 
day, and multiplied by 100, to produce percent baseline stimulations (% baseline stimulations). 
These data were averaged across mice for each treatment and compared with one-way ANOVAs 
(Wiebelhaus et al. 2014). A significant ANOVA was followed by Dunnett’s post hoc test to 
compare treatment groups with VEH controls. 
Data from repeated-treatment studies were analyzed using both % MCR and % baseline 
stimulations measures. For tolerance studies each day in phase 2 was compared within each group 
to each other day as well as to average data from phase 1. Additionally, % baseline stimulations 
were also analyzed between groups by day. Selected frequency-rate curves from phase 1 day 7 
(i.e. pre-drug), and days 1, 2 and 7 from phase 2 were used to assess both tolerance across days 
and the acute effect of CP55,940 each day. Precipitated withdrawal studies compared the 
frequency-rate curves between baselines, CP55,940 tests, and rimonabant tests in phase 1 day 7 
and phase 2 day 7.  
2.4 Catalepsy 
2.4.1 Procedure.  
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Catalepsy was measured during 60 s test periods. At the start of each test period, the 
forepaws of the mouse were placed on a metal bar raised 4.5 cm from a metal platform. If a mouse 
removed its forepaws from the bar, the forepaws were replaced up to four times or until the testing 
period ended, whichever occurred first. The total time the mouse retained its forepaws on the bar 
was recorded. During the spontaneous and precipitated withdrawal experiments, catalepsy was 
measured immediately after ICSS baseline and test components. Approximately 75 min lapsed 
between these measurements during ICSS studies, so the same interval was used in control 
experiments without ICSS. 
2.4.2 Data Analysis.  
Catalepsy data are expressed as the change from baseline measurements after a 75 min 
pretreatment and analyzed utilizing two-way ANOVA. To determine whether the expression of 
catalepsy correlated with rate-decreasing effects of repeated dosing with CP55,940, a Pearson 
correlation was conducted between the change from baseline in catalepsy versus the % baseline 
stimulations. 
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3. Results 
3.1 Potency, Time Course and Rimonabant Antagonism of CP55,940 Effects on ICSS 
 Whereas cocaine (10 mg/kg) facilitated ICSS (Figure 31), CP55,940 (30 min pretreatment) 
produced dose-related reductions in ICSS. The % baseline stimulations measure shows that 
CP55,940 (0.3-1.0 mg/kg) depressed ICSS with no evidence for facilitation at any dose (Figure 
27A, (F (2.640, 18.89) = 40.1) p < 0.001). The ED50 (95% confidence limits) of CP55,940 to 
produce rate-decreasing effects was 0.15 (0.12-0.18) mg/kg. Similarly, CP55,940 produced dose-
dependent rightward and downward shifts in the ICSS frequency-rate curve (Figure 27B, (F (9, 
63) = 85.9, p < 0.001). Finally, time-course studies revealed that 0.3 and 1.0 mg/kg CP55,940 
decreased ICSS within 5 min, and these rate-decreasing effects persisted for up to 8 h (F (18, 132) 
= 20.27, p < 0.001). 
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Figure 27. Acute administration of CP55,940 suppressed ICSS through a CB1 receptor 
mechanism of action. A. (%Baseline stimulations) and B. (%MCR). CP55,940 dose-dependently 
decreased ICSS. n=8; filled squares indicate p<0.05 vs. VEH 1, C. CP55,940-induced ICSS 
depression persisted for up to 8 h (n=6-7, filled squares indicate p<0.05 vs. respective vehicle 
control, *p<0.0001 0.3 mg/kg vs. 1.0 mg/kg CP55,940).  
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 Whereas rimonabant (3.0-30.0 mg/kg) administered alone had no effect on % baseline 
stimulations (Figure 28 and Figure 32), it dose-dependently prevented the depressive effects of 
CP55,940 (1.0 mg/kg) on ICSS (Figure 28A: F (2,12) = 104.7, p < 0.001). Analysis of the 
frequency-rate data indicated no effect of rimonabant alone (Figure 28B: F (18, 108) = 1.131, p = 
0.333), and a dose-dependent reversal of CP55,940-induced suppression of ICSS (Fig 28C: F (27, 
162) = 18.4, p < 0.001). 
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Figure 28. A. The CB1 antagonist rimonabant (3.0 or 10.0 mg/kg) did not affect ICSS when 
administered alone, but blocked the rate-decreasing effects of CP55,940 (n=7, filled squares 
indicate p<0.05 VEH vs. 1.0 mg/kg CP55,940, *p<0.0001 vs. 10.0 mg/kg rimonabant) B. 
Frequency-rate  analysis of rimonabant alone and vehicle test revealed no significant difference 
(n=7). C. CP55,940 (1.0 mg/kg) suppressed ICSS, which was prevented by rimonabant (n=7, 
filled squares indicate p<0.05 vs vehicle 2).  
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3.2 Effects of Repeated CP55,940 
 The average % baseline stimulations for each mouse during seven days of vehicle 
injections was used for comparison to assess effects of phase 2 treatments with vehicle or different 
CP55,940 doses (seven day averages (±2.14 SEM) for the number of baseline stimulations per 
component: Group 1: 97.73 (±2.14), Group 2: 102.49 (±1.57), Group 3: 99.11 (±2.52)). Figure 
29A shows effects of repeated vehicle or 0.3 mg/kg CP55,940 on % baseline stimulations during 
phase 2 (F (14, 91) = 3.3, p < 0.001)). Repeated treatment with vehicle during phase 2 did not alter 
ICSS. However, the first injection of CP55,940 (0.3 mg/kg) significantly reduced ICSS to a similar 
degree as in the dose-effect study (see Figure 27A). Tolerance to rate-decreasing effects developed 
by day 3 in both CP55,940-treated groups, and on day 5, both groups of CP55,940-treated mice 
no longer displayed differences from the vehicle-injected mice. Repeated treatment with vehicle 
during phase 2 also produced no change in frequency-rate measures of ICSS (Figure 29B; F (27, 
108) = 0.74, p = 0.81). The CP55,940-treated groups showed an initial suppression of ICSS on day 
1 and partial recovery of ICSS occurred on later days (Figure 29C; F (27, 135) = 3.4, p < 0.0001; 
Figure 29D; F (27, 135) = 1.784, p < 0.05).  
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Figure 29. Partial tolerance developed to a fixed dose of CP55,940 (0.3 mg/kg). A. Tolerance 
developed to the rate-decreasing effects of CP55,940 by day 2 in CP55,940 Group 1 (n=6, 
$$p<0.01, $$$p<0.001, $$$$p<0.0001 vs. day 1) and by day 3 in CP55,940 Group 3 (n=6, 
*p<0.05, **p<0.01, ***p<0.001 vs. day 1, although rates of responding never returned to vehicle 
levels within either group. B. The response rates for the repeated vehicle group remained ±20% 
of their phase 1 average, indicating no effect of repeated injections on ICSS (n=5).C, D. 
Frequency-rate analysis revealed similar pattern of tolerance in mice receiving repeated 
administration of CP55,940 (CP55,940 Group 2 and 3 (filled squares p<0.05 vs. pre-drug, 
****p<0.0001 day 1 vs. day 7).  
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 Repeated treatment with 0.3 mg/kg CP55,940 also increased catalepsy in ICSS mice as 
well as in a separate group of mice that did not undergo ICSS training and testing. (Supp. Figure 
34A, F (14, 105) = 2.693, p < 0.01).  Catalepsy was assessed after baseline ICSS and after 
CP55,940 administration to assess the role of this motor behavior. The cataleptic effects of 
CP55,940 were greatest on day 1 of treatment and reduced by day 2, but significant catalepsy 
persisted throughout the seven days of repeated administration. There was no correlation between 
the degree of catalepsy and the degree of ICSS suppression (Supp. Figure 34B; r = 0.07, p=0.69). 
 Termination of vehicle or CP55,940 treatment did not alter ICSS during the subsequent 
seven days (Figure 30A; interaction day vs group F (40, 280) = 0.8, p = 0.74). In addition, 
administration of 10 mg/kg rimonabant did not depress ICSS when it was administered before or 
after repeated treatment with CP55,940. Figure 30B shows that rimonabant did not alter ICSS as 
measured by % baseline stimulations in this group of mice (F (18, 90) = 0.80, p = 0.69). Figure 
30C shows the effects of 10 mg/kg rimonabant on full frequency-rate curves before CP55,940 
treatment (F (18,90) = 0.80, p = 0.69). The final dose of 0.3 mg/kg CP55,940 produced acute 
suppression of ICSS relative to the pre-drug baseline, and rimonabant blocked this suppression 
(Figure 30D, F (18, 90) = 2.0, p< 0.05). 
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Figure 30. There was no evidence of spontaneous or precipitated withdrawal following 7 days of 
once daily injections of 0.3 mg/kg CP55,940. A. Basal ICSS responses for each phase of testing 
(tests were performed prior to injections of vehicle or drug).Throughout the 21 days of testing, 
each group did not deviate ±20% on during basal testing. B. Rimonabant (10.0 mg/kg, i.p.) did 
not affect ICSS in mice treated repeated with either vehicle or CP55,940 (n=6) C. Frequency-rate 
curves on the same days revealed no effect of rimonabant after 7 days of vehicle on phase 1 day 
7 (n=6). D. CP55,940 (0.3 mg/kg) administered on seven consecutive days suppressed ICSS. 
Rimonabant (10.0 mg/kg) 4 hours after the final CP55,940 injection returned responding to 
baseline levels, consistent with pharmacological blockade of CB1 (n=6, filled square indicate 
p<0.05 vs baseline). 
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4. Discussion 
 Acute administration of CP55,940 dose-dependently and time-dependently depressed 
ICSS in mice. The observation that rimonabant prevented the rate-decreasing effects of CP55,940 
indicates that these effects were CB1 receptor mediated. The fact that rimonabant given alone did 
not alter ICSS indicates that CB1 receptors play a negligible role in basal responding in this ICSS 
procedure. Partial tolerance developed after repeated exposure to a fixed dose of CP55,940, but 
there was no evidence to suggest that this tolerance to rate-decreasing effects of CP55,940 
unmasked expression of abuse-related rate-increasing effects. Moreover, neither spontaneous nor 
rimonabant-precipitated withdrawal altered ICSS in mice treated repeatedly with 0.3 mg/kg 
CP55,940, suggesting that this regimen of CP55,940 treatment was not sufficient to produce 
dependence. Finally, catalepsy did not correlate with reduced ICSS after exposure to CP55,940. 
Taken together, these results indicate that CP55,940 did not produce reward-like effects in ICSS 
after either acute or repeated administration.  
4.1 Acute effects of CP55,940 in ICSS 
Acute administration of CP55,940 suppressed ICSS in mice with a potency approximately 
57 (35-95)-fold greater than that of THC (Wiebelhaus et al. 2014). The observed difference in 
potency is consistent with the affinities of THC and CP55,940 for CB1. Reported in vitro Ki values 
for THC are approximately 40 nM, whereas CP55,940 Ki is approximately 0.9 nM, reflecting a 
difference in affinity of 45 fold for the CB1 receptor (Compton et al. 1993). Potencies between 
THC and CP55,940 in vivo range from 4- to 15-fold in catalepsy, tail withdrawal, and rectal 
temperature assays (i.v. route of administration) in male ICR mice (Compton et al. 1992) and up 
to 82-fold in a drug discrimination procedure (i.p. route of administration) in male C57BL6/J mice 
(McMahon et al. 2008). Previous studies examining the acute effects of CP55,940 found that a 
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dose range of 0.01-0.05 mg/kg did not affect ICSS, but doses of 0.1 mg/kg and higher depressed 
ICSS in rats (Arnold et al. 2001; Mavrikaki et al. 2010; Kwilasz and Negus 2012). The present 
study represents the first publication reporting the effects of CP55,940 on ICSS in mice, and we 
found that a similar dose range reduced ICSS in this species. Importantly, there was no evidence 
for ICSS facilitation at low CP55,940 doses that did not suppress ICSS in mice, consistent with 
previous studies investigating synthetic cannabinoids in rat ICSS (Arnold et al. 2001; Mavrikaki 
et al. 2010; Kwilasz and Negus 2012). Although facilitation of ICSS by THC has been reported 
previously in rats (Gardner et al. 1988; Katsidoni et al. 2013), it should be noted that facilitation 
generally occurs at low doses in select strains of rats (Lewis and Sprague-Dawley) in a subset of 
published studies, and the magnitude of facilitation is relatively small compared to that produced 
by psychomotor stimulants such as cocaine (for review, see Negus and Miller 2014). Furthermore, 
THC attenuates ICSS in mice. Given the failure of CP55,940 to produce evidence of ICSS 
facilitation even at doses as low 0.03 mg/kg, the results of the present extend the range of 
conditions under which cannabinoids fail to facilitate ICSS in rodents. 
 Whereas rimonabant completely prevented CP55,940-induced depression of ICSS, this 
drug given alone did not alter ICSS. Previous studies in rats and mice also found that ICSS was 
not altered by CB1 receptor antagonist doses sufficient to block effects of exogenous cannabinoids 
(Vlachou et al. 2005; Vlachou et al. 2006; Kwilasz and Negus 2012; Katsidoni et al. 2013). These 
findings suggest that endocannabinoids acting at CB1 receptors do not tonically modulate neural 
substrates that mediate ICSS. 
4.2 Tolerance to the rate-decreasing effects of CP55,940 
 In the present study, the depressive effects of 0.3 mg/kg CP55,940 on ICSS underwent 
tolerance by the second day of treatment. While this tolerance persisted for the remaining seven 
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days of drug administration, tolerance was not complete, as CP55,940 continued to attenuate ICSS. 
For comparison, complete tolerance developed to THC-induced depression of ICSS in rats treated 
for 22 days with an escalating regimen of THC doses (Kwilasz and Negus 2012), but no tolerance 
developed to depression of ICSS by repeated treatment with the synthetic cannabinoid 
WIN55,212-2 (Mavrikaki et al., 2010). Although assessment of rightward shifts in the dose 
response relationship to quantify the magnitude of tolerance were not conducted, these apparent 
discrepancies in tolerance development to a single dose of drug may be related to the rank order 
of efficacies of these cannabinoids at CB1 receptors (WIN55,212-2>CP55,940>THC) (Breivogel 
et al. 1998).  Similarly, the extent of antinociceptive tolerance to mu opioid agonists was found to 
be inversely related to efficacy of the agonists at mu receptors (Yaksh 1992; Duttaroy and Yoburn 
1995). More generally, it appears that low- vs. high-efficacy ligands occupy higher proportions of 
receptors to produce equivalent acute effects, down-regulate a higher proportion of receptors 
during chronic treatment, and are more sensitive to reductions in the density of functional receptors 
produced by that downregulation.  
5. Conclusions 
 The findings in the present study indicate little evidence for abuse potential and 
dependence for CP55,940. Tolerance developed quickly but incompletely to the rate-decreasing 
effects of CP55,940 on ICSS. The bulk of studies investigating the effects of synthetic 
cannabinoids on ICSS examined acute drug administration, and only one study of which we are 
aware examined repeated administration of a synthetic cannabinoid in rats (Mavrikaki et al. 
2010). Thus, the present body of work represents the first study to examine tolerance and 
dependence of a synthetic cannabinoid in a mouse ICSS procedure. Although there was no 
evidence for spontaneous or rimonabant-precipitated withdrawal, the depressive effects of 
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CP55,940 on ICSS showed partial tolerance following repeated administration. It is reasonable to 
suspect these findings could be extended to other bicyclic cannabinoids which have a history of 
abuse such as CP47,497 (Papanti et al. 2013; Koller et al. 2014). Overall, these experiments 
reveal the greatly increased potency of synthetic cannabinoids and their potentially detrimental 
effects on brain reward following acute or repeated administration.  
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Figure 31. Select mice that completed at least one experiment were anesthetized with 2-3% 
isoflurane and humanely sacrificed via cervical dislocation. Whole brains were harvested and 
immersed in 8-10 ml of 10% formalin for 7-10 days to allow for tissue fixation. The brains were 
sliced in 50 m sections using a Leica VT1000S Vibratome, mounted on Superfrost+ slides 
(ThermoFisher Scientific, Waltham, MA), and allowed to dry overnight. The sections were 
stained for Nissl with cresyl violet and imaged using a Zeiss Discovery V20 Stereo Zoom 
microscope. A. Electrode tips are localized to the lateral hypothalamus in mice which qualified 
for testing in ICSS utilizing the requirements detailed in the Methods section. B.  A 
representative section from a mouse showing a partial electrode tract as well as localization of 
the tip (8x, 16x, and 24x magnification). 
138 
 
 
Figure 32. Cocaine HCl (10 mg/kg) served as a positive control to demonstrate ICSS-facilitating 
effects in mice. Cocaine increased responding in both A. %baseline stimulations and B. 
frequency-rate curves (F (1.051, 5.257) = 19.20, p < 0.01, n=6, *p < 0.05 vs. saline 1, filled 
squares p<0.05 vs. baseline). 
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Figure 33. A single, high dose of rimonabant (30 mg/kg, 45m s.c.) did not suppress ICSS in A. 
%baseline stimulations (F (1.481, 5.925) = 0.23, p=0.74) or B. frequency-rate (F (18, 72) = 
1.125, p=0.3500). 
  
140 
 
 
Figure 34. A. Tolerance developed to the cataleptic effects of CP55,940 in mice implanted with 
electrodes in the medial forebrain bundle (F (14, 105) = 2.69, p < 0.05, n=6-8, #p<0.05 vs. day 1 
for 0.3 CP55,940 – ICSS, ****p<0.0001 vs. day 1 for 0.3 CP55,940 – no ICSS). In vehicle and 
0.3 mg/kg CP55,940 – ICSS groups, each mouse was assessed for catalepsy following ICSS 
baseline and test passes, with 75 min elapsing between measurements. The 0.3 mg/kg CP55,940 
– no ICSS group served as a control to determine if ICSS testing prior to catalepsy testing had 
any effect on the development of tolerance to the cataleptic effects of CP55,940. B. No 
significant correlation (r = -0.22, p = 0.15) was found between ICSS depression (30-60 min after 
injection) and catalepsy (75 min following injection). 
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Chapter 4: Discussion 
 
4.1  Synthetic cannabinoids remain a prominent public health concern 
 As more case reports emerge detailing the deleterious effects of SC use, there is a great 
need to discover the mechanism by which they engender their dangerous and potentially deadly 
effects. Their structures vary considerably; thus the potential for toxic metabolites distinct from 
those found in marijuana is high. Few studies have examined the various metabolites in blood or 
urine following SC ingestion, and potential toxicological effects of these metabolites have not 
yet been elucidated. Another potential mechanism for the elevated risk of use lies within the 
pharmacological properties of the abused SC. As has been detailed in previous sections, SCs are 
generally more potent and efficacious at the CB1 receptor, and health complications resulting 
from SC ingestion are generally congruous with peripheral and central CB1 expression. Thus, if 
enhanced, in vivo activation of CB1 is one of the determining factors to cause serious health 
complications, there is a need for a way to quickly ascertain efficacy to produce CB1 activation. 
Additionally, the abuse-related effects of enhanced CB1 efficacy are not well understood, 
especially under repeated dosing conditions. Here, we developed a model utilizing receptor 
theory as a framework to use mice which possess 100%, 50%, and 0% CB1 expression in a 
model of cannabimimetic activity. The compounds A-834,735D, WIN55,212-2, CP55,940, 
JWH-073, CP47,497, and THC were selected, based upon previously published results and 
personal communications, to span the efficacy continuum and assess stratification by efficacy in 
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vivo. Abuse-related effects of a representative high-efficacy cannabinoid (CP55,940) were tested 
employing the ICSS procedure after both acute and repeated administration. Finally, studies of 
agonist-stimulated [35S]GTPS experiments corroborated our in vivo results, although the 
observed rank order of efficacy did not entirely agree with previous reports. 
4.2. Theoretical predictions versus agonist-stimulated [35S]GTPS binding in high and low 
receptor conditions 
 To elucidate whether CB1-mediated G-protein activation correlated with agonist dose 
ratios in WT and HET mice, agonist-stimulated [35S]GTPS binding studies were conducted in 
WT, HET, and KO tissue. Agonist-stimulated [35S]GTPS binding assesses ligand potency and 
efficacy to affect the exchange of GTP for GDP at the G-protein, the first step in the canonical 
GPCR signal transduction pathway. Although the ligands for this body of work were selected 
utilizing the available body of literature, not all of these drugs had been tested under the same 
experimental conditions. WIN55,212-2, CP55,940, JWH-073, and THC were all tested in one 
study (Griffin et al, 1998), and the rank order generated for the experiments conducted here is in 
accordance with those results. Unpublished results comparing A834,735D versus CP55,940 
(Thomas and Wiley, 2014) and CP47,497 and CP55,940 (unpublished results, Lichtman lab) also 
agree with our a priori rank order efficacy prediction. Additionally, the literature lacks a rigorous 
assessment of potential off-target G-protein stimulation utilizing CB1 KO tissue despite known 
examples of non-CB1, non-CB2 mediated WIN55,212-2 stimulated [
35S]GTPS binding. 
Therefore, a series of binding experiments were performed in high (cerebellum) and low (spinal 
cord) CB1 receptor density tissues to assess the loss of efficacy as it relates to total receptor 
expression in WT and HET samples. 
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 Radioligand binding with [3H]SR141716A confirmed high CB1 expression in cerebellum 
and low expression in spinal cord in WT mice, and that  HET mice displayed roughly 50% 
expression in each case. No specific binding was detected in KO samples, confirming the 
selectivity of rimonabant. As discussed in the introduction, the Emax in each tissue should vary 
with receptor expression such that high expression will yield high Emax values and low 
expression will yield low Emax values. All ligands stimulated [
35S]GTPS binding to a greater 
degree in cerebellum relative to spinal cord. In cerebellum, WIN55,212-2 elicited the highest 
Emax values, but unlike the other agonists tested, it also stimulated G-protein activation in KO 
tissue consistent with previous findings (Monory et al, 2002). To quantify and express only CB1-
mediated G-protein activity, the KO stimulation was subtracted from WT and HET stimulation 
for all drugs in cerebellar tissue. With this manipulation, A-834,735D, WIN55,212-2, CP55,940, 
JWH-073, and CP47,497 produced similar maximum stimulation in WT samples whereas THC 
achieved a relatively lower maximum. In HET samples, the predicted 50% decrease in Emax was 
not observed for the three highest efficacy ligands (A-834,735D, WIN55,212-2, and CP55,940), 
but rather a 20% decrease was observed. This smaller than expected decrease is likely indicative 
of a receptor reserve to produce G-protein activation, which is somewhat surprising. The 
stoichiometry of the receptors and G-proteins is important to consider when interpreting these 
results. Cannabinoids possess a low degree of efficiency to activate G-protein, with the full 
agonist WIN55,212-2 stimulating GDP-GTP exchange at three G-proteins per receptor activated 
indicating an amplification factor of 3 (Sim et al, 1996b). It is unknown if this amplification 
factor is a general property of cannabinoid receptors or if it is ligand-specific. In spinal cord, the 
expected 50% reductions were observed for all ligands except for THC, which did not have 
detectable efficacy to stimulate any GDP-GTP exchange in HET tissue. This result indicates low 
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receptor reserve conditions similar to apparent low receptor reserve for some the in vivo effects, 
though it should be noted the basal activity of spinal cord was nearly twice that of cerebellum 
(~4000 counts versus ~2000). This basal activity is likely not due exclusively to CB1 receptors 
alone but rather reflects the sum of the constitutive activity of all GPCRs present in the sample 
aside from purinergic activity. Whether G proteins are pre-coupled to their receptors remains 
contentious, though if this is this case, then the high basal activity in the spinal cord might also 
reflect sequestration of a portion of the G-proteins by non-CB1 receptors, functionally reducing 
the overall ability of the system to respond to cannabinoid ligands. G-proteins may also affect the 
conformation of the receptor they interact with, thereby also potentially affecting the affinity of 
the ligand for the receptor. Kenakin illustrates this by demonstrating the discrepancy between the 
use of agonist versus antagonist radioligands to measure affinity under conditions where [G] < 
[RT], [G] = [RT], and [G] >>> [RT] (Kenakin, 1997). Presuming an agonist favors the G-protein 
bound state, low [G] would reduce the potency of agonists while high [G] would increase 
potency. While the EC50 values reported here do vary somewhat between brain regions for some 
agonists, no discernable pattern emerged to suggest this to be the case. Overall, the results were 
expected in both cerebellum and spinal cord. 
4.3  Differential sensitivity of catalepsy, hypothermia, and antinociception in the 
cumulative dosing CB1 efficacy determination model 
 The cumulative dosing cannabinoid triad procedure revealed differential sensitivity of 
each endpoint to a 50% reduction in CB1 receptor expression. The hypothesis that efficacy would 
vary inversely with the potency shifts measured between WT and HET mice was tested, with KO 
mice serving to detect any non-CB1 effects for each measure. As an ancillary goal, this procedure 
was designed as a high throughput method to test in vivo efficacy of novel, putative 
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cannabimimetic ligands. Catalepsy, hypothermia, and antinociception are likely mediated by 
distinct CNS regions, which may account for observed differences among the measures. 
Antinociception was the most sensitive of the three triad measures to a 50% reduction in 
CB1 expression, and it was the only measure to display graded downward shifts in the dose 
response curve. The choice of a 10 second cutoff for tail withdrawal latency avoids tissue 
damage that could confound results, especially in repeated testing situations such as time course 
or cumulative dosing studies. Animal welfare concerns also limit the duration of testing, as tissue 
damage may occur at temperatures above 52C or if the cutoff extends beyond ten seconds. 
Though raising the time limit may better differentiate between high efficacy ligands it would 
preclude the use of repeated testing to avoid tissue damage. The intensity of the stimulus (i.e. 
temperature of the water bath) is another variable which can be manipulated. As in the case of 
the 10 second time limit, the upper limit of the temperature was chosen to allow repeated testing 
and avoid confounding tissue damage. However, an alternative approach to differentiate between 
high-efficacy cannabinoids ligands such as A-834,735D and WIN55,212-2 would be to raise the 
stimulus intensity to elicit antinociception (e.g., increase the temperature of the hot water 
noxious stimulus). Although drugs of moderate efficacy may begin to resemble THC (i.e. no 
effect in HET mice), resolution would be gained at the top of the efficacy continuum. Reducing 
the stimulus intensity by reducing the temperature should have the opposite effect, in essence 
causing greater differentiation between low-efficacy compounds but less differentiation between 
moderate and high-efficacy compounds. 
The tail-flick response (D’Amour and Smith, 1941) is a spinal reflex conducted primarily 
by fast conducting A fibers from the source of the noxious insult to the dorsal horn. From there, 
the signal is transmitted along the spinothalamic tract to the thalamus, and parallel fibers project 
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along the spinomesecephalic tract to the PAG. Descending projects from the PAG through the 
rostroventromedial medulla to spinal neurons provide top-down control of the reflex (Morgan et 
al, 2008). Importantly, CB1 is expressed in the dorsal root ganglion (Bridges et al, 2003), the 
dorsal horn (Farquhar-Smith et al, 2000), and the PAG (Herkenham et al, 1990) with appreciable 
abundance, although its expression in the PAG is somewhat higher than in spinal cord. When 
utilizing CB1 HET mice, expression was 50% of that observed in WT mice. Given that CB1 
expression is already relatively low, receptor reserve may have been depleted sufficiently to 
detect downward shifts in the dose-effect relationship in HET mice. Indeed, the low–efficacy 
agonist THC did not produce dose-dependent increases in tail withdrawal latency in HET mice 
while doing so with relatively low potency in WT mice compared to the other agonists tested. 
CP47,497 and JWH-073 did elicit dose-dependent increases in tail withdrawal latency in HET 
mice but did not achieve above a 50% effect to allow ED50 potency comparisons. CP55,940, 
WIN55,212-2, and A-834,735D all achieved maximal effects in HET mice though they did so 
with varying potency. The final efficacy rank order was similar to the hypothesized order (A-
834,735D ≥ WIN55,212-2 > CP55,940 > JWH-073 ≥ CP,47497 > THC), though the decline in 
potency was much steeper when compared to hypothermia. This finding suggests the tail 
withdrawal assay under these conditions has the highest efficacy requirement of the three 
endpoints, though this sensitivity may be adjusted as discussed above. 
Hypothermia displayed modest shifts in dose-effect curves between WT and HET mice 
for the synthetic cannabinoids tested, whereas THC did not elicit CB1-mediated reductions in 
body temperature in HET mice. The observed distribution of efficacy was consistent predicted in 
vitro results (A-834,735D = WIN55,212-2 ≥ CP55,940 ≥ JWH-073 ≥ CP,47,497 > THC), though 
only CP47,497 differed significantly from the other synthetic cannabinoids. The hypothermia 
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measure provides a somewhat gradual separation of potency ratios with declining efficacy, and 
therefore, it may be useful for differentiation of agonists with moderate to low efficacy. This 
moderate gradation of efficacy may be due in part to the relatively moderate expression of CB1 
in brain areas reported to modulate body temperature, notably the preoptic area (POA) of the 
anterior hypothalamus (AH) (Rawls et al, 2002) and possibly the periaqueductal grey (PAG) 
(Lichtman et al, 1996). The density of CB1 expression in these brain areas is approximately 2 
pmol/mg in rats (Herkenham et al, 1990). Based on the observation that a 50% reduction in CB1 
expression resulted in significant rightward shifts in the dose-response curves of cannabinoids 
tested suggest that hypothermia is a sensitive measure to differentiate between ligands of varying 
efficacy. These brain regions may also dynamically interact with one another as there are 
descending neuronal projections from the AH to the PAG and ascending projections in the other 
direction, though the interplay between these structures in regards to thermoregulation in the 
context of cannabinoids remains to be elucidated.  
Ceiling effects for hypothermia measure were arbitrarily imposed based upon 
observations during pilot studies, in which an 8C drop in body temperature was observed to 
coincide with maximum effects in the catalepsy and antinociception. Maximum hypothermia 
values actually observed sometimes reached -12C for individual animals, though mean values at 
maximum doses tended to not exceed -10C from baseline across drugs. It is possible an 
adjustment of the ceiling to -10C or -12C may reveal apparent differences in Emax between 
ligands that vary in efficacy, though this may preclude calculation of potency ratios in cases of 
moderate- to low- efficacy ligands, for which the calculated maximum percent effect does not 
sufficiently sample the linear portion of the dose-effect relationship.  
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The catalepsy measure was the most resistant to a 50% reduction in CB1 expression and 
did not display potency ratios that diverged appreciably from a ratio of 1 for all drugs tested. 
Even THC, which is generally regarded as a very low-efficacy cannabinoid, displayed a very 
small shift in the dose-effect curve between WT and HET mice. The experimenter-imposed 
ceiling, underlying receptor expression, and multiple neural circuits mediating motor control 
may contribute to this apparent lack of sensitivity to reductions in CB1 receptor population. 
Catalepsy is described as a fixed, rigid posture that is measured in seconds of immobility in 
either the ring or bar test. Here, we measured the latency of a given mouse to remove its 
forepaws from the elevated bar four times. For these experiments, a 60 second window was used 
to quantify this response to cannabinoids, so an ED50 represents the effective dose to produce 30 
seconds of immobility. The actual duration of catalepsy many last for many minutes beyond the 
initial observation period, and as a result the maximum effect engendered by administration of 
each agonist to produce immobility was not measured. Practical considerations prevent the 
prolonged study of catalepsy in the context of the triad but it should be noted that the 
“maximum” effect reported here does not reflect a natural resolution of the cataleptic response 
but rather an experimenter imposed limit. Regardless, the potency ratios between WT and HET 
mice are the primary endpoint of interest and the small shifts elicited likely speak to the 
underlying receptor expression and/or neurobiology of the behavior.  
The CB1 receptor is expressed at very high densities in striatal regions of the midbrain in 
the rat (Herkenham et al, 1990), and expression in WT (3.33 ± 0.13 pmol/mg) and HET (1.89 ± 
0.14 pmol/mg) mice are comparably high (Selley et al, 2001). Additionally, the receptor reserve 
to produce catalepsy is quite high as only a small fraction of receptor must be occupied to 
produce immobility (Dhawan et al, 2006). Thus, even under condition where 50% of the 
149 
 
available receptor pool is eliminated, the number of receptors needed to achieve a maximum 
effect remains well above what would be necessary to effect a large shift in potency. However, 
this apparent large receptor reserve does not entirely account for the differences among the 
ligands in HET mice. These mice showed no decreases in potency as measured by overlapping 
confidence limits for ED50 estimations. The rank order of the shifts in potency measured (JWH-
073 ≥ A-834,735D ≥ CP47,497 ≥ CP55,940 > WIN55,212-2 ≥ THC) are also intriguing as they 
do not align with the predicted order (A-834,735D ≥ WIN55,212-2 > CP55,940 > JWH-073 > 
CP47,497 > THC). Although variability must remain a consideration, this may reflect differences 
in signaling events that are sufficient to produce catalepsy and are differentially activated by 
these compounds.  
Cannabinoid signaling in the striatum and output neurons is a complicated web of 
signaling events that involves subregions such as the caudate-putamen (CP), the internal and 
external globus pallidus (GPi and GPe), entopeduncular nucleus (EP), and the substantia nigra 
(SN). The CP receives excitatory input from the neocortex and sends GABAergic projections to 
the GPi, GPe, EP, and SN. From there, dopaminergic neurons from the SN project back to the 
CP, while GABAergic neurons from the SN as well as the GPi project to the thalamus, which 
then projects back to the neocortex. In addition, the GPe and the SN send GABAergic 
projections to the subthalamic nucleus, which contains excitatory inputs back to the GPe, GPi, 
SN, and and EP. CB1 expression is most abundant on excitatory glutamatergic neurons and 
inhibitory GABAergic neurons, and as a result there are many levels of regulation of synaptic 
transmission exerted by cannabinoids in this neuronal network. Microinjections of a CB1 agonist 
into the GP suppressed locomotor activity, whereas microinjections into the SN stimulated 
locomotor activity (Sañudo-Peña et al, 1999), and systemic injections seem to produce biphasic 
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stimulation at low doses and stark locomotor suppression and catalepsy at doses exceeding 2.5 
mg/kg (Sañudo-Peña et al, 2000). The exact relationship between the neurocircuitry in the 
striatal regions and the resulting behavior remains complex and poorly understood. However, 
systemic injections that produce global activation of CB1 receptors seem to produce primarily 
inhibition of locomotor activity. 
. Although the neurocircuitry is quite complex, CB1 receptor expression in these regions 
remains quite high even in HET mice relative to other brain regions. Thus doses required to 
produce catalepsy would be expected to be similar in WT and HET mice, even in the case of a 
low efficacy agonist such as THC. Although the other agonists did not display the expected 
pattern of efficacy distribution, THC did elicit the largest (~2 fold) shift, consistent with the 
hypothesis.  
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Figure 35. Adapted from Breivogel and Childers, 1998. This schematic displays the 
neuroanatomical projections among striatal structures. CB1 receptors are highly expressed 
throughout striatal structures on GABAergic and glutamatergic neuron terminals, represented by 
+ and - symbols.  
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4.4  Potential limitations of the of the in vivo CB1 efficacy determination model 
 The cumulative dosing employed possesses limitations relative to dosing with separate 
groups of subjects (as discussed in the Introduction). Tachyphylaxis could certainly exacerbate 
potency differences, especially for low efficacy drugs, and variance in the pharmacokinetics of 
the test drugs could result in different optimal pretreatment times. Regardless, the half-lives of 
cannabinoids are in general quite long, and time-course studies revealed a long duration of action 
of all drugs tested using relatively high doses. Additionally, in the case of THC, cumulative 
dosing yields relatively similar brain levels as compared to a bolus dose 20 minutes prior to 
harvest (Falenski et al, 2010). That said, the pharmacokinetic and pharmacodynamic information 
regarding many compounds utilized in these studies is not well explored, and will not be 
examined for clandestinely synthesized SCs in the future. Generally, the half-lives of 
cannabinoids tend to be quite long, often on the order of hours, thus cumulative dosing is often 
applicable. However, there may be SCs which possess considerably shorter duration of action; 
therefore, rigorous assessment of peak effects along with adsorption, distribution, metabolism, 
and excretion will likely be necessary to further validate the model. This is especially true for 
CB1 HET mice, given the paucity of information regarding specific cannabinoid actions in that 
context. 
 The in vivo determination of efficacy at the CB1 receptor under these conditions is not 
able to differentiate between downstream signaling events, but rather, each dependent measure 
reflects the a function of all of the relevant signal transduction and associated biochemical events 
that occur to elicit a response. For instance, if interplay among multiple CB1-mediated pathways 
(e.g. G-adenylyl cyclase-PKA, G-GIRK channels, BARR2-ERK1/2) ultimately determines 
antinociception in the tail flick procedure, agonist-stimulated [35S]GTPS binding alone will only 
153 
 
account for part of the biochemical signaling. The drugs chosen for these experiments span the 
efficacy continuum, although only one biochemical correlate of functional CB1 (agonist-
stimulated [35S]GTPS binding) activity was selected as a correlate. This decision was largely 
due to the relative abundance of knowledge regarding this signal transduction pathway in ex vivo 
preparations including acute activation and diminished activation after rats or mice were made 
tolerant. These data correlate well with in vivo effects, though given recent findings, it is unlikely 
these cannabinoids act solely via the canonical G-protein pathway. Whether the GDP-GTPS 
exchange accurately accounts for the in vivo effects could be investigated more thoroughly in 
theory, although the relative paucity of highly biased, bioavailable CB1 ligands precludes this 
sort of investigation at this time. 
 Although both sexes were used in all cumulative dosing triad experiments, sex-related 
differences among the ligands were sparse and did not conform to a discernable pattern (Table 
8). Although the total number of mice used for each experiment (n=7-10 per genotype) was 
sufficient to detect meaningful differences among genotypes, an even split between sexes 
resulted in half that number when separated for analysis of sex effects (n=3-5). As a result, these 
comparisons were likely underpowered. Thus any significant differences detected between sexes, 
among genotypes, may not be meaningful. Future studies could focus on ascertaining the 
veracity of these sex differences, both by increasing the sample size as well as monitoring 
estrous cycles in females. Gonadectomies could also provide a useful method to interrogate sex 
hormone effects of various SCs tested should sex differences be detected. 
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THC WT HET KO 
Catalepsy ns ns ns 
Hypothermia ns ns ns 
Antinociception ns ns ns 
    
CP47,497 WT HET KO 
Catalepsy ns 30 ns 
Hypothermia ns ns ns 
Antinociception ns 100 ns 
    
JWH-073 WT HET KO 
Catalepsy ns ns ns 
Hypothermia ns ns ns 
Antinociception ns ns ns 
    
CP55,940 WT HET KO 
Catalepsy 0.3 ns 1, 3 
Hypothermia ns ns VEH 
Antinociception ns ns ns 
    
WIN55,212-2 WT HET KO 
Catalepsy ns ns ns 
Hypothermia ns ns ns 
Antinociception ns ns ns 
    
A-834,735D WT HET KO 
Catalepsy 1 ns ns 
Hypothermia ns ns ns 
Antinociception ns ns ns 
 
Table 8. Two-way ANOVAs followed by Holm-Sidak post hoc analysis were conducted 
between males and females in WT, HET, and KO mice for the catalepsy, hypothermia, and 
antinociception measures. Significant differences were found for CP47,497, CP55,940, and A-
834,735D, but not for THC, JWH-073, and WIN 55,212-2. Group sizes were small (n=3-5), thus 
Type I and Type II errors could not be ruled out in each case. NS indicates no significant 
ANOVA, all other symbols indicate specific doses for which significant sex differences were 
detected. 
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4.5  Correlations of agonist-stimulated [35S]GTPS binding with in vivo data: the 
potential for alternative pathways 
 The underlying purpose of GTPS binding experiments was to discover the degree to 
which G-protein activity correlated with each of the triad measures. Especially when considered 
in the context of the agonist-antagonist interaction studies, these correlations would help reveal 
whether the potency shift observed between WT and HET mice in vivo correlated with actual 
differences in Emax measured in vitro. For in vivo data, dose ratios were calculated by dividing 
the WT ED50 by the HET ED50 for each triad measure and then plotted against the WT Emax from 
in vitro experiments. Correlations emerged for the hypothermia and antinociception measures 
under low receptor density conditions, suggesting G-protein activation as the primary signal 
transduction pathway for CB1-mediated hypothermia and antinociception. Additionally, losses in 
potency in HET mice are related to reductions in functional activity at CB1 in vitro.  
There are numerous alternate pathways documented in addition to Gi/o inhibition of 
adenylyl cyclase activity. After dissociation of the  subunit from the G-protein heterotrimer, the 
 dimer can interact with GIRK channels (Ho et al, 1999), and BARR1/2 recruitment is also 
possible, which can interfere with G-protein coupling (Breivogel et al, 2013), spur 
internalization (Daigle et al, 2008b), or recruit other pathways such as ERK1/2 (Flores-Otero et 
al, 2014). The results of Flores-Otero and colleagues are particularly intriguing as they suggest 
lengthy exposure to cannabinoid agonists shift signal transduction away from G-proteins and 
towards BARR2-mediated ERK1/2 phosphorylation. Utilizing radioligand binding techniques 
with high concentrations of MgCl2 greatly extends the length of time that GTPS remains bound 
to the G-proteins, which likely does not reflect the physiological equilibrium between GDP and 
GTP which occurs in vivo, and more importantly, would not capture this shift. This has the 
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additional consequence in the case of cumulative dosing, where prolonged exposure to the drug 
could result in measurement of multiple pathways at once, each dose possessing its own 
independent time courses to shift the equilibrium. 
4.6  Lack of acute abuse-related facilitation or withdrawal effects in ICSS by CP55,940 
 Testing with the synthetic cannabinoid CP55,940 in the ICSS assay revealed no evidence 
for facilitation at any dose tested. Two high doses were tested in time course studies and revealed 
exclusively rate-suppressing effects for the duration of the testing period. Pretreatment with 
rimonabant reversed the rate-suppressing effects, indicating a CB1-mediated mechanism of 
action. All of these results point to a lack of abuse liability for CP55,940 that is consistent with 
other reports for the same drug and other synthetic cannabinoids (Arnold et al, 2001; Vlachou et 
al, 2004). To date, only THC over a low and narrow dose range has displayed facilitating effects 
in ICSS. Species and/or strain differences may play a role as facilitation has only been shown in 
Lewis and Sprague-Dawley rats (Gardner et al, 1988; Katsidoni et al, 2013). 
Given the abundance of cannabinoid abuse in humans, these results remain perplexing. It 
may be that ICSS is not well-suited to measure the abuse-related effects of THC and other 
cannabinoids. Another option is related to the relatively small facilitation of ICSS observed after 
dosing with cannabinoids. The ratio of signal to noise may preempt the ability to measure the 
abuse related effects. As discussed in the introduction, other assays of abuse liability also display 
mixed results when testing for abuse liability, so perhaps this is not surprising. Although 
humans, rodents, and non-human primates possess similar reward circuitry, there may be an 
aspect of the human experience of marijuana use that is not readily measured in preclinical 
assays. Thus, the majority of experiments using conventional preclinical assays of abuse 
potential fail to capture the apparent abuse-related effects that relate to human use. 
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4.7  Tolerance, but not dependence, following repeated administration of CP55,940 in 
ICSS 
 ICSS has been previously employed to measure tolerance and dependence for opioids 
(Altarifi and Negus, 2011), cocaine (Stoker and Markou, 2011), and nicotine (Stoker et al, 2012). 
This type of assay has also been performed following 22 days of administration of WIN55,212-2, 
although no evidence for tolerance or withdrawal related changes in rates of responding were 
detected (Mavrikaki et al, 2010). Conversely, rats repeatedly dosed with THC displayed 
tolerance to the rate-decreasing effects, though they did not exhibit rate-increasing effects at any 
dose nor evidence or withdrawal and/or dependence (Kwilasz and Negus, 2012). These results 
are interesting in the context of the results reported here with CP55,940 in which partial 
tolerance to the rate-decreasing effects occurred. In our studies, WIN55,212-2 maintained most 
of its efficacy to elicit triad effects, while CP55,940 produced slightly larger losses in potency in 
CB1 HET mice implying that WIN55,212-2 is more efficacious in the whole animal. Given that 
both Mavrikaki et al. and our ICSS experiments utilized fixed doses, it is possible compensatory 
mechanisms would reduce the receptor population and the higher efficacy ligand could still elicit 
rate-decreasing effects of the same magnitude, whereas the somewhat lower efficacy 
cannabinoid would display some tolerance. Varying the dose of THC during repeated 
administration does result in differing degrees of tolerance to rate-decreasing effects, though no 
signs of dependence were unmasked similar to our results (Kwilasz and Negus, 2012).Repeated 
administration of a single dose of an agonist to produce tolerance does not, however, provide any 
information as to the loss of potency. In each case described above, cumulative dose-effect 
experiments before and after the repeated treatment with the selected agonist would have been a 
more effective approach. Still more effective would have been to vary the efficacy of the drug 
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used for the preceding and flanking potency assessments as has been done with drug 
discrimination (Hruba et al, 2012), or to vary the efficacy of the tolerance-inducing agents. An 
expanded approach might include varying the dose of the toleragen at ED16, ED50, and ED84 
values to assess the dose-response relationship to induce tolerance. Regardless, efficacy might be 
an important determinant in the tolerance to the rate-decreasing effects of cannabinoids, but the 
abuse-related rate-increasing effects seem to only be detectable utilizing the low-efficacy ligand 
THC, and even then rather unreliably. 
 To test for dependence, both spontaneous and precipitated withdrawal experiments were 
performed following the same dosing regimen (0.3 mg/kg CP55,940, i.p., for seven days). In 
both cases, no disruptions in baseline responding following cessation of testing were observed, 
and rimonabant (10 mg/kg, i.p.) produced no rate-decreasing effects alone or after repeated 
dosing with CP55,940. This result is supported in the literature given the relative paucity of 
studies reporting significant spontaneous signs of withdrawal. The lack of precipitated 
withdrawal may also be related to CP55,940’s ability or lack thereof to produce compensatory 
changes in the relevant underlying neural substrates mediating changes in ICSS during 
withdrawal. It may simply be that receptor occupancy was not high enough for the potent and 
efficacious ligand to engender sensitivity to rimonabant. To test this hypothesis, a higher dose 
should be used, though practical considerations must be made in the case of cannabinoids. High 
doses of cannabinoids for prolonged periods of time may elicit handling-induced seizures, which 
is consistent with CB1 hypoactivity (von Rüden et al, 2015). Although not investigated, electrical 
brain stimulation poses a potential risk to animals with already increased susceptibility to 
seizures, which may impede the feasibility of these studies. Day to day rate-decreasing effects 
are also possible given the long half-life and duration of action of many cannabinoids which may 
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also confound sensitivity to tolerance. If none of these limitations are manifested, however, the 
relationship of efficacy, tolerance, and dependence for the CB1 receptor may be elucidated. 
4.8  Overall Conclusions 
 In this thesis, I have characterized the relationship of CB1 ligands to cannabimimetic 
effects as measured by the cannabinoid triad (catalepsy, hypothermia, and antinociception), 
agonist-stimulated [35S]GTPS experiments, and abuse-related effects as measured by ICSS. The 
cannabinoid triad represents a novel approach of assessing in vivo efficacy of putative 
cannabinoids, endocannabinoids, and potential therapeutics such as anabolic or catabolic enzyme 
inhibitors. The cumulative dosing triad in CB1 transgenic mice offers many advantages over 
other means of assessing in vivo efficacy.  This assay is quick, robust, and experimental 
parameters may be easily modified and optimized to ascertain differences along the efficacy 
continuum. Additionally, emerging pharmacological tools may aid in the investigation of 
downstream mechanisms as they relate to CB1 receptor density. The effect of a noncompetitive 
CB1 antagonist could be assessed in WT mice to interrogate receptor reserve for agonists on 
different CB1-dependent endpoints, or ligands which possess extreme bias could assess the 
relative contribution of various pathways to an in vivo endpoint. Importantly, each endpoint is 
differentially sensitive to reductions in receptor population providing insights into the underlying 
neurobiology of the endocannabinoid system. Both hypothermia and antinociception appear to be 
reliable measure of CB1-mediated G-protein activation in vivo, while catalepsy appears to be a 
reliable control for cannabimimetic activity in cases where it has been lost in the other two 
measures. Although antinociception and hypothermia are highly correlated with G-protein 
activation, multiple CB1-mediated pathways may contribute to in vivo endpoints, which may 
have implications for therapeutic application of biased ligands.  
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In vitro studies utilizing spinal cord and cerebellum tissue from CB1 WT, HET, and KO 
mice demonstrate theoretically anticipated reductions in magnitude of functional activity 
concordant with reductions in receptor density. We have also demonstrated for the first time a 
dose-effect relationship in CB1 KO tissue with the high efficacy ligand WIN55,212-2. Although 
non-CB1 stimulation has been previous reported, this stimulation has not thus far been assessed 
in a thorough manner during efficacy determination experiments. These results support the 
notion that selectivity of ligands remains important when assessing in vitro versus in vivo effects. 
Additionally, five of the six ligands tested here displayed similar efficacy in both high and low 
receptor conditions, suggesting that assay conditions could be further optimized to differentiate 
ligands of very high efficacy. One way to accomplish this would be to adjust the GDP/GTPS 
ratio by addition of either reagent. The presented conditions did not readily differentiate between 
A-834,735D and CP55,940 though the expectation based upon preliminary results suggested A-
834,735D might have been up to twice as efficacious to stimulate binding. Increasing the GDP 
concentration should elevate Emax values for most ligands tested, with the highest efficacy 
compounds displaying the largest increases (Savinainen et al, 2001).  
Though evidence for withdrawal was not detected in ICSS following repeated treatment 
with CP55,940, this is the first study of its kind to assess withdrawal-related effects on reward 
processes in ICSS for cannabinoids and it serves to expand knowledge related to the topic. It 
may be that ICSS is not sensitive to detect cannabinoid withdrawal. Overall, synthetic 
cannabinoids are generally more potent and efficacious than THC both in vivo and in vitro. Thus 
they carry an increased element of risk when used by humans, especially those users that may 
already be tolerant. 
4.9  Future directions 
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 Though the cumulative dosing procedure was used mainly to look at the relationship 
between efficacy and potency shifts in CB1 WT and HET mice, this model is quite amenable to 
examining efficacy under a variety of conditions. Exogenous cannabinoids can vary greatly in 
efficacy and so too can endogenous cannabinoids. Two primary endocannabinoid have been 
identified: anandamide (AEA) and 2-arachinodonoylglycerol (2-AG). In agonist-stimulated 
[35S]GTPS experiments, AEA has higher efficacy than THC but does not achieve the same level 
of activation as synthetic cannabinoids such as HU-210 and CP55,940 (Burkey et al, 1997a). 2-
AG is much higher in efficacy than even some synthetic cannabinoids, especially under 
conditions of very high GDP concentrations (Savinainen et al, 2001). Exogenous administration 
of AEA and 2-AG does not typically produce cannabimimetic effects as they are rapidly 
catabolized by fatty acid amide hydrolase (FAAH) (Giang and Cravatt, 1997) and 
monoacylglycerol lipase (MAGL) (Dinh et al, 2002), respectively. The advent of selective 
pharmacological inhibitors of both FAAH (Ahn et al, 2009) and MAGL (Niphakis et al, 2013) 
will afford the ability to assess the in vivo efficacy of AEA and 2-AG in WT and HET mice. 
Pretreatment with an enzyme inhibitor will allow the accumulation of exogenously administered 
endocannabinoids, and the transgenic triad model can then be used to provide information about 
the functional in vivo activity of both AEA, 2-AG, as well as other endocannabinoids, such as 
noladin ether (Hanus et al, 2001), or hemopressin (Heimann et al, 2007). Importantly, CB1 KO 
mice distinguish between CB1 and non-CB1 actions of these and other ligands. 
 With the ongoing discovery of clandestinely synthesized cannabinoids, a need exists to 
rapidly assess these compounds for their in vitro and in vivo potency and efficacy. The 
procedures outlined here provide a systematic, high throughput approach to screen the huge 
variety of novel structures available. A library of compounds already exists to conduct structure 
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activity relationships for the novel backbone structures being produced. Many changes in 
structure are small, such as fluorination or chlorination, which result in a decrease in 
susceptibility to be detected and to evade scheduling. Interestingly this has resulted in SAR 
relationships to reduce detection, but the pharmacological implications of these changes have not 
yet been investigated. For instance, UR-144, XLR-11, and A-834,735 are structurally related 
CB1 ligands produced by Abbott Laboratories, and each possesses a heat degradant in which the 
tetramethylcyclopropyl ring opens. This change renders them much more efficacious to stimulate 
GTPS binding, but this does not capture the entire biochemical chain of events from receptor 
binding to behavior that would be assessed in the CB1 transgenic triad. It is unknown why this 
change results in such a large increase in efficacy, but the degree to which it relates to efficacy 
for a variety of biochemical assays would be interesting to study alongside the triad. Many 
synthetic cannabinoids agonists have nanomolar affinity for CB2 as well as CB1, and as a result a 
similar approach using CB2 transgenic mice (Buckley et al, 2000) may also be used for CB2 
relevant endpoints including inflammatory or neuropathic pain and the loss of potency in CB2 
HET mice. The feasibility of cumulative dosing is an empirical question that can be answered 
systematically to determine the effect of repeated testing and repeated injections versus 
cumulative treatment with a potentially therapeutic ligand. 
 As discussed above, ICSS might not be well-suited to measure cannabimimetic abuse-
related effects. CPP and SA are likely not good candidates either, but the drug discrimination 
procedure provides an alternative option. While not strictly an abuse liability assay, 
cannabimimetic agents such as nabilone (Lile et al, 2011) substitute for THC in humans, and 
many cannabimimetic agents display substitution for THC (Wiley et al, 2014, 2015), and vice 
versa (Järbe et al, 2012, 2014). Importantly, this substitution occurs in a CB1-dependent manner 
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for humans (Huestis et al, 2001), non-human primates (McMahon, 2006), and rodents (Järbe et 
al, 2011). Therefore, drug discrimination represents one of the better options to assess the 
subjective effects of putative cannabinoids and by proxy their abuse liability. Although CB1 KO 
mice would be unlikely to acquire a cannabimimetic agent as a discriminative stimulus, CB1 WT 
and HET mice likely would providing the unique opportunity to assess the effect of receptor 
density on the discriminative properties of cannabimimetic agents. The intensity of the CB1 
stimulus may also be controlled by varying the training dose of the cannabimimetic agent and 
looking at differences in potency to substitute for the training drug in CB1 WT and HET mice. 
Utilizing a very high efficacy CB1 ligand such as A-834,735D, one could fade the training dose 
of the test drug, and at each level of the training drug a selection of agonists which vary in 
efficacy could be assessed. The hypothesis that very high efficacy drugs would maintain their 
potency better than low-efficacy drugs at low training is testable, and results would permit 
inferences into the mechanisms underlying substitution. Consistent with the anatomical 
distribution of CB1 expression, generalization from cannabimimetic agents appears to be a 
centrally mediated phenomenon (Järbe et al, 2011), and as a result the cannabinoid abuse 
liability of these agents may be inferred. Another alternative approach would be to use THC as 
the discriminative stimulus, providing a low efficacy ligand to fade, and assess the maintenance 
of potency by high efficacy cannabinoid ligands in HET mice.  
 The effects of SCs upon dependence-related phenomenon are not well-characterized. One 
approach to explore this aspect of their pharmacology is to conduct rimonabant-precipitated 
withdrawal studies and vary ligands based upon efficacy. Receptor occupancy seems to drive 
tolerance in the case of opioids (Pawar et al, 2007), though similar studies have not yet been 
conducted for cannabinoids, and the relationship between efficacy and the severity of withdrawal 
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has not yet been explored. Utilizing the cumulative dosing triad as a guide for efficacy and 
potency determinations, one could compare the impact of repeated administration of these drugs 
on adaptive changes at the CB1 receptor. From there, the dose-response relationship of 
rimonabant to precipitate spontaneous signs of cannabinoid withdrawal (e.g., paw flutters and 
head shakes) may reveal differences among the agonists differing in efficacy. It remains 
unknown whether repeated administration of highly efficacious SCs would result in a greater 
magnitude of observed withdrawal signs. In this design, the use of CB1 KO mice will be critical 
to control for potential off-target effects that might occur with high doses of SCs given 
repeatedly. Other aspects of withdrawal could be captured with measures of anxiety-like 
phenotypes (e.g. marble burying or elevated plus maze) or assays of learning and/or memory 
(e.g. Morris water maze or object recognition tasks). 
 SC will likely continue to be a public health problem for years to come, and so long as 
clandestine chemists synthesize novel cannabimimetic agents there will be a need to assess both 
their basic pharmacological properties as well as potential abuse-related effects. Though overall 
use seems to be declining, severe health complications associated with SC abuse continue to 
arise (Debruyne and Le Boisselier, 2015). Here, we utilized CB1 transgenic mice to elucidate 
differences in efficacy in an in vivo model of cannabimimetic activity, while utilizing ICSS as an 
assay of abuse liability. Overall, this in vivo approach effectively stratified agonists of varying 
CB1 efficacy that showed a strong positive relationship with efficacy in the in vitro model of 
cannabimimetic activity, and would have excellent utility to assess CB1 efficacy of emerging 
SCs, endogenous cannabinoids, and potential cannabinoid-based medications. 
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